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When aptamers emerged almost two decades ago, “selection-ologists” quickly 
realized the aptamer’s clinical potential - both as a diagnostic tool and as a therapeutic.  
Since that time, nearly hundreds of medically relevant targets have been successfully 
selected against.  Moreover, many have proven efficacy in tissue culture and animal 
models.  However, only one has successfully advanced to clinical use.  Several key 
limitations in aptamer-based drugs may explain the dearth of aptamers in the pharmacy.  
Issues of expression level, delivery, and targeting will need to be addressed before 
aptamers can reach their full clinical potential.  This work broaches on aspects of these 
limitations and leads into ways of transitioning the aptamer into clinical use. 
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 1 
INTRODUCTION 
 
The ability to select nucleic acid-based binding species (aptamers) has led to the 
development of protein inhibitors and gene modulators that are small, readily synthesized 
nucleic acids.  The techniques for optimizing, stabilizing, and delivering nucleic acid 
therapies are just beginning to be developed, but the same engineering flexibility that has 
so far allowed the generation of multiple, high affinity and high specificity binding 
species appears to also apply to the methods for adapting nucleic acids to clinical 
applications.  Below, I briefly review the selection of various aptamers and their 
applications to a variety of disease states, and then address the hurdles that must be 
overcome for the use of aptamers as delivered drugs and gene therapies. 
 
IN VITRO SELECTION & APTAMERS 
 
Aptamers are nucleic acid binding species generated by iterative rounds of in vitro 
selection, or SELEX (Figure i.1; reviewed in Ellington and Conrad, 1995; Famulok and 
Mayer, 1999; Marshall and Ellington, 2000; Yan et al., 2005).  Briefly, randomized pools 
of RNA or ssDNA are incubated with target molecules under carefully chosen selection 
conditions.  Binding species are partitioned away from non-binders, amplified to generate 
a new pool, and the process is repeated until a desired ‘phenotype’ is achieved or until 
sequence diversity is significantly diminished.   
 Figure i.1. The process of in vitro selection or SELEX. 
Multiple cycles of selection and amplification tend to winnow a pool of upwards 
of 1015 molecules to only those few species that have the highest affinities and 
specificites for a target.  Previously selected aptamers have typically bound their targets 
with Kd values in the nanomolar range and can discriminate against closely related 
proteins that differ by only a few amino acids (reviewed in (Conrad et al., 1996; Osborne 
et al., 1997).  One early example of this is an aptamer that could bind to theophylline, but 
not to caffeine, which differs by one methyl group (Jenison et al., 1994).  Aptamers can 
also discriminate between closely related protein targets.  Conrad et al. selected aptamers 
that could bind to the beta II isoform of protein kinase C in the nanomolar range, but 
bound 10-fold less well to the very closely related related beta I isozyme (Conrad et al., 
1994; Jenison et al., 1994).  Similarly, Tuerk et al. selected anti-HIV-reverse transcriptase 
 2 
 3 
(RT) aptamers that bound to HIV-1 RT with a Kd of 25 pM, but bound almost four orders 
magnitude lower to HIV-2 RT, which has 60% sequence identity (Tuerk and MacDougal-
Waugh, 1993; Tuerk et al., 1992).  More recently, the Ellington Lab has isolated 
aptamers that could distinguish between HIV RT variants.  While the mutant protein 
(M3) and the wild-type protein (WT) only differed by 8 amino acids (~2%), an aptamer 
identified during the selection showed differential binding between these two protein by 
almost 100-fold (personal communication).  Equally impressive, aptamers selected to 
bind to haemagglutinin from the Influenza A/Panama strain were able to discriminate 
between the haemagglutinin of three other viral strains, which only differed in amino acid 
sequence by between 10 to 15%.  Additional analysis of aptamer binding to these viral 
proteins suggested that the discrimination between variants was dictated by only 4 amino 
acid mutations on the surface of the protein (Gopinath et al., 2006).   
Targets for selection have ranged from simple organic molecules to proteins, 
complexes, and even whole cells (see the Aptamer Database at 
http://aptamer.icmb.utexas.edu for a comprehensive compilation).  By varying key 
parameters of a selection, aptamers with finely tuned physical and functional properties 
have been selected, potentiating a wide range of applications.  Aptamer selections have 
progressed from targeting isolated proteins and simple proof-of-principle concepts 
towards targeting cell surfaces or tissues and generating reagents that have more direct 
applications in manipulating cellular pathways and modulating gene expression.  In 
particular, because of their excellent binding characteristics and general lack of toxicity, 
aptamers are emerging as promising therapeutic reagents.   
Aptamers have now been selected against a wide array of biomedically relevant targets.  
Some early examples of such aptamers are shown in Table I; however, to date, so many 
exist that it would be hard to compile comprehensively.  Several aptamers have even 
entered clinical trials.  For example, anti-thrombin and anti-nucleolin aptamers are  
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Table I.  Early examples of medically relevant aptamers 
Target Kd (nM) Therapeutic applications Reference
HIV-1 reverse transcriptase 1 Viral replication
Tuerk et al. (1992)
Schneider et al. (1995)
HIV-1 integrase 10 Viral replication Allen et al. (1995)
HIV-1 Rev <1 Viral replication Giver et al. (1993)
HIV-1 nucleocapsid 2.3 Viral replication Berglund et al. (1997)
HIV-1 Tat 0.12 Viral replication Yamamoto et al. (2000)
HIV-1 gp120 171 Viral infection Sayer et al. (2002)
HIV-1 Gag 10 Viral replication Lochrie et al. (1997)
RSV 40 Infection Pan et al. (1995)
Hepatitis C NS3 650 Viral replication Hwang et al. (2000)
Influenza hemaglutinin NA Viral nfection Jeon et al. (2004)
hNE n/a Inflammation Charlton et al. (1997)
p-Selectin 0.016-0.71 Inflammatory response Jenison RD et al. (1998)
hnps-PLA2 118 ARDS, Septic shock Bridonneau et al. (1998)
IgE 10 Allergies Wiegand et al. (1996)
IFN-g 6.8 Inflammation and immune response Kubik et al. (1997)
L-selectin 3 Inflammation O'Connell et al. (1996)
CD4 NA Immune response Kraus et al. (1998)
Anti-acetylcholine autoantibodies 60 Myasthenia gravis Lee & Sullenger (1997)
sLex 0.085 Cell adhesion; inflammation Jeong et al. (2001)
human complement C5 20-40 Inflammation Biesecker et al. (1999)
Neutrophil Elastase Na Inflammatory response Bless et al (1997)
PTPase 18 Oncogenesis, viral regulation Bell et al. (1998)
b-2-integrin 500-1000 Cell adhesion; inflammation Blind et al. (1999)
NF-kB 1 Apoptosis Lebruska & Maher (1999)
ERK2 1-5 Cell overpoliferation Seiwert et al. (2000)
hTNF-α Na Regulation of immune defense Xinrui et al. (2004)
TGFβ-2 Cell growth and differentiation Archemix patent
bFGF 0.35 Angiogenesis Jellinek et al. (1993)
KGF 0.0002 Epithelial hyperproliferative disease Pagratis et al. (1997)
PDGF 0.1 Tumor development Green et al. (1996)
VEGF 0.14 Neovascularization Green et al. (1995)
Tumor microvessels NA Gliblastoma detection Blank et al. (2001)
Tenasin-C 5 Tumor cell detection Hicke et al. (2001)
NFAT 10-100 T-cell differentiation and immune response Cho et al. (2004)
RET Angiogenesis Cerchia et al. (2005)
◊ -thrombin 25 Thrombosis
Bock et al. (1992)
Kubik et al. (1994)
Latham et al. (1994)
Activated protein C 110 Thrombosis Gal et al. (1998)
HER3 Tumor development Chen et al. (2003)
Cell cycle, 
growth, 
signaling & 
regulation
Anti-viral
Immune 
response and 
inflammation
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currently in Phase I clinical trials for human coronary bypass surgery and tumorigenesis, 
respectively.  Anti-VEGF aptamers (Macugen) concluded Phase II/III clinical trials for 
macular degeneration and was the first aptamer to receive FDA approval (2003). 
 
THE ADVANTAGES OF USING APTAMERS 
 
Aptamers have several features that make them especially good therapeutic 
candidates relative to other biopolymer drugs.  Aptamers are relatively small and can 
readily access sites on antigens that have previously been difficult to target.  As an 
example, Trypanosoma brucei, the causative agent of sleeping sickness, produces a 
variable surface glycoprotein (VSG) that is difficult for the immune system to generate 
antibodies against.  Nonetheless, aptamers selected against whole trypanosomes in vitro 
were able to access and bind to constant regions located within a flagellar pocket masked 
by the variable surface (Lorger et al., 2003).   
Another advantage of in vitro selection methods is the ability to craft selections so 
as to yield aptamers with desired specificity profiles.  Without much effort, the 
specificities of aptamers can be rendered wide or narrow.  For example, aptamers 
selected against one Trypanosoma strain were able to target multiple different strains.  In 
another selection, in order to ensure good breadth of binding, White et al. devised so-
called ‘toggle’ selections (White et al., 2001).  Aptamers against thrombin were selected 
in which target protein between rounds was ‘toggled’ from human to porcine.  Since the 
resultant aptamers could bind both targets, they could be used both for animal and 
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clinical trials.  In contrast, negative selections can be incorporated during the selection 
process to greatly reduce affinity for even closely related targets.  Using negative 
selection, aptamers have been selected that can discriminate between phosphorylated and 
unphosphorylated variants of a protein (Bianchini et al., 2001).   
Aptamers can also be engineered for different sites of localization and expression.  
While antibodies are typically directed against extracellular targets, aptamers can be 
expressed from within the cell in a gene-therapy approach, termed ‘intramer’ therapy 
(reviewed in (Famulok et al., 2001)).  By modulating the levels of intracellular 
expression, it may be possible to adapt the amounts of intramer therapeutics produced to 
differing amounts of a target protein at different stages of a disease or in different 
individuals.  Aptamers can also be introduced exogenously, in order to modulate the 
function of targets in the bloodstream or on cell surfaces.  Moreover, as further described 
in this thesis, various types of signals can be appended to aptamers to direct them to 
different sites within a cell or to specific organs and tissues.  
Most importantly, aptamers have yet to demonstrate significant toxicity.  The 
Rossi lab at the City of Hope National Medical Center had reported interferon response 
from phage polymerase-transcribed siRNAs, but delivery of random cellular RNA and 
synthesized RNA did not trigger a similar response (Kim et al., 2004).  While some 
nucleoprotein complexes (Malmegrim et al., 2002) and nucleosomes (Burlingame and 
Rubin, 1996; Van Bruggen et al., 1996) have been known to induce auto-antibody 
responses in certain individuals, aptamers do not seem to be immunogenic, by and large.  
Experiments designed to test the cytopathic and toxic effects of nucleic acid therapies so 
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far show no side effects.  Kohn et al. transduced CD34(+) cells from pediatric patients 
with aptamer-length decoys of the HIV Rev-responsive element and introduced the 
transduced cells into patients.  No toxic effects were seen, and the transduced genes were 
still detectable, albeit at very low levels, a year after infusion (Bauer et al., 1997).   
 
 
APTAMERS IN CLINICAL APPLICATIONS 
 
The ability to craft selections to target whole cells as well as protein targets may 
allow aptamers to be ‘blindly’ developed against a number of pathogens, transformed 
cells and disease types.  The added fact that aptamers appear to have low immunogenicity 
and toxicity may make them especially useful in combating diseases related to the 
immune system and inflammation. 
 
Aptamers against disease markers 
 Given the aptamer’s ability to finely discern subtleties in targets, aptamers could 
be of great utility in recognizing, or perhaps even treating, diseased cells.  One of the 
greatest specificity challenges facing the immune system is the ability to distinguish 
subtle but pathological alterations in metabolism and physiology - for example, in 
cellular transformation and oncogenesis.  The ability to discern a cancerous cell from 
normal epithelial tissue therefore represents a challenge that aptamer therapeutics are 
uniquely suited for.   
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Aptamers have been generated against a number of tumor-related targets.  One 
notable and early example is vascular endothelial growth factor (VEGF), which 
contributes to neovascularization and vascular permeability of solid tumors.  A number of 
anti-VEGF aptamers have been selected and bind to the protein with low nanomolar to 
picomolar affinities (Jellinek et al., 1994; Ruckman et al., 1998).  Aptamers against 
VEGF have proven effective in inhibiting tumor proliferation in multiple cancer types.  
Wilms tumors induced in nude mice underwent 84% weight reduction when treated with 
daily intraperitoneal (i.p.) injections of 200 micrograms of an anti-VEGF aptamer for 5 
weeks.  None of the aptamer-treated mice (n = 10) showed adverse effects compared to 
controls (Huang et al., 2001).  Similarly, human neuroblastoma tumors xenografted into 
mice exhibited a 52% reduction in growth after daily i.p. injections of 250 micrograms 
aptamer for five weeks.  The tumor reduction was on par with an anti-VEGF antibody but 
lower than a previously designed inhibitor composed of VEGF decoy receptors attached 
to an antibody segment (Holash et al., 2002; Kim et al., 2002).  Further development of 
anti-VEGF aptamers has allowed them to reach human clinical use, although so far for 
age-related macular degeneration rather than for cancer.   
Other growth factors have also been targeted for reduction of tumors.  Basic 
fibroblast growth factor (bFGF) is a cytokine often associated with wound healing and 
whose expression affects cell proliferation, angiogenesis and tumor spread.  Serum levels 
of bFGF have been statistically shown to be higher in breast cancer patients than non-
cancerous patients (Granato et al., 2004).  Jellinek et al. selected aptamers against bFGF 
that could form complexes with Kd values as low as 3 nM (Jellinek et al., 1993).  Golden 
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et al. used a modified selection scheme called photo-SELEX to select even tighter-
binding anti-bFGF aptamers(Golden et al., 2000).  In photo-SELEX, random pools are 
synthesized with a photosensitive nucleotide, such as 5-bromo-2’-deoxyuridine (BrdU; 
(Golden et al., 1999; Jensen et al., 1995)).  Following incubation with a target, the 
mixture is irradiated with 308 nm light.  At this wavelength, BrdU cross-links with 
proximal aromatic and sulfurhydryl moieties on amino acids.  The cross-linked sequences 
can be readily separated from non-binding species and re-amplified.  The photo-SELEX 
derived aptamers bound with Kd values as low as 16 pM, did not significantly bind to 
VEGF or PDGF, and retained their binding affinity even in 10% serum.   
Many tumor antigens are membrane-associated, and a number of cell surface 
proteins have served as aptamer targets.  Lupold et al. selected aptamers against the well-
known prostate-specific membrane antigen (PSMA).  PSMA is a hydrolase 
overexpressed on the surface of at least some prostate tumors.  By using a recombinant 
variant of prostate-specific membrane antigen (xPSM) these researchers were able to 
isolate two aptamers, xPSM-A9 and –A10.  Both aptamers inhibited xPMS activity with 
Kis in the low nanomolar range.  Both A9 and A10 were shown to bind a PSMA-
expressing prostate tumor line, LNCaP, but not to a different prostate tumor line, PC3, 
which does not express the protein (Lupold et al., 2002).   
 
Aptamers against immune disorders 
While these examples above illustrate how aptamers can recognize and possibly 
inhibit cancer markers, the same principles can be applied to other diseases states.  For 
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example, aptamers may be particularly well-suited for treating disorders of the immune 
system.  Currently, treatment for immune disorders commonly involves 
immunosuppressive drugs.  Not only are toxic side effects an issue, patient health is 
compromised by having a weakened immune system.  The demonstrated specificity of 
aptamers, as well as their apparent lack of immunogenicity and toxicity, argue that 
aptamer therapies would not similarly disrupt the system.   
Indeed, instead of weakening the immue system, aptamers can potentially be used 
to temper culprit antibodies.  In an early display of this potential, Tsai and Keene  
performed a selection against serum from a patient with systemic lupus erythematosus 
(SLE).  SLE patients produce anti-DNA autoantibodies leading to autoimmune damage in 
many organs.  The mechanism of the autoimmunogenicity is not clear, and the types and 
structures of nucleic acids recognized by these antibodies have not been fully elucidated.  
Interestingly, the aptamers selected by Tsai and Keene resembled portions of U1 small 
nuclear RNA (snRNA) that had been shown to react with autoantibodies.  These authors 
further showed that their aptamers could inhibit an autoantibody reaction caused by U1 
snRNA (Tsai and Keene, 1993).   
Selections relevant to the neuromuscular disease myasthenia gravis (MG) have 
also been carried out.  In MG, auto-antibodies down-modulate nicotinic acetylcholine 
receptors (AChRs) on the surface of skeletal muscle cells.  Lee and Sullenger  selected 
aptamers against a rat anti-AChR antibody, mAb198, and the resultant complex had a Kd 
of 60 nM (Lee and Sullenger, 1997).  Hwang et al. then re-selected for aptamers with up 
to 10-fold stronger binding than the previously selected aptamers.  At a concentration of 
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3 micromolar, the anti-AChR aptamer, Ex-SE-RNA, was able to inhibit mAb198 
antibody-induced down-modulation by up to 80%.  A slightly reduced activity was seen 
when assayed with antibodies from patients with MG in place of mAb198.  Ex-SE-RNA 
was able to inhibit autoantibodies from MG patient serum in a dose-dependent manner 
with an IC50 of 2 micromolar (Hwang and Lee, 2002).  In later work, anti-AChR 
aptamers were truncated and attached to PEG moieties for better in vivo retention without 
disruption of the inhibitory effect (Hwang et al., 2003).  
An MG-like autoimmune state, called experimental autoimmune myasthenia 
gravis (EAMG), can be induced in animals by injection with AChR or transfer of anti-
AChR antibodies.  Hwang et al. tested the ability of their truncated and PEGylated 
aptamer to alleviate EAMG in rats.  In non-aptamer-treated animals, muscular AChR 
content was reduced by 51% and muscular weakness manifested within 24 hours.  
Animals treated with aptamer showed only approximately 17% AChR loss (Hwang et al., 
2003).  To the extent that different antibodies might arise in either MG or EAMG than 
those that have currently been selected against, new aptamers could nonetheless readily 
be generated using whole serum or purified antibodies, even on a patient-by-patient basis.  
Such individually crafted therapeutics may not be currently cost-effective, but with the 
advent of allele-specific diseases and drug effects, modern medicine is increasingly 
focused on the individual.  To the extent that individual-specific aptamers can be more 
readily identified, produced, and delivered than individual-specific organic compounds, 
aptamers may represent an important addition to this trend. 
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Of course, immune disorders are not limited to severe autoimmune reactions.  
Inflammation, in of itself, can lead to chronic ailments that include arthritis, 
myocardititis, nephritis and colitis.  Anti-inflammatories, corticosteroids, and other 
medications can address the symptoms of these diseases, but they are not treatments per 
se and long term use can lead to undesirable side effects.  Again, aptamers may enable 
specific factors involved in inflammation to be targeted, rather than down-regulating the 
entire system. 
As an example, oncostatin M (OSM) is a cytokine strongly implicated in 
rheumatoid arthritis and may have roles in mediating cell growth and differentiation.  
Aptamers with a Kd of 6 nM have been selected against human OSM.  One of the 
aptamers (ADR58) was able to block binding of OSM to its receptor in a dose-dependent 
manner with an IC50 of 1 micromolar.  The aptamers were shown to be specific for 
human OSM (relative to mouse OSM, 42% identity; TNF-alpha; and the OSM 
structurally-related leukemia inhibitory factor) and could also specifically block 
interactions with the OSM receptor (Rhodes et al., 2000).    
Selectins are another group of surface proteins that may be targets for the 
development of potent anti-flammatory drugs.  Selectins bind to and mediate leukocyte 
cell adhesion to molecules such as sialyl Lewis X (sLex) on endothelial cells.  
Subsequently, the leukocytes are transferred (or “rolled”) from the initial site of 
interaction to the site of injury.  Selectins are thus integral to the extraction of leukocytes 
from blood vessels during inflammation and a disruption of this interaction would 
essentially interrupt the innate immune response.   
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Aptamers have been selected against L-selectin, which is expressed on leukocytes 
as opposed to E- and P-selectins, which are inducibly expressed on endothelial cells and 
platelets, respectively.  The anti-selectin aptamers demonstrated nanomolar affinities 
specifically for L-selectin, and much reduced affinities for P- or E-selectin.  Hicke et al. 
also demonstrated inhibition of L-selectin binding to sLeX by their aptamers with an IC50 
of approximately 3 nM.  They further showed that their aptamers could inhibit PBMC 
“rolling” in an in vitro, cell-based assay.  In an experimental precursor to actual human 
delivery, Hicke et al. also assayed their aptamer in SCID mice.  The anti-selectin 
aptamers were able to inhibit trafficking of lymphocytes to peripheral and mesenteric 
lymph nodes as effectively as an antibody control.  Biodistribution of lymphocytes 
throughout the rest of the body, as measured by accumulation of lymphocytes in organs, 
was not affected (Hicke et al., 1996).  
 
Aptamers against whole cells 
One problem with many diseases, though, is that the specific disease marker may 
not be known.  With cancerous cells, the type of cancer, progression or severity and 
location may all affect marker types and expression levels.  An inherent problem with 
cancerous cells is that they often do not adequately trigger a response from the immune 
system.  A number of possible mechanisms for this evasion have been proposed, and 
these may act in combination.  Tumor cells may down-regulate tumor-associated-
antigens, express immunosuppressive cytokines or just fail to produce antigens 
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significantly different from ‘self’ cells (reviewed in (Mocellin et al., 2004)).  Having to 
first identify and purify cancerous targets for selections would be incredibly tedious. 
Aptamers can be raised against transformed cells and tissues without a prior 
knowledge of a relevant target.  In this way, selections against whole cells can 
specifically target a phenotype, rather than an individual protein, and thus obviate the 
need to identify and purify tumor antigens.  Moreover, there exists the possibility that 
purified targets may not behave in the same manner as they do in the context of the cell 
surface.   
Aptamers have been selected that can detect slight changes in cell surface 
expression, especially changes that might elude immune surveillance.  In an early step 
toward whole cell selections, Morris et al. showed that aptamers selected against a cell 
can have similar binding affinities to those raised against purified protein targets (Morris 
et al., 1998).  Selections against human red blood cell (RBC) ghosts produced a diverse 
pool of selected aptamers with affinities in the low nanomolar range (1 to 2 nM).  Using a 
procedure they termed ‘deconvolution selection’, these researchers were able to identify 
the cell surface targets more definitively.  Selected aptamers were conjugated to 
photoreactive phenyl azide groups, incubated with RBC ghosts and then irradiated.  Four 
major cross-linked products were excised from polyacrylamide gels, re-amplified, and the 
procedure was repeated.  After four rounds, four individual selected pools corresponding 
to tight binding of each of the four major cross-linked products were isolated.  
Cell selection techniques or variations on them have now found use in the 
identification of other anti-tumor aptamers.  Transformed rat YPEN-1 endothelial cells 
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(EC) were used as targets to generate ssDNA aptamers against glioblastoma (Blank et al., 
2001).  Starting with a counter-selection against murine N9 microglial cells, aptamers 
were selected that specifically bound microvessels of rat glioblastomas but not normal rat 
brain tissue or peritumoral areas as measured by flow cytometry and fluorescence 
microscopy.  The authors also performed a ‘scratch test’ (damaging a monolayer) with 
cultured endothelial cells.  One high-affinity aptamer, III.1, localized to the scratch 
following application, suggesting that the aptamer target might be involved in 
proliferation or cell repair.  The aptamer was thereafter also employed for target 
identification.  Affinity purification of the cross-linked aptamer-target complex and 
peptide mass spectrometry identified the aptamer target as the rat homologue of the 
mouse protein pigpen.  Consonant with the scratch test observations, inhibition of pigpen 
has been shown to inhibit angiogenesis and proliferation in EC (Alliegro and Alliegro, 
2002).   
Similarly, ssDNA ligands were selected against differentiated PC12 cells and 
negatively selected against the corresponding parental cell line (Wang et al., 2003).  
During the subtractive step, the pool DNA was exposed to undifferentiated cells, and any 
binders were eliminated.  When presented with a 1:1 mixture of differentiated and normal 
cells, the aptamers bound specifically to the differentiated variety; no binding to 
undifferentiated cells was observed.  The best aptamer bound target cells 100-fold better 
than a control oligonucleotide, as determined by fluorescence quantitation with FITC-
labeled ligands.  Like previous phage display selections, these two sets of experiments 
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showed that tumor-cell specific aptamers could be selected simply by incubating pools 
with pathological cells while subtracting the background of normal cells. 
More recently, the Tan group performed several selections against whole cells.  In 
one of the selections, aptamers were generated that could distinguish between B-
lymphocytes and T-lymphocytes.  By performing positive and negative selections, 
respectively against CEM and Ramos cells, a whole array of aptamers were isolated, 
most of which bound only the T-cell line.  Moreover, these aptamers could distinguish 
the target cell type in mixed cultures of cells (Shangguan et al., 2006).  In a follow-up 
study, the cell-surface targets of some of the aptamers were identified.  The interaction of 
one of the aptamer:target pairs, sdc8 and its target, protein tyrosine kinase 7, triggered 
internalization of that aptamer, a trait that could prove useful for a number of 
applications, as will be described later.  The Tan group has gone on to select aptamers 
against liver cells (Shangguan et al., 2008) and lung cells (Chen et al., 2008). 
 
Aptamers against viruses. 
The adaptable nature of aptamers has also made it possible to target a number of 
pathogens that have hitherto proven elusive.  In particular, viruses present a unique 
problem for the immune system in their often rapid replication and varied immune 
evasion strategies.  Aptamers may be of use in abetting the immune system against these 
elusive targets, perhaps recognizing features that antibodies might not access, such as was 
the case with Trypanosoma above. In some instances, multiple viral targets whose 
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variability might otherwise overwhelm the immune system could be targeted by multiple 
aptamers in parallel.   
 
Aptamers against HIV 
Many viruses, such as HIV and influenza virus, generate too much variability for 
the immune system to combat either in a single infection or over an individual’s lifetime.  
Additionally, viruses such as HIV can often exist in a latent state that has, to date, proven 
nearly impossible to detect in clinical settings and therefore, hard to treat.  Reservoirs of 
these viruses often exist as extremely degenerate ‘quasispecies.’  For example 9% 
variation between Hepatitis C (HCV) virions can exist within a single host (Bukh et al., 
1995).   In the case of HIV, over the course of an infection whole populations of virus 
have shifted tropism or acquired altered traits (reviewed in (Malim and Emerman, 2001) 
The life cycle of HIV has been well characterized (reviewed in (Gomez and Hope, 
2005; Nielsen et al., 2005)).  Briefly, HIV docks onto host cells through recognition 
between its gp120 protein and the host receptor CD4.  Interaction of the gp120/gp41 
spike with a coreceptor causes a conformational shift that exposes gp41 to the cell surface 
where it can fuse with the host membrane.  The viral core is injected into the cytoplasm 
where reverse transcription converts the viral RNA genome into double-stranded DNA 
(dsDNA) via the viral protein reverse transcriptase (RT).  The viral genome transits as 
part of the pre-integration complex (PIC) to the nucleus with the aid of the viral matrix 
and vpr proteins where it inserts into the genome through the action of integrase.  
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Partially dependent on the location of integration in the genome, the virus can begin 
active expression or remain latent for several years. 
The full 9 kb transcript of the viral genome contains introns which cause the 
transcript to be spliced to yield 4 kb and 2 kb fragments.  The larger transcript fragments 
encoding for many of the virus’s structural proteins cannot be translated since it is 
continuously spliced.  The Rev protein is expressed early in the viral life cycle from the 2 
kb fragment that is able to exit into the cytoplasm.  Rev is a cytoplasmic-nuclear 
transporter that binds to a specific sequence within one of the introns of HIV, the Rev  
Responsive Element.  Binding is most specific to a 33 nt sequence within the RRE called 
the Rev Binding Element (RBE).  Rev binding prevents processing of the intron, and Rev 
mediates the transport of the full-length RNA to the cytoplasm where late proteins can be 
translated from the full transcript.  Another early expressed protein, Tat, concurrently 
upregulates transcription of the virus producing more RNA for Rev to transport.  Viral 
structural and packaging proteins are recruited to the cell membrane where virion 
components assemble and eventually bleb off through the membrane.  One of the 
proteins, the nucleocapsid, binds to a special sequence on the genome, the Psi sequence, 
and effectively shunts some viral RNA to packaging instead of translation.  
The replication of HIV has been rapid and highly successful at evading the 
immune system.  HIV currently infects over 30 million people worldwide, killing over 2 
million people each year.  While HAART (highly active anti-retroviral therapy) and other 
therapies have forestalled the onslaught of AIDS to some degree, no cure exists, and less 
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harsh treatments are much in demand.  That is, the current regimen of antiviral therapies 
used to kill the virus are also, to a lesser degree, slowly killing the host.   
Compounding the problem of aggressive treatments is the increasing development 
of resistance to conventional anti-HIV drugs.  For a number of years, therapeutic 
regimens were essentially limited to three classes of antiretrovirals:  nonnucleoside 
reverse transcriptase inhibitors (NNRTIs), nucleoside analogue reverse transcriptase 
inhibitors (NRTIs) and protease inhibitors (PIs).  These inhibitors essentially only 
addressed two targets: reverse transcriptase and protease, both of which the virus could 
readily mutate.  The hypermutability of HIV proteins has given rise to an increasing 
number of drug-resistant HIV strains (Richman, 2001).  For example, one mutation, 
K103N, can eliminate susceptibility to all three members of the NNRTIs.  Likewise, 
certain mutations eliciting resistance to one or more members of the NRTIs or the PIs 
often result in reduced susceptibility to other members of the same class (Gallant, 2000).  
It has been estimated that HIV resistance will affect 30 to 50% of all individuals 
undergoing HAART (Perrin and Telenti, 1998).  Thus, a few key mutations in the HIV 
genome may be enough to deplete a significant fraction of the current antiretroviral 
repertoire. 
But the problem of resistance is not merely an issue for patients on long-term HIV 
therapy.  Studies have shown that even newly infected individuals are carrying resistance 
genes.  In a study of 80 HIV positive patients in 1999, 16.3% carried antiretroviral 
resistance and 3.8% carried multiple drug resistance (Boden et al., 1999).  Similarly, 
Little et al. surveyed 141 patients within one year of patient seroconversion and found 
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levels of resistance in 26% of the viruses studied.  Moreover, treatment of newly infected 
patients with drug-resistant virus is increasingly less effective with slower patient 
response to treatment and quicker relapse (Little et al., 2002).  These patients must enter 
HIV therapy with significantly reduced options given the emerging resistances.   
A newer class of anti-retrovirals, the entry inhibitors, was introduced in 2004.  To 
date, resistance has not surfaced in the general population.  However, even before the 
introduction of enfuvirtide (also known as T-20, DP178 and Fuzeon; Roche), the first of 
the fusion inhibitors to be approved, a resistant variant was isolated in the laboratory, 
suggesting that resistance to this class is forthcoming (Rimsky et al., 1998).  
Another class of anti-retrovirals currently seeking FDA approval, Maraviroc 
(Pfizer), targets the human protein CCR5, an HIV coreceptor, instead of viral genes.  A 
study from 2007 demonstrated that while some laboratory strains failed to develop 
resistance to Maraviroc, six primary isolates developed high level resistance.  The 
strategies of resistance ranged from switching of coreceptor tropism to mutations in the 
envelope coding region within the virus (Westby et al., 2007).  Again, this suggests that 
resistant variants are imminent.  
Many current treatments for this highly mutable virus have sufficed in prolonging 
the lives of afflicted individuals.  But no single treatment has yet overcome the problem 
of viral heterogeneity.  Especially because of problems with drug resistance, aptamers 
may be of particular use in the development of anti-HIV therapies.  There are several 
rationales for why the use of aptamers as therapeutic agents may slow or even eliminate 
the development of viral resistance: 
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1. Aptamers may be raised against a wide range of viral targets.  Attacking 
multiple targets in parallel should substantially reduce the probability that a 
resistant virus will arise, since each target must acquire an independent set of 
mutants.  This is, of course, the strategy that has already been utilized in triple 
drug therapies to partially manage the ravages of HIV. To generate barriers 
against mutation, multiple drugs can be administered serially or in parallel as 
combination therapies.  However, each new organic drug introduced into an 
individual must be separately advanced through clinical trials, and then tested 
for cross-reactivity with the other, equally idiosyncratic therapeutics.  A great 
advantage of aptamers is that their salient pharmacokinetic characteristics are 
likely to be uniform, and thus the development of combination therapies may 
prove to be as simple as the generation of a new aptamer against a different 
viral epitope or target.  Such combination therapies could potentially involve 
aptamers that targeted all phases of a viral life cycle.  One set of aptamers 
could be directed against specific extracellular epitopes that might otherwise 
be shielded from the significantly larger components of the immune system.  
Another set of aptamers against intracellular targets could potentially address 
the treatment of latent reservoirs, such as those seen with HIV.  
 
2. Aptamer therapeutics may be more ‘resistant to resistance’ than conventional 
drugs.  Aptamers occupy a larger surface area of a protein than a conventional 
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drug.  Thus, a single mutation in a protein could have a proportionately smaller 
effect on an aptamer than on a small organic drug.  Even when mutations that 
reduce binding may arise, the fact that aptamers frequently bind to critical and 
multiple sites on proteins may mean that these mutations lead to reduced viral 
fitness.  This has been nicely highlighted by work from the Prasad lab which 
isolated mutant reverse transcriptases (RTs) capable of resisting an anti-RT 
aptamer.  A single mutation on the protein conferred mild resistance to the 
aptamer while multiple mutations generated higher levels of resistance.  
Regardless, in both isolates, the mutations lay close to the minor groove 
binding track of RT and significantly reduced viral fitness in culture.  Viruses 
harboring the resistant RTs were significantly less capable of replication and 
showed no detectable infectivity after three weeks in tissue culture (Fisher et 
al., 2002).  In other words, in order to ‘resist’ the aptamer, the virus had to 
severely compromise its own integrity. 
 
3. It is likely that more, and more diverse, aptamers can be raised against a given 
target than is the case for conventional pharmaceuticals.  That is, multiple 
aptamers could be used against a single protein binding to different epitopes 
such that mutants that eliminate binding of one aptamer may not inhibit 
binding of another aptamer.  Additionally, selections could be performed on 
known mutants of viral proteins to remain a step ahead of the virus.  That is, 
along with aptamers against a given protein, aptamers that recognizes the 
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common mutants could also be administered to preemptively stall them as they 
arise. 
 
4. Very importantly, aptamers have not demonstrated toxicity in vivo, an 
important factor to consider in immunocompromised patients.   
 
 Because of their potential against HIV, some of the earliest antiviral aptamers 
were directed against HIV.  Aptamers have been selected against a number of HIV 
proteins including:  reverse transcriptase (RT) (Burke et al., 1996; Tuerk et al., 1992),  
Rev (Giver et al., 1993a; Giver et al., 1993b), Tat (Yamamoto et al., 2000), gp120 (Sayer 
et al., 2002), integrase (Int) (Allen et al., 1995) and the nucleocapsid (NC) (Berglund et 
al., 1997)(for review see (Joshi et al., 2003)).  Most of these aptamers have also shown 
antiviral efficacy in infected tissue culture cells.  For example, anti-RT aptamers were 
able to reduce HIV infectivity 90 – 99.5%  in 293T cells (Joshi and Prasad, 2002).  Anti-
Rev aptamers have been shown to effectively subdue HIV infection in several tissue 
culture lines (Good et al., 1997; Konopka et al., 1998; Konopka et al., 2000). In an 
experiment that presages gene therapy, an anti-Rev aptamer expression construct was 
transduced into CD34(+) cells and the differentiated cells were significantly more 
resistant to HIV infection than control cells (Bai et al., 2002).   
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Aptamers against other viruses 
Aptamers have also been raised against a number of other viral and pathogen 
proteins.  Aptamers raised against the NS3 protein from Hepatitis C Virus (HCV) 
inhibited protease activity in vitro by up to 90% (Fukuda et al., 1997; Fukuda et al., 2000; 
Kumar et al., 1997; Urvil et al., 1997).  The group further engineered their anti-NS3 
aptamers to bolster their expression levels and efficacy in tissue culture, and thereby their 
potential therapeutic utility.  Aptamers were cloned into stem IV of the Hepatitis delta 
virus (HDV) ribozyme, and HDV-aptamers chimeras were expressed as concatamers 
from a chicken beta-globin (CAG) promoter.  An additional HDV ribozyme was later 
added to the 3’ end of the aptamer construct to remove 3’ poly(A) sequences.  In 
principle, the cis-acting HDV ribozymes should cleave away the aptamers from the body 
of the mRNA to ensure unencumbered folding. The HDV-aptamer constructs inhibited 
NS3 protease activity by up to 50% in tissue cultured liver cells; inhibition increased 
proportionately to the number of concatamers expressed (Nishikawa et al., 2003).   
More recently, Fukuda et al. appended a poly-14-U tail to the 3’ end of a 
minimized version of their NS3 protease aptamer (Fukuda et al., 2004; Fukuda et al., 
2000).  Such poly(U) sequences had previously been shown to bind to the helicase 
portion of NS3 (Kanai et al., 1995).  The resulting construct demonstrated stronger 
inhibition of both protease and helicase activity than either of the single components.  
The aptamers maintained their specificity and inhibitory effect while tolerating 
modifications to their 3’ ends, again demonstrating the extremely adaptable nature of 
aptamer drugs relative to organic reagents or antibodies.   
 25 
Aptamers have also been selected against a conserved internal ribosome entry site 
(IRES) in the 5’ UTR of HCV (Aldaz-Carroll et al., 2002; Kikuchi et al., 2003).  
Biotinylated DNA probes complementary to a small section of domain II of the IRES 
were tethered to streptdavidin beads on a surface.  An RNA pool was then incubated with 
the probe-bound domain II, and unbound species were washed away.  Binding of each 
round was monitored in real-time using surface plasmon resonance.  The best binders 
were in the low nM range and inhibited in vitro IRES-dependent translation (Kikuchi et 
al., 2003).   
Based on this body of work alone, an anti-HCV intramer therapy could be 
envisioned that targeted three separate viral activities (protease, helicase, and IRES), and 
that might be included on a single, internally processed transcript. 
Another prominent virus, the influenza virus, has been a target for aptamer 
selection.  Influenza presents two important membrane surface glycoproteins that can be 
targeted by the immune system, hemagglutinin (HA) and neuraminidase (N), 
combinations of which are sometimes phenotypically unpredictable and often baffle the 
immune system.  HA plays a key role in initiating infection and is highly variable.  The 
receptor binding site is relatively conserved; however, it resides within a pocket that is 
not likely exposed to the immune system (Hilleman, 2002; Jeon et al., 2002).  Therefore, 
vaccines are directed against the variable portions of the surface proteins and must be 
adjusted each year.  Aptamers were selected that could access this receptor-binding 
pocket.  Jeon et al. identified a conserved peptide segment (HA91-261) of the receptor 
binding site in HA which, though not normally exposed on the virus, could readily elicit 
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immune response when cloned and expressed in mice as a peptide.  DNA aptamers were 
selected against the HA peptide.  At 50 pM, the anti-peptide aptamers were able to reduce 
mortality of tissue culture cells infected with 500 TCID50 by 80%.  In mouse studies, 
aptamers (125 pmole/mouse) were introduced intranasally one day before, the day of, or 
two days after infection w/ 2,500 TCID50 influenza virus.  Over two weeks, the body 
weights of the infected mice were monitored.  Untreated mice lost about 20% of their 
body weight while treated mice displayed minimal weight loss and showed faster 
recovery.  Histological examination of lung tissue also showed that lung viral titer was 
1.2 log lower in mice treated before or after infection and 2.4 log lower in mice treated 
with aptamers coincident with infection.  In other words, aptamers were able to inhibit 
infection both therapeutically and prophylactically.  Importantly, aptamers were able to 
inhibit three different strains of the virus (Jeon et al., 2004).   
Aptamers have also been selected against whole viruses, circumventing the need 
to identify or purify individual proteins, and providing a more native context for target 
recognition.  In an early demonstration of this, aptamers were selected against whole 
Rous Sarcoma Virus (RSV).  Treatment of RSV with 20 nM of the selected aptamer 
reduced viral protein production in infected quail cells by ~90%, while 160 nM aptamer 
obliterated protein expression.  Selected aptamers were able to completely neutralize 
RSV particles without adverse effects on the host cell.  At higher concentrations (15-20 
fold), the aptamers were also able to inhibit a different strain of RSV whose surface 
glycoprotein shared ~95% homology with the strain used in the selections (Pan et al., 
1995). 
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Aptamers have also been selected against human cytomegalovirus (HCMV).  A 
number of high-affinity aptamers were isolated from the selection, but only a few 
families proved useful in treating HCMV infection.  Since the surface proteins of HCMV 
have not been fully characterized, those aptamers not inhibiting HCMV may represent 
aptamers binding to other surface proteins not involved in receptor recognition or 
infection.  When HCMV was treated with either of two aptamers, L13 or L19, and then 
applied to human foreskin fibroblasts, the viral titer was significantly reduced.  An IC50 
of approximately 100 nM and 35 nM was observed for L13 and L19, respectively.  As 
with the anti-RSV aptamers, the anti-HCMV aptamers were added to the virus prior to 
infection.  The two anti-CMV aptamers did not compete for binding, suggesting that they 
acted at different sites on the virus.  Crosslinking experiments showed that the aptamers 
bound to gB and gH, two HCMV surface glycoproteins important for viral entry and 
infection.  While the aptamers were able to inhibit two different strains of HCMV, 
inhibition was specific for HCMV, as the aptamers had no effect on herpes simplex virus-
1 (HSV1) which displays homologous gB and gH proteins (Wang et al., 2000). 
 
 
TRANSITIONING APTAMERS INTO CLINICAL USE 
 
In principle, aptamers may be particularly well suited as drugs.  However, most of 
the work described above has been performed in vitro or tested in tissue culture cells.  
While the in vitro selection of aptamers has been an established technology for almost 
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two decades, its utility has principally been for the study of proteins and mechanisms in 
vitro.  The use of aptamers as drugs has been forestalled in part by issues relating to 
delivery, stability, and pharmacokinetics.  While the literature is fraught with aptamers 
selected against medically relevant targets, many of them would have a difficult time 
actually reaching their targets in vivo.  To make full use of aptamers as therapeutics, 
aptamers that were originally selected in vitro must be adapted to function as effectively 
in vivo.     
Some of the most relevant considerations include how to appropriately deliver 
aptamers into the body or into cells, how to protect aptamers against degradation, how to 
target aptamers to therapeutically relevant sites, and how to maintain or control aptamer 
activity or expression.  In considering these issues, aptamer therapeutics can be thought 
of in two ways:  as exogenously delivered drugs and as endogenously delivered gene 
therapies (or ‘intramers’).  It should be noted that while exogenous therapeutics will 
typically target circulating or cell surface proteins and endogenous therapeutics will 
conversely target intracellular proteins, these concepts are not mutually exclusive, and 
there is no reason that such therapies could not be used together, especially against 
particularly intractable targets, such as viruses. 
 
Exogenous delivery 
Finding appropriate means to deliver aptamers may be one of the largest obstacles 
to developing aptamers to become therapeutics.  Current efforts to deliver aptamers to 
animal models or patients typically require injection or surgical implantation.  While 
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exogenous aptamer delivery is still in its infancy, a variety of nucleic acids have been 
introduced into human and animal systems by subcutaneous (s.c.; under the skin), 
intravenous (i.v.; into the bloodstream) intraperitoneal (i.p.; into the abdomen), 
intravitreal (i.v.t.; into the eye) injection, by inhalation or as direct injections into muscle 
or tissue.   
 
Delivery by injection 
The easiest delivery method relies on simple injection followed by passive 
transfer into the appropriate tissues; that is, subcutaneous (s.c.), i.p. or direct bolus 
injections.  Nucleic acids delivered this way can ultimately enter the bloodstream or be 
taken up by nearby cells.  As an example, a DNA template that contained the β-
galactosidase gene was introduced using a pressure-based injector.  DNA was found in 
cells up to 2 cm away from the injection site, and beta-galactosidase expression was also 
seen (Furth et al., 1995).   
However, one disadvantage of s.c., i.p. and direct administration is the vast 
quanitity of sample needed.  Liu et al. have demonstrated that volumes of plasmid DNA 
even larger than conventionally used and injected at a faster rate was needed for better 
expression and DNA stability.  Ten micrograms of a luciferase expression plasmid in 
different volumes of saline were injected into mice to determine parameters for optimal 
expression of exogenous delivery of DNAs.  The authors found that a volume of between 
80 - 120 mL/kg (e.g. 3 mL plasmid DNA into 30g mice) gave the highest levels of 
expression, with expression predominately in the liver and, to a much smaller degree, in 
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the kidney, spleen, heart, and lung.  Luciferase expression was also significantly higher 
when the solution was administered within 5 sec compared to 30 sec.  Expression levels 
peaked at 8 hrs and declined over the course of several days.  Repeated administration 
reproduced the same expression trends suggesting that subsequent dosing of exogenously 
delivered genes can make up for lack of long-term expression.  However, at the volumes 
used in these experiments, the injected solution nears the volume of blood in the mice; a 
proportionately large volume for a human injectable might limit clinical applications.  In 
addition, while weight and most biochemical markers remained within a normal range 
over 7 days, alanine aminotransferase (ALT), an enzyme predominantly found in the liver 
and that is often associated with liver damage, did rise drastically on the first day of 
injection, but returned to normal within three days (Liu et al., 1999).   
Delivery of aptamers in this manner has demonstrated systemic effects.  Anti-
PDGF aptamers hold potential as prophylactics and therapeutics for angioplasty, heart 
bypass or other injury to vessel lumen.  An anti-PDGF aptamer was administered 
intraperitoneally to rats before and after vessel injury and inhibited generalized vessel 
stress response.  A 50% reduction in lesion size at 2 weeks was observed in this study 
involving 134 animals.  Unfortunately, after treatment ended, benefit was lost and vessel 
lesions worsened (Leppanen et al., 2000).   
Alternatively, aptamers may be delivered intravenously (i.v.).  Delivery by i.v. 
versus s.c. has the advantages of quick introduction of high concentrations of a 
therapeutic into the bloodstream and rapid clearance from the bloodstream which may be 
preferrable in some applications.   For example, for the inhibition of thrombin, a plasma 
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clotting enzyme, effects need to be rapid.  Several anti-thrombin aptamers were selected 
from an N60 random DNA pool.  A 15mer truncated version of one aptamer bound with 
a Kd of approximately 100 nM and increased clotting of fibrinogen almost 7-fold from 25 
sec to 169 sec (Bock et al., 1992).  The aptamer  was introduced intravenously during 
canine heart surgery to prevent clotting.  At a minimum dosage of 0.5 mg/kg/min, 
clotting time rose from 106 sec before treatment to 187 sec after infusion began and 
ultimately reached a blood concentration of 11.4 µM.  The aptamer matched heparin anti-
clogging capabilities during surgery.  No gross differences were seen between animals 
treated with heparin compared to those treated with aptamer, and wounds clotted 
normally after surgery.  Interestingly, aptamer half-life was approximately 2 min before 
and shortly after surgery, but rose to almost 8 minutes during surgery, presumably 
because blood had been diverted to a heart-lung machine, and organs could not remove 
the aptamers from circulation.  The relatively quick clearance after and not during 
surgery meant no further treatment was necessary to remove the effects of the aptamer 
once surgery was over.  The aptamers had no apparent toxicity allowing for a much 
broader therapeutic window, unlike heparin, which must be constantly monitored during 
infusion and which requires antagonists to counteract (DeAnda et al., 1994).   
Given some of the problems surrounding systemic delivery, injections at a 
specific site of action may be best suited for the delivery of nucleic acid aptamers.  In this 
regard, anti-hNE aptamers have been shown to provide localized protection.  hNE is a 
serine protease that participates in degradation of targets in response to various cellular 
signals.  However, uncontrolled or mis-expression of hNE leads to self-proteolytic 
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processes that contribute to vascular breakdown in diseases such as emphysema, cystic 
fibrosis, acute respiratory distress syndrome and others.  A model for rat lung injury can 
be induced by intrapulmonary application of anti-BSA IgG followed by BSA.  The 
subsequent immune reaction causes lung leakage and hemorrhage, and the level of injury 
can be correlated to level of lung vascular permeability as measured by leakage of 125I-
labelled BSA administered into the bloodstream.  In injured rat lung, instillation of an 
anti-hNE aptamer, NX21909, directly into the intratracheal space inhibited permeability 
in a dose-dependent manner.  At the highest dosage tested (40 nmol), permeability was 
reduced by 38%.  By contrast, 200 nmol of a recombinant protein inhibitor, secretory 
leukocyte protease inhibitor (SLPI), reduced permeability by 54%.  The degree of lung 
injury can also be inferred by measuring the content of lung myeloperoxidase (MPO), an 
enzyme often associated with inflammation.  NX21909 reduced MPO by 53% compared 
to 37% by SLPI (Bless et al., 1997).  
 As another example of direct injection, intravitreal administration has become 
popular, as the eye is easily administered to and provides an isolated in vivo site for 
testing.  The anti-VEGF aptamer EYE001 is perhaps the most advanced example of an 
aptamer therapeutic.  When injected into the vitreous humor of rhesus monkeys, EYE001 
was detectable and intact 28 days later (Drolet et al., 2000).  Studies to determine the 
pharmokinetic profile of the delivered aptamer, and ultimately to define safe human 
dosages, used 0.25 – 2.0 mg/eye in a single bilateral dose in addition to biweekly bilateral 
dosage.  Administered in bolus, no toxic effects were observed and no antibody response 
was elicited in the animals.  Anti-VEGF aptamers have been approved by the FDA and 
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are delivered directly into the intravitreal space in the eye to control neovascularization 
that can lead to diseases like macular degeneration.  During its Phase II clinical trials, 
87.5% of patients receiving the aptamer showed stabilized or improved vision three 
months after aptamer treatment without adverse drug side effects (2003).  
 
Other physical methods  
 Additional methods of delivery range from physical manipulation of individual 
cells to surgical implantation in a tissue.  Aptamers can be directly introduced into cells 
by microinjection; aptamer-treated cells with particular phenotypes could subsequently 
be expanded or even xenografted into an organism.  In one example, an anti-E2F aptamer 
was directly injected to fibroblasts in vitro and inhibition of cell proliferation was 
observed (Ishizaki et al., 1996).  Microinjection was a particularly good delivery 
technique for this particular aptamer because of its relatively high Kd (10^-7 M); it is 
likely that high doses of aptamer would have been required to elicit a similar effect if it 
was passively delivered.   
 Introduction or implantation of drug delivery devices is a field unto itself, and it is 
unsurprising that aptamers can be similarly administered using these technologies.  In a 
particularly innovative physical method exploiting microspheres, an anti-VEGF aptamer 
was released to cornea tissue in vivo.  Poly(lactic-co-glycolic)acid (PLGA) microspheres 
containing anti-VEGF RNA aptamer (EYE001) were non-invasively placed on harvested 
rabbit sclera and were shown to release aptamer in a controlled and sustainable manner.  
The aptamer-PLGA microspheres demonstrated pronounced inhibition of proliferation 
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over 20 days (Carrasquillo et al., 2003).  While these studies were performed in vitro, this 
system aspires to replace the current regimen of intravitreal injections (2003).   
 Another eye tissue study employed aptamers for inhibition of bFGF-mediated 
angiogenesis in the cornea.  The 2’-fluoro modified RNA Ang2 aptamer was shown to 
inhibit neovascularization when surgically implanted into live rat cornea.  “Slow-release” 
polymer/sucrose pellets were used to deliver the aptamer in a controlled fashion.  In the 
aptamer-treated group, up to 40% reduction in neovascular development was observed.  
These studies have helped to clarify the role of Ang2 in vivo, and have also identified an 
additional target for antiangiogenesis therapies (White et al., 2003). 
 Additionally, it may be even possible that aptamers could be delivered orally or 
intranasally, as was the case with anti-influenza aptamers above.  The in vivo stability of 
an orally administered "hybrid oligo" 25mer was examined.  A 35S-labeled 
phosphorothioate oligonucleotide with stabilizing 2'-O-methyl-oligoribonucleotides 
present at both 3' and 5' ends was orally delivered at a dose of 50 mg/kg to rats and was 
found to be present in the gut up to 6 hours later.  Absorbed through the GI tract, intact 
oligonucleotide was detected in plasma and various tissues, while degradation products 
predominated in urine (Agrawal et al., 1995). 
 
Aptamer stabilization and pharmacokinetics 
 A major caveat of exogenously delivering aptamers is that unmodified RNA and 
DNA can begin degrading in serum within minutes.  A number of nucleic acid 
modifications have been introduced over the years to stabilize nucleic acids for in vivo 
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applications including the use of modified bases, phosphorothioate linkages, peptide 
backbones, DNA/RNA chimeras, and Spiegelmers (reviewed in (Brody and Gold, 2000; 
Cerchia et al., 2002; Famulok and Mayer, 1999).  In one example, Jellinek et al. showed 
that 2’-aminopyrimidine-modified RNA can remain relatively stable for days.  Similarly, 
Pieken et al. showed that incorporating 2’-fluoropyrimidine or 2’ aminopyrimidine 
modifications into a hammerhead ribozyme increased its stability in serum greater than 
1000-fold (Jellinek et al., 1995).  Modifications can also be appended to the ends of 
aptamers to confer greater stability.  A 3’-3’ linkage, for example, can be added to 
prevent 3’ exonuclease degradation (reviewed in (Brody and Gold, 2000).  
 Modified residues can be introduced during either enzymatic or chemical 
synthesis, or can be added post-transcriptionally.  Commercial transcription kits are also 
available that can incorporate modified bases into a transcript making the production of 
stabilized aptamers much more practical.  Modified polymerases that can accommodate 
the modified residues are now commercially produced, and a selection scheme has been 
reported that yielded a T7 polymerase capable of incorporating three of the four 2’-O-
methyl NTPs (Chelliserrykattil and Ellington, 2004).  
 Recently, the Famulok group was able to transfect HeLa cells with an aptamer 
against the N-terminal segment of cytohesin-2 with the transfection reagent, Metafectene.  
Interestingly, the RNA aptamer was not modified or otherwise protected.  Their assays 
were able to detect the presence of the aptamer in cells for up to 6 hr post-transfection.  
This is perhaps the first example of an unprotected aptamer directly transfected into cells 
(Theis et al., 2004). 
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 While chemical modifications may lead to aptamers that are not as readily 
degraded, this does not solve the problem of physiological clearance from the blood.  Lee 
et al. found the average initial half-life of a DNA 15-mer introduced into cynomolgus 
monkeys by constant infusion (at 0.1, 0.3 or 0.5 mg/kg/min) or bolus injection (at 11.25 
or 22.5 mg/kg) was just 1.4 minutes (Lee et al., 1995b).  Several groups have found that 
the rate of nucleic acid clearance could be reduced by generating high molecular weight 
conjugates.   Tucker et al. and others have attached 40 kD polyethylene glycol (PEG) 
moieties to the ends of the anti-VEGF aptamer, EYE001, and subsequently extended 
aptamer half-life to 9.3 h after I.V. administration (Tucker et al., 1999; Watson et al., 
2000).  Dougan et al. attached biotin to the 3’ ends of anti-thrombin aptamers and showed 
a reduction in degradation.  However, clearance from rabbit and mouse bloodstreams was 
not affected.  Further appending streptavidin to the aptamers’ termini extended the 
lifetime of the biotinylated anti-thrombin aptamers by10 to 20-fold (Dougan et al., 2000).  
Attaching lipids to aptamer ends has also been shown to extend plasma lifetime (de Smidt 
et al., 1991; Willis et al., 1998).  In the case of controlled release of an anti-VEGF 
aptamer from PLGA microspheres, it was determined that initial co-lyophilization of the 
aptamer with trehalose before encapsulation allowed slow and steady release of the 
aptamer (2 microgram/day) over the course of 20 days in vitro.  The released aptamers 
were able to inhibit proliferation of cultured human umbilical vein endothelial cells.  
PLGA-aptamer conjugates were delivered directly into rabbit sclera, and their timed 
release over 6 days was shown to be comparable to that observed in the in vitro studies 
(Carrasquillo et al., 2003). 
 37 
Controlling aptamer dosage: 
 As aptamers move further toward use in vivo, being able to control the ‘dosage’ 
of aptamer therapies may be more important.  Even though aptamers have so far shown 
little or no toxicity, it may nonetheless be useful to shut off or modulate the effects of an 
aptamer. 
 Aptamer levels in the blood may be controlled simply by further understanding 
clearance and distribution parameters and modulating aptamer dosage appropriately.  In 
the anti-VEGF aptamer administration mentioned above, Tucker et al. administered 1 
mg/kg of a stabilized anti-VEGF aptamer into rhesus monkey either subcutaneously (s.c.) 
or intravenously (i.v.).  At time zero, plasma concentration was 25.5 µg/mL in i.v.-treated 
animals and only about 0.1 µg/mL in animals receiving aptamers s.c..  Eight to twelve hrs 
after administration, though, animals in both treatment groups had reached a plasma 
concentration of approximately 5 µg/mL.  Elimination half-life was 9.3 hrs for i.v.-
administrated aptamers and 12 hrs for s.c.-administered aptamers (Tucker et al., 1999).  
Initial high plasma concentrations can therefore be best achieved by i.v. administration.  
However, aptamers showed slightly longer duration of circulation with s.c. 
administration.    
 In the case where anti-thrombin aptamers were used as anticoagulants (see 
above), the Sullenger group developed an antisense ‘antidote' to quickly neutralize the 
aptamer, if necessary.   Human plasma was treated with aptamers, then with ‘antidote’ 
oligonucleotides complementary to the aptamer sequence.  Reversal of the aptamer anti-
clotting effect was seen within 10 min (Rusconi et al., 2002).  This response time is 
 38 
comparable to the protamine treatment typically used to reverse the effects of the more 
commonly used anticoagulant, heparin.  Protamine, though, has been known to trigger 
immune responses in some patients, and an overdose of protamine can actually lead to 
more excessive bleeding (reviewed in (Porsche and Brenner, 1999).   
More recently, Rusconi et al. demonstrated the efficacy of their antidotes in vivo.  
A cholesterol moiety was appended to an anti-factor IXa aptamer (Ch-9.3t) and increased 
the aptamer’s half-life in the porcine bloodstream to 1-1.5 hr, relative to 5-10 min for the 
unconjugated aptamer.  The cholesterol modified aptamer had anticoagulant properties 
similar to the unconjugated aptamer, and increased the activated clot time by 73.5 sec.  A 
bolus injection (5 mg/kg) of an antidote oligonucleotide, 5-2C, then reduced the 
anticoagulant effects of the aptamer by 95% over 10 min.   
 
Targeted delivery 
 A crucial consideration in drug design is how to direct therapies to diseased or 
appropriate sites.  By honing treatment to only the cells that require it, systemic and side 
effects would be reduced as well as the amount of drug required for an effect.  A number 
of different strategies have been investigated in an effort to tackle this problem.   
Antibodies directed against cell-specific receptors and markers have been used to 
direct cargos to specific sites.  For example, the Lieberman group made fusions of an 
anti-Env antibody fused to protamine to deliver siRNAs specifically to env-expressing 
cells.  Anti-gag siRNA delivered in this manner was able to reduce infection in primary 
T-cells by 50%.  The group went on to demonstrate the uptake of their complexes into 
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grafted env-expressing tumor cells and the reduction of tumor growth when anti-
oncogenic siRNAs were delivered.  Importantly, they reported that their siRNAs did not 
trigger any interferon response (Song et al., 2005). 
The transferrin receptor is another very promising target, particularly as 
antibodies against the transferrin receptor, such as OX26, localize well to the brain 
(Bickel et al., 2001; Moos and Morgan, 2001).  In a demonstration of specific and 
targeted delivery, Xia et al. made use of the transferrin receptor (TfR) to deliver 
therapeutics genes into rat brains.  Glial-derived neurotophic factor (GDNF) has shown 
utility for treating Parkinson’s disease.  However, the protein is too large to cross the 
blood-brain barrier, and administration has relied on direct injection of the protein itself 
into the brain or within the context of a viral vector.  Xia et al. cloned the gene for GDNF 
into an expression plasmid, encapsulated the plasmid within a PEGylated liposomal 
complex attached to an anti-rat-TfR monoclonal antibody and the complex was 
administered by a single i.v. injection 2 weeks after experimental Parkinson’s disease was 
induced in rats.  Expression of GDNF was significantly increased within 24 hr.  
Importantly, the GDNF was cloned behind the tyrosine hydroxylase promoter, which 
restricts expression to specific cells that secrete catecholamines.  As such, expression of 
GDNF was restricted to parts of the brain, the liver and the adrenal gland.  A rat 
behavioral test based on apomorphine induction of rotation was used as an indictor of 
Parkinson’s-like effects.  Rat behavior was followed for up to 42 days after treatment.  A 
dose-dependent reduction in abnormal rotation behavior was seen in rats treated with 
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GDNF (Xia et al., 2008).  The group has also used this system to deliver siRNA to the rat 
brain (Xia et al., 2007) and the GUSB gene into mice brain (Zhang et al., 2008). 
Aside from antibodies, the small molecule ligands of receptors themselves have 
been used for targeted delivery.  Again, the transferrin:TfR pair has been a leader in this 
area (for a comprehensive review, see (Qian et al., 2002).  This pair has been used to 
deliver toxins, small molecule drugs, siRNA, labeling agents and even genes. 
Another model receptor for targeted delivery is the folate receptor (FR).  Like 
TfR, antibodies against FR as well as folic acid itself have been used for a variety of 
delivery functions.  Because of its prevalence on certain types of cancers, FR-mediated 
delivery may prove very important, and FR conjugates have been widely used to localize 
imaging agents (reviewed in (Sudimack and Lee, 2000). 
Along this same path, aptamers may be particularly useful in this area.  They are 
like antibodies in that they can recognize specific cell surface ligands and may, therefore, 
mediate delivery in a similar manner.  Aside from the anti-PSMA aptamers selected by 
Lupold et al., which has already demonstrated delivery of different cargos (Chu et al., 
2006a; Chu et al., 2006b; Farokhzad et al., 2006; Farokhzad et al., 2004; McNamara et 
al., 2006), other aptamer-mediated deliveries have been reported.  Similar to the PSMA-
mediated delivery of siRNA, the Rossi Lab has appended anti-Tat siRNA to an anti-
gp120 aptamer sequence.  These chimeras were specifically taken up by gp120-
expressing cells.  Moreover viral replication in CEM cells was significantly reduced in 
cells treated with the chimeras compared to buffer alone.  Interestingly, even though the 
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aptamer had been selected against a CCR5-tropic virus, in these experiments, the aptamer 
functioned with a CXCR4-tropic virus (Zhou et al., 2007). 
Guo et al. made use of anti-CD4 aptamers and unique chimeric RNA scaffolds for 
delivery.  The packaging RNA (pRNA) from φ29 bacteriophage normally forms a 
hexamer ring from 3 sets of dimers that directs viral DNA into its capsid.  Guo et al. were 
able to use the dimer of pRNA to form the basis for delivery particles.  As one example, a 
chimera created with the pRNA dimer, an anti-CD4 aptamer and siRNA effectively 
delivered siRNA specifically to CD4-expressing lymphocytes (Guo et al., 2005). 
Given the rapidly expanding number of aptamers, several other potential targeting 
aptamers may soon emerge.  For example, the Ellington Lab is currently undertaking 
aptamers against TfR, which should be applicable for the same delivery purposes that the 
TfR antibody has achieved.   
 
Endogenous delivery 
 While aptamers can be introduced locally or systemically to antagonize the 
function of extracellular targets, endogenous delivery or gene therapy approaches may 
prove useful for modulating the activities of intracellular targets.  So-called ‘intramer’ 
therapies would involve continuous expression of a therapeutic aptamer within a cell.  
However, efficiently delivering aptamers into cells remains a prominent challenge.  
Research has so far focused on developing vectors or vehicles that can efficiently enter 
cells, express high levels of aptamers, and remain non-toxic. 
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Cellular transduction 
 To advance intramer or gene therapies, a number of different strategies have been 
pioneered to deliver aptamer expression cassettes directly into cells.  Amongst the most 
popular have been viral vectors, which have the advantage of being both delivery 
mechanisms and expression cassettes.  Over the years, viral vectors have been radically 
modified to better regulate expression levels, localize transcripts, and transfect different 
types of cells.  The different types, advantages, disadvantages, and uses of viral vectors 
have been extensively discussed (reviewed in (Robbins et al., 1998; Walther and Stein, 
2000).  Viral vectors have been commonly used in tissue culture systems; however, 
safety issues remain a significant concern when applied to humans.  Retroviruses, for 
example, could potentially integrate into undesirable locations in the host genome 
causing insertion mutations.  They could also recombine with naturally occurring or 
endogenous retroviruses to regain function, or worse, give rise to a novel virus.   
 Different approaches have been applied to reduce safety concerns, including the 
removal of key genes involved in pathogenicity.  For example, retroviruses generally 
consist of three major structural genes (gag, pol and env) flanked by 5’ and 3’ LTRs.  
These genes give rise to proteins necessary for infection, reverse transcriptase, 
integration, and packaging.  In the simplest class of retroviral vectors, therapeutic 
constructs are cloned into a provirus in which all the genes involved in packaging and 
budding have been removed from the viral genome.  The provirus is transfected into a 
packaging cell line which provides all the necessary proteins in trans to make complete 
viruses.  Viruses can thereby be generated that can only infect and integrate once.  An 
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intramer construct could potentially be expressed from the viral LTR or internally cloned 
promoters.  
 Viral delivery was used by Bai et al. to test the safety of anti-HIV nucleic acids.  
These authors cloned an anti-HIV aptamer and anti-HIV ribozymes into a Gag- and Pol-
deficient Moloney murine leukemia virus (MMLV) backbone.  The vector was 
transfected into 293T packaging cells stably expressing Gag and Pol genes, and product 
virus was used to transduce human CD34(+) cells.  Expression of the small nucleic acids 
did not affect CD34(+) growth and differentiation in SCID-hu mice.  Moreover, cells 
transduced with the antiviral constructs showed marked resistance to the early stages of 
HIV infection (12 days).  Later timepoints still showed some resistance, although it was 
not as pronounced.  Interestingly, only a small fraction of the treated cells, likely a 
dividing sub-population, were stably transduced but were nonetheless able to expand and 
confer long-term prophylactic effects.  By using a lentiviral vector which could infect 
non-dividing cells even greater transfection efficiencies and anti-viral efficacies might be 
achieved (Bai et al., 2002).          
 
Cellular  transfection  
 Although efforts have been made to inactivate viral vectors, and next generation 
vectors are likely significantly safer, there remains the fear that any viral preparation that 
will be used for gene delivery may still contain replication competent virus.  Plasmids 
eliminate the safety concerns associated with viruses and have somewhat greater 
flexibility of design.  However, finding an efficient means to deliver plasmids has been a 
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challenge.  Cells, particularly muscle and skin, have been shown to readily take up 
nucleic acids delivered in their proximity, but the mechanism is unknown and gene 
expression is typically short-lived.   
 The most popular vehicles for the delivery of plasmid or other expression vectors 
are lipid amalgams, particularly cationic lipids (reviewed in (Li and Huang, 2000; 
Torchilin et al., 2002; Tranchant et al., 2004).  The lipids interact to form liposomes, and 
the positively charged head group can hold tightly to negatively charged nucleic acids.  
Following endocytosis, the nucleic acids can be released within the host cell.   
 Liposomes offer a quick and efficient means of delivering genes into tissue 
culture cells and ex vivo systems but have not demonstrated the same success in humans.  
Liposomal delivery into animals and humans has been relatively inefficient, unstable and, 
in some cases, cytotoxic compared to viral-mediated delivery.  Studies have shown that 
liposomes are rapidly cleared, readily disrupted under physiological conditions, or 
otherwise neutralized by endogenous factors (reviewed in (Kumar et al., 2003; Miller, 
2003; Tranchant et al., 2004).  
 Even so, lipids have been used for gene delivery in clinical trials (Caplen et al., 
1995; Nabel et al., 1993; Stopeck et al., 1997) and have shown great promise when 
optimized formulations are used or when combined with other delivery techniques.  
Adding PEG moieties, for example, has helped to stabilize liposomal complexes 
(lipoplexes), both in terms of resistance to inactivation and longer circulation times.  For 
example, methoxypolyethylene glycol-conjugated liposomes circulate on the order of 
hours, compared to minutes for non-conjugated liposomes (reviewed in (Moghimi and 
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Szebeni, 2003).  Nicolazzi et al. investigated differently charged PEG-lipid formulations 
and showed that a bi-anionic PEG-lipid complex increased circulating lipoplex 
concentrations by 5- to 7-fold 30 min after injection into mice (Nicolazzi et al., 2003).  
Ultimately, by using different sized PEGs and altering the charge or chemistry of the 
PEGylated complexes it has proven possible to craft ‘stealth liposomes’ that stabilize the 
complex, prevent neutralizing interactions, and evade immune responses (reviewed in 
(Moghimi and Szebeni, 2003).  However, the length and charge of PEGylated liposomal 
complexes can affect transfection efficiency, and thus these affects must be balanced in 
any given formulation (reviewed in (Li and Ma, 2001; Pedroso de Lima et al., 2003; 
Zuhorn and Hoekstra, 2002). The chemistry surrounding PEG moieties is exceptionally 
versatile.  PEG conjugates can be prepared which are chemically cleavable or 
biodegradable, and can therefore better release genes after entry into the cell.  Targeting 
sequences or signals can be readily appended to PEG, and the resultant nucleic acid 
complexes have been used to target expression vectors to tumor endothelium cells and 
lung cells (reviewed in (Audouy and Hoekstra, 2001; Kumar et al., 2003). 
 Lipoplexes have also been modified with peptides to confer stability, enhanced 
uptake into cells or nuclear localization of genes (reviewed in (Duzgunes et al., 2003).  
Attachment of the plasma iron transporter, transferrin, to lipoplexes has been shown to 
increase endocytosis of liposomes and generally increased transfection efficiency.  
Similarly, treating lipoplexes with poly-lysine or protamine sulfate can also increase 
transfection into cells.  It has been proposed that such cationic peptides act to condense 
nucleic acids, making the lipoplex tighter, more stable, and ultimately easier to transport.  
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The combination of transferrin and protamine has been shown to act synergistically in 
further increasing transfection efficiencies (Tros de Ilarduya et al., 2003; Tros de Ilarduya 
et al., 2002). 
 
Other delivery methods 
Aside from lipids and viral vectors, other biopolymers are also being exploited for 
gene delivery.  Polyethylenimines (PEIs) have promoted efficient transfection into cells 
(reviewed in (Erbacher et al., 1999; Godbey et al., 1999; Lemkine and Demeneix, 2001)).  
Gelatin, chitosan and other compounds have been also been used to make microspheres 
that can transfer nucleic acids (reviewed in (Fini and Orienti, 2003; Li and Huang, 
2000)).  One promising technique that has emerged in recent years involves using 
nanoparticles for delivery.  Nanoparticles are submicron materials or capsules that can be 
made from a variety of synthetic polymers.  Because of their small size, nanoparticles 
readily access deep tissue and are taken up into cells in a time- and concentration-
dependent manner.  Nanoparticles have shown remarkable stability in serum and are 
easily modified.  For example, ‘dots’ have been made that are essentially biodegradable, 
allowing for time-release delivery of therapeutics (reviewed in (Muller et al., 2000; 
Panyam and Labhasetwar, 2003; Vijayanathan et al., 2002)).  Anti-PSMA aptamers have 
been conjugated to nanoparticles and effectively delivered into prostate tumor cells (see 
Chapter 3).   
Inorganic nanoparticles, such as quantum dots (QDs) may also prove useful for 
both delivery and diagnostics.  QDs are fluorophores which have the ability to absorb 
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across a broad range of wavelengths while emitting within a very discreet range.  
Modifications of the surface have also allowed for conjugation to various compounds and 
increased circulation stability.  Ballou et al. found that QDs stabilized with PEG and 
delivered into mice could still be seen after 1 month in the liver, lymph nodes and bone 
marrow.  After four months, fluorescence was just barely detectable, but QDs could still 
be seen in the lymph nodes and bone marrow (Ballou et al., 2004).  QD conjugates may 
provide the ability to track the delivery of therapeutics in real time.  For example, Gao et 
al. were able to image the localization of anti-PSMA antibody conjugates in live mice 
using a whole-body illumination system (Gao et al., 2004).   
Techniques as well as materials can be varied in order to enhance delivery.  For 
example, liposomes do not appear to promote nucleic acid delivery into muscle tissue.  
Instead, Mir et al. injected a luciferase expressing plasmid into the leg muscle of mice 
and electric pulses were applied (8 pulses at 20 ms per pulse, 200 V/cm; 1 Hz) and a 
reproducible and significant 10 to 100-fold increase in luciferase expression was detected 
over the course of the experiment (ranging from a 25-fold increase over non-electro-
transferred control at 3 hrs to a 734-fold increase on day 121).  Similar experiments in 
other animals (rat, rabbit, monkey) with other reporters yielded reproducible but more 
modest effects (Mir et al., 1999).  Electroporation has also been used in several clinical 
trials and has proven particularly well-suited for targeting tumors and melanomas 
(reviewed in (Gehl, 2003)).  Recently, electroporation has been used for the high 
efficiency transfection of a number of previously difficult-to-transfect primary cells such 
as CD34+ cells, lymphocytes, cardiomyocytes and neurons by electro-transferring DNA 
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directly into the nucleus.  This technique, called ‘nucleofection’, also has the added 
benefits of delivering into cells without the need for mitotic division and allowing for 
expression of a transgene in hours rather than days (Gresch et al., 2004).  Because of this, 
electroporation may prove important for ex vivo transfection of progenitor cells for stem 
cell therapy.   
Another device, the gene gun, makes use of high pressure to deliver DNA-coated 
gold particles directly into cells.  While ballistic transfection has been successful, 
unintended damage to cells has been an issue and delivery with the gene gun has so far 
been limited to a short subcutaneous depth range.  Newer designs in gene gun 
technology, though, have significantly reduced cell damage, and DNA can now be 
biolistically delivered to animal liver (Kuriyama et al., 2000) and heart (Nishizaki et al., 
2000).    
 
Expression cassettes 
To achieve continuous and high intracellular expression levels from introduced 
vectors many different promoter systems and expression cassettes have been designed.  
Most cassettes employ a strong promoter; both Pol II and Pol III promoters have both 
been used extensively for aptamer expression.  Pol II transcripts generally consist of 
mRNAs and snRNAs, and tend to be relatively short-lived, but are more actively 
transcribed.  Conversely, Pol III transcripts, such as tRNAs, U6, and 5S RNA, are not 
transcribed as frequently, but are very stable (reviewed in (Jackson et al., 2000; Paule and 
White, 2000)).  Some promoters are cell-type specific, providing another option for 
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aptamer targeting.  For example, the prostate specific antigen promoter (PSAP) has been 
shown to drive expression in prostate cell lines, but not in non-prostate or PSA- cell lines 
(Pang et al., 1995).  Similarly, tissue-specific promoters have been identified for several 
cell types including, but not limited to: bone (Ko et al., 1996; Stein et al., 2000), liver 
(Kuriyama et al., 1991; Macri and Gordon, 1994), endothelial (Hewitt et al., 1996; Ozaki 
et al., 1996), skin melanoma (Vile and Hart, 1993) and brain glioma cells (Miyao et al., 
1993).  Expression constructs also incorporate various processing signals to aid in 
aptamer localization or stability.  Levels or sites of expression can be manipulated by 
including enhancers, nuclear localization signals (NLSs) or locus control regions (LCRs).  
For example, a minimized PSMA enhancer and PSMA promoter were used to drive the 
expression of cytosine deaminase, which converts the non-toxic prodrug 5-fluorocytosine 
to toxic 5-fluorouracil.  Prostate tumor cells, C4-2, were transfected with the construct 
and treated with the prodrug.  Cells expressing the deaminase showed greater than 50-
fold decrease in prodrug IC50 illustrating the suicidal effect of the expressed construct.  In 
contrast, lung, colon and breast cell lines did not show significant change in cell toxicity 
(O'Keefe et al., 2000). 
Because of the typically small size of aptamers and the necessity for aptamers to 
fold properly to be functional, it has become common to include processing signals or 
ribozymes that will cleave an aptamer from a nascent RNA transcript.  In an early 
example of this, Sullenger et al. designed a vector that expressed small RNAs as a tRNA 
chimera.  Processing signals were placed at the 3’ end of the chimera to ensure 
transcription termination (Sullenger et al., 1990).  Later modifications included a 
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processing signal upstream of the aptamer cloning site so that aptamers could be cleaved 
from the tRNA chimera and a 3’ hairpin structure to stabilize the RNA (Lee et al., 
1995a).  The chimera was expressed from a tRNAimet promoter cloned into the 3’LTR of 
an MMLV vector backbone, and recombinant proviral DNA was transfected into 
packaging cell lines to grow viral particles.  By putting the expression cassette into the 3’ 
LTR, transduced recombinant retroviruses would be expressed twice, from both the 
integrated 5’ UTR and 3’ LTR (Hantzopoulos et al., 1989). 
These ‘double-copy’ vectors have now been used numerous times to demonstrate 
the inhibition of targets by small, expressed nucleic acids in transduced tissue culture 
cells (Bertrand et al., 1997; Chaloin et al., 2002; Kechli et al., 1998).  However, using an 
earlier version of the vector Martell et al. found that a previously selected aptamer against 
transcription factor E2F (Ishizaki et al., 1996) had low binding efficiency (Martell et al., 
2002).  The aptamer formed complexes with a Kd of 2-4 nM in vitro, but when expressed 
in the context of the vector sequences the Kd increased to 200 nM.  Martell et al. 
surmised that flanking sequences from the expression construct impaired folding of the 
aptamer and attempted to repair these defects via a so-called expression cassette 
selection.  Random sequence regions were added to either side of the aptamer and in vitro 
selections were performed with the expression cassette RNA pool.  Re-selected aptamers 
had a Kd of 15 nM and could now be effectively expressed in cells.   
Some more recent expression constructs for the in vivo expression of aptamers 
have made use of cis-acting ribozymes to release aptamers.  Joshi and Prasad flanked 
anti-RT aptamer sequences with hammerhead ribozymes behind a CMV promoter and 
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showed strong inhibition of HIV replication in tissue culture cells (Joshi and Prasad, 
2002)).  Nishikawa et al. effectively expressed anti-HCV aptamers by lodging them 
between HDV ribozymes. 
 
Aptamers for regulating gene expression. 
In addition to aptamers that modify the activities of proteins, it may be possible to 
use aptamers as control elements for gene expression.  Aptamer-mediated gene 
expression may prove useful in designing gene therapies.  Just as an ‘antidote’ controls 
the activity of an exogenous aptamer, a small organic could control the activity of a 
therapeutic protein.  To this end, Werstuck and Green introduced aptamers against 
antibiotics (Kan A and tobramycin) or Hoechst dyes into the 5’ untranslated region 
(UTR) of a reporter gene, in the hopes that drug- or dye-binding would modulate 
transcription or translation.  After proofing their system in vitro, Werstuck and Green 
cloned two anti-dye aptamers, H10 and H19, into the 5’ UTR of beta-galactosidase and 
assayed enzyme activity in the presence and absence of Hoescht dye H33342.   
Expression was mediated in a dye-dependent manner with up to 90% reduction in beta-
galactosidase expression at 10 mM Hoescht dye (Werstuck and Green, 1998).  Likewise, 
Suess et al. inserted an anti-tetracycline (tet) aptamer near the start codon of GFP in yeast 
cells and found tetracycline-mediated inhibition of translation (Suess et al., 2003).  
Regulatory aptamers may have even more general utility for the control of cell biology.  
Grate and Wilson introduced a malachite green binding motif upstream of CLB2, one of 
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the cyclins that directs transition from G2 to mitosis.  Cell cycle progression was 
disrupted in yeast in the presence of a malachite green analog (Grate and Wilson, 2001).   
Modulating the conformation of a 5’ UTR with a small organic was a strategy 
apparently well in place long before it was envisioned by biotechnology.  In 2002, Ron 
Breaker and his co-workers characterized the first so-called riboswitch, a regulatory RNA 
sequence found upstream of thiamine biosynthesis genes.  The thiamine riboswitch could 
bind thiamine, undergo a conformational change, and create an RNA structure that 
effectively blocked translation of the downstream gene (Winkler et al., 2002).  A number 
of additional riboswitches have now been found, and have been shown to regulate 
transcription termination as well as translation initiation (reviewed in (Brantl, 2004; 
Nudler and Mironov, 2004; Vitreschak et al., 2004; Winkler and Breaker, 2003).  
Mirroring the naturally found riboswitches, transcriptional activators and 
translational inhibitors have been designed based on aptamer affinity.  Buskirk et al. 
attached random pool RNA to MS2 hairpins that directed the sequences to an MS2 coat 
protein fused to LexA in a yeast system.  Interaction of functional RNAs with the LexA 
operator transcription unit promoted the production of His3 which allowed for survival in 
histidine-deficient media.  One clone activated transcription 53-fold greater than the 
common transcriptional activator, Gal4 (Buskirk et al., 2003).  Mandal et al. cleverly 
combined selection technology with rational design to produce aptamer-based 
translational inhibitors.  Stem loops placed near the ribosome binding site (RBS) 
upstream of a beta-gal reporter gene were shown to inhibit translation.  An anti-
theophylline aptamer was attached to a previously selected communication module 
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(Soukup and Breaker, 2000) and replaced the stem-loop.  Upon binding of theophylline, 
the aptamer-construct shifted the regulatory unit by one nucleotide and recovered 
translational activity (Suess et al., 2004). 
While effector-dependent regulation of gene expression may allow the 
construction of intricate synthetic genetic circuits, aptamers can also potentially regulate 
proteins in an effector-dependent manner.  Vuyisich and Beal employed a novel selection 
scheme to produce anti-protein aptamers that would be activated by neomycin (Vuyisich 
and Beal, 2002).  In this selection, 6 rounds of selection were performed using standard 
selection procedures against the DNA repair enzyme formamidopyrimidine glycosylase 
(Fpg).  Then further rounds were carried out in which bound RNAs were eluted in the 
presence of neomycin.  Selected aptamers were able to bind Fpg in the low nanomolar 
range (7.5 nM) and could inhibit 1 nM Fpg at 100 nM.  In addition, though, the aptamers 
now lost their ability to inhibit Fpg activity with increasing neomycin concentrations; this 
property was not observed in a control selection that did not employ neomycin elution.  
The authors envisioned that such a system could be readily adapted as an on-off switch 
for pathway and cell cycle studies.   
 
SUMMARY 
 
Aptamers are small molecule nucleic acid-based affinity ligands that could have 
far-reaching applications in therapeutics and medicine.  Obstacles that have impeded 
transitioning of the aptamer for clinical use are gradually being surmounted.  Herein are 
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reviewed a number of approaches that have been validated for stabilizing and delivering 
aptamers in vivo.  Clearly, progress has been made to address or circumvent issues of 
delivery, expression and stability.   
Recently, great progress has been made on how to effectively target aptamers to 
specific sites of action.  For example, aptamers such as the anti-PSMA aptamers selected 
by Lupold et al. described above pave the way for detection of and delivery of a number 
of types of cargo into specific types of cells.  Importantly, the ability to site-specifically 
deliver cargos such as siRNAs into cells lays down a means to tailor therapies and tune 
dosage.  As gene therapy needs become more realized, the use of gene expression 
modulators, be they siRNA or intracellularly expressed aptamers (intramers) or some 
other strategy, will become uniquely necesssary for disrupting pathological signal 
transduction or other metabolic or regulatory pathways.  Once in place, aptamer-mediated 
therapeutics should enable a whole range of applications.   
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CHAPTER 1: 
ADAPTING IN VITRO SELECTED APTAMERS FOR IN VIVO FUNCTION. 
 
INTRODUCTION 
A first step to demonstrating the applicability of in vitro selected aptamers for 
therapeutic use is to demonstrate that in vitro selected aptamers can function in vivo.  As 
a model system, we have chosen to proof previously selected anti-HIV aptamers in a 
tissue culture system.  Aptamers may be particularly useful against this disease for a 
number of reasons, as described in the Introduction. 
 
Anti-Rev aptamers bind Rev in vivo 
 Our lab has previously selected aptamers that bind tightly to the HIV protein, Rev 
(Giver et al., 1993a; Giver et al., 1993b).  Two aptamers from the selection, Aptamer 1 
(Apt1) and Aptamer 2 (Apt2; Figure 1.1) were assayed for their ability to bind Rev in 
vivo using a tissue culture-based Rev functional assay (Symensma et al., 1996).  Briefly, 
Apt1 or Apt2 was cloned into a Rev-dependent reporter plasmid, pDM138 (Figure 1.2).  
This plasmid contains the HIV-1 intron between splice donor site 4 and splice acceptor 
site 6, which houses the RRE.  Also within the intron is a chloramphenicol 
acetyltransferase (CAT) gene.  When this plasmid is expressed in mammalian cells, the 
CAT gene is typically spliced from the transcript, and no CAT activity is detected.   
 
 Figure 1.1.  Aptamers selected against the HIV-1 protein Rev, Apt1 and Apt2.   
Also shown is the native Rev-binding sequence, the RBE, and a non-binding sequence,  
the CC mutant. 
 
 
 
However, in the presence of Rev and a functional RRE, mRNA transport of 
unspliced mRNAs occurs and CAT activity is observed.  The more effectively Rev can 
bind to the intronic binding site, the more CAT activity is detected (Seed and Sheen, 
1988).  A Rev expression plasmid, pRSV-Rev (Hope et al., 1990a; Hope et al., 1990b), 
was co-transfected with the pDM138-based aptamer expressing constructs into CV-1 
cells.  If Rev is capable of binding the aptamer, then the intron is processed, and CAT is 
not translated.  Conversely, if the aptamer successfully interacts with Rev, then Rev 
mediates transport of the full unspliced intron RNA to the cytoplasm where CAT would 
be expressed and detected in the assay.   
The wild-type RRE and an RBE whose function was compromised by the 
introduction of two mutations (CC mutant, Figure 1.1) were used as positive and 
negative controls, respectively.  Expression levels were normalized relative to total  
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 Figure 1.2.  The pDM128/pDM138 Rev-responsive reporter system.  a).  pDM128 contains  
the full intron from HIV-1 which has the natural RRE and RBE.  Binding of Rev to the RBE 
sequence allows for transport of the whole transcript, including the CAT gene.  b). pDM138 
allows for modular substitution of the RBE and/or RRE sequence with various decoys.  The  
ability of each decoy to bind Rev is directly correlated to the amount of CAT activity. 
 
protein extracted and to control experiments carried out in parallel with pDM128, the 
pDM138-like plasmid carrying the wild type RRE.  
Chimeric RREs bearing Apt1 and Apt2 were both shown to be Rev-responsive in 
tissue culture cells and had activities equivalent to the wild-type RRE when Rev was in 
excess.  The chimeric RREs showed better Rev-responsiveness than the wild-type RRE 
under conditions of limiting Rev (Symensma et al., 1996).  These results are consistent 
with a model of Rev binding which suggests that Rev first binds and with highest affinity 
to the RBE (or in the case of our chimeric RREs, to the aptamers), and then multiple 
Revs cooperatively accumulate along a long duplex in the RRE adjacent to the RBE 
(Daly et al., 1993; Malim and Cullen, 1991; Zapp et al., 1991).  This is contrary to 
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another model proposed by Kjems and Sharp wherein multiple Rev binding sites occur 
along the length of the RRE (Kjems and Sharp, 1993).   
We adapted the functional Rev assay used by Symensma et al. to further 
investigate the manner in which Rev binds to the RRE.  At the same time, we hoped to 
glean information on how to best design inhibitors and to see if the aptamers could 
potentially be used as therapeutics.  More specifically, since the aptamers could bind Rev 
as well or potentially better than the native RBE, it should prove possible to use the 
aptamers as decoys, thereby diverting Rev from its role in the HIV life cycle.  We sought 
to demonstrate that these aptamers not only bind to Rev, but that, by doing so, they could 
also inhibit Rev’s function.  We explored three different expression vectors and different 
assemblies of decoys to explore how best to inhibit the Rev:RBE interaction.   
 
RESULTS & DISCUSSION: 
 
Anti-Rev aptamers as decoys of HIV  
We adapted the Rev functional assay used by Symensma et al. to co-express Rev 
along with the Rev-responsive CAT-expression plasmid, pDM128, and other plasmids 
expressing either aptamer alone or aptamer within the context of the RRE (Figure 1.2).  
In this assay, Rev must choose between binding to the wild-type RRE sequence 
expressed from pDM128 or the aptamer sequence expressed from one of the decoy 
expression vectors.  If the wild-type sequence has higher affinity for Rev, then splicing of 
CAT-expressing intron is inhibited and the Rev-depended expression of CAT can be 
detected.   
In the absence of aptamer or if the wild-type sequence has a higher affinity for 
Rev than the aptamer, Rev expressed from pRSV-Rev would bind the RRE within 
pDM128, inhibit splicing of the HIV intron therein and transport the full unspliced RNA 
to the cytoplasm where CAT can be translated.  If, on the other hand, the aptamer 
construct has a higher affinity for Rev, then the aptamer essentially competes with the 
RRE sequence of pDM128 and Rev binding to CAT expression is subsequently reduced.  
An aptamer with a high affinity for Rev should result in better disruption of the 
Rev:pDM128-RBE interaction and lower CAT expression levels.  For these experiments, 
a β-galactosidase expression plasmid, pRSV-βgal, was also co-transfected as a 
transfection and expression standard.  The wild-type Rev binding element, the RBE, was 
also tested as well as a non-functional sequence, the CC mutant. 
To ensure high levels of aptamer expression, we explored three different gene 
cassettes for expressing the aptamers: two vectors expressing the aptamers under a 
tRNAimet promoter as a tRNA fusion (Lee et al., 1995; Sullenger et al., 1990a; Sullenger 
et al., 1990b), and one  where aptamer expression is driven by the mU6 promoter 
(Noonberg et al., 1994).  The two tRNAmeti vectors, pDCT2 and pDCT5T are nearly 
identical and differ in that pDCT2 contains the 3’ tRNA processing signal to post-
transcriptionally cleave the aptamer from the tRNA to reduce the possibility that vector 
sequences might interfere with aptamer activity (Figure 1.3).  Both Apt1 and Apt2 were 
cloned into each of the vectors in place of the RBE within the context of the RRE or as  
 76 
 Figure 1.3.  Vectors for expressing anti-Rev aptamers. 
 
 
singly-expressing aptamers without flanking RRE sequences.  Constructs were assayed 
with either saturating or limiting amounts of Rev to assess the limits of possible decoy 
effects.   
Following transfection of the expression constructs, Northern blot analysis 
indicated that different aptamers were expressed at different levels.  Therefore, in order to 
gauge the relative efficacy of individual aptamers, the percent inhibition of pDM128-
mediated CAT expression for each decoy was divided by the corresponding expression 
levels of the decoys (as determined by Northern analysis by Tonia Symensma; data not 
shown) and normalized inhibition values are shown.  It should be noted that the y-axis of 
this data is expressed in arbitrary units, the purpose being to provide a graphical means of 
directly comparing aptamers.   
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With the pDCT5T vector, minimal inhibition of CAT activity was seen by 
expression of the RBE or of Apt1.  Apt2 produced a modest inhibition.  Addition of 
flanking RRE sequences to the decoys did enhance the inhibition slightly, but not greatly.  
Sequences expressed from the pDCT2 or mU6 vectors, however, showed much greater 
levels of inhibition.  In both of these vectors, Apt2 performed better than the wild-type 
RBE.  Unlike with the pDCT5T vector, addition of the flanking RRE sequences in the 
mU6 vector seemed to abet inhibition only slightly.  With decoys expressed from the 
pDCT2 vector, Apt2 gave up to 86% inhibition of Rev function relative to controls 
(Figure 1.4).  
In general, aptamer-RRE chimeras did not appear to significantly enhance the 
decoying effect compared to the native RRE.  However, for the most part, the extension 
of RNA sequence in the aptamer-RRE chimeras gave an improvement in Rev binding 
over constructs expressing just RBE or aptamer alone.  Additionally, in all three vectors, 
the RRE sequence clearly inhibited as well or better than the RBE sequence alone.  This 
suggests that either the context of the RBE within the RRE aids in folding or binding, or  
 
 
Figure 1.4.  Rev-binding aptamers effectively decoy Rev function. 
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that sequences in other parts of the RRE might also contribute to Rev binding.  Therefore, 
it would appear, that replacing the high-affinity RBE site with an analogous high affinity 
sequence did not impair or improve the Rev-binding function of the whole RRE.  Indeed, 
previous work has shown that the Rev:RBE interaction involves multiple Rev proteins 
binding to the same RNA transcript, although the exact nature of this multimerization 
was unclear. 
 
Multiple Rev proteins bind to the RRE 
Two models have been proposed for how multiple Revs bind the RRE.  The 
Kjems and Sharp concatenation model suggests that other, possibly lower-affinity, Rev-
binding sights occur elsewhere along the RRE (Kjems and Sharp, 1993).  Mann et al. and 
Zemmel et al., however, suggest an alternate ‘molecular rheostat’ version in which a Rev 
protein must first bind the high-affinity RBE, and then other Rev proteins multimerize 
along the length of the RRE stem I from the site of the first binding (Mann et al., 1994; 
Zemmel et al., 1996).  Both models suggest that increasing the number of Rev proteins 
bound to the RNA increases effectiveness of the interaction.  It should prove possible, 
therefore, to make a more effective inhibitor by increasing the number of Rev-binding 
sites on our decoy RNA.  
We synthesized concatamers of the RBE ranging from one to five RBE units (T1 - 
T5), with each unit separated by a pyrimidine linker aimed at forcing each RBE into its 
own discreet fold (Figure 1.5).  Nuclease digestion of the T5 construct confirmed that 
each RBE was indeed folding into its own discreet structure (Figure 1.6).  
 Figure 1.5.  Concatemers of RBE sequences are separated by pyrimidine linkers.  The 4-unit 
concatemer. T4, is shown as an example. 
 
 
 
         
Figure 1.6.  Nuclease digestion of T5 supports the proposed structure that each RBE 
folds into discreet structures.  Lanes 6 and 13 are alkaline hydrolysis controls of T5. 
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Each concatamer construct was cloned into and tested in our in vivo Rev 
functional assay and showed stepwise Rev function with each additional RBE 
concatemer, thus demonstrating a modular and cumulative approach to increasing decoy 
function (Figure 1.7). 
 
Figure 1.7.  Modular and stepwise increase in Rev binding associated with  
an increase in concatenation of RBE sequences. 
 
These results initially seemed to support the Kjems and Sharp model wherein 
individual binding sites contribute to Rev binding.  However, it was also possible that we 
were only seeing the early stages of the Mann and Zemmel model.  That is, if Rev 
concentrations were limiting, then an initial high binding step and subsequent 
multimerizing binding events would appear stepwise. 
To address this, the in vivo functional assay was also performed as a function of 
Rev concentration.  Rev concentration was adjusted by altering the amount of Rev 
plasmid transfected and the wild-type RRE, T5 and T2 were tested (Figure 1.8).  Not 
unexpectedly, T5 demonstrated a higher Rev-responsiveness than T2, with approximately 
2.5-fold higher activity at saturating concentrations of Rev.  This would seem to support 
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the Kjems and Sharp model that each binding site contributes to the overall binding 
activity.  However, both T2 and T5 reached maximal activity at 0.01 µg Rev, whereas the 
wild-type RRE did not reach maximum until 0.05 µg Rev.  This suggests a qualitative 
component to Rev binding that is not as obvious as specific binding sites and lends 
credence to the molecular rheostat model in that multiple high-binding sites are not 
sufficient to achieve full function.  It remains a possibility, though, that the total number 
of binding sites were not tested to the fullest extent in our assays.  In the end, it is most 
likely that both discreet and cooperative binding contribute to the Rev function and the 
two models are not mutually exclusive. 
Figure 1.8.  Rev-responsiveness as a function of Rev concentration.  (A). The wild-type RRE reaches 
maximal Rev-responsiveness at 0.05 µg transfected Rev, whereas (B) T2 and T5 reach maximal Rev-
responsiveness at 0.01 µg transfected Rev. 
 
 
CONCLUSIONS & FUTURE DIRECTIONS 
 
We have demonstrated that anti-Rev aptamers from an in vitro selection could 
decoy Rev function in tissue culture cells.  This bodes well for the potential use of such 
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aptamers against HIV, a well-suited target for aptamers since aptamers are non-
immunogenic, have great specificity and may avoid the typical resistance issues 
associated chemical drugs against HIV.  Additionally, HIV has multiple crucial proteins, 
all of which could be possible aptamer targets.  While targeting one protein may not 
prevent viral infection, the use of combinations or multimers of aptamers may make 
significant dents in HIV’s ability to replicate. 
In a step toward developing a multimeric therapy against HIV, we concatenized 
RBE monomers and demonstrated the increasing and stepwise anti-Rev functionality 
with each additional monomer.  We, therefore, show that decoy sequences can possibily 
have modular and cumulative effects against the virus.   
During these experiments, we were also able to cursorily investigate the nature of 
the Rev:RRE interaction that is so crucial for HIV replication.  By creating the tandem 
RBE sequences, we looked at whether Rev bound discreetly to the RBE, then 
multimerized along the RRE , as a molecular rheostat, or whether multiple binding sites 
also existed on the RRE.   We determined that while additional binding sites did increase 
Rev binding in a step-wise manner, a less clear and qualitative component is also 
involved.  Therefore, the two models for Rev binding are not mutually exclusive. 
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MATERIALS & METHODS: 
 
Materials.  
Plasmids pDM128 (Hope et al., 1990b) pDM138 (Huang et al., 1991), and 
pRSVRev (Zapp and Green, 1989) were supplied by Thomas Hope.  Plasmid pRSV-βgal 
was supplied by Maria Zapp. The plasmid mU6 was supplied by Sarah Noonberg.  
Plasmids pDCT2 and pDCT5T were provided by Bruce Sullenger and Eli Gilboa, 
respectively.   
The variants of pDM138 containing aptamers, aptamer:RRE chimeras or RBE-
based constructs were constructed by Lori Giver .  Aptamers and aptamer:RRE constructs 
were cloned into the Pol III expression plasmids, mU6, pDCT2 and pDCT5T, by Lily Xu.   
Plasmids used in transfection experiments were purified by Qiagen columns. 
Media, reduced-serum media, supplements, phosphate-buffered saline, and 
Lipofectamine and fetal bovine serum (fbs) were purchased from Invitrogen.  
Radiolabeled 14C-chloramphenicol was purchased from Perkin Elmer and enzymes for 
the cellular assays were purchased from New England BioLabs.  Transcription kits were 
from Epicentre Technologies. 
 
Cell culture  
African green monkey kidney (CV-1) cells were grown according to standard 
ATCC procedures in high-glucose Dulbecco’s modified Eagle medium supplemented 
 85 
with fetal bovine serum (11%), penicillin (2.5 U/ml), streptomycin (2.5 mg/ml), and L-
glutamine (2 mM) (Invitrogen).  Cells were grown at 37°C with 5% CO2 and 95% 
humidity.  For Rev functional assays, cells were grown in 24-well cell culture plates 
(Corning Costar). 
 
Cellular assays for CAT activity  
Rev interactions with the delivered aptamers and concatemers were determined by 
measuring the amount of CAT activity in cells after delivery of aptamer and Rev 
expressing constructs.  The reporter plasmids were co-transfected with a Rev expression 
plasmid, pRSVRev, as follows: one day prior to transfection, CV-1 cells were counted 
with a hemacytometer, and 55,000 cells were seeded into each well of a 24-well cell 
culture plate.  The next day, the cells (at 70 to 80% confluency) were transiently 
transfected with Lipofectamine in duplicate with either a Rev-responsive reporter plasmid 
(pDM128; 0.2 mg) or derivatives of pDM138 containing RBE concatemers (0.2 mg), 
pRSVbgal (0.5 mg) as a control for transfection efficiency, and a Rev expression plasmid 
(pRSVRev).  The amount of pRSVRev used in each transfection was varied between 
limiting pRSVRev (0.01 mg), saturating pRSVRev (0.2 mg), or a titration of pRSVRev 
(0.002 mg to 0.2 mg).  Cells were prepared for transfection by pre-incubation for 30 min 
in 1 ml of OptiMEM reduced-serum medium (Invitrogen).  Plasmid DNAs (1.2 mg in 
total, including various amounts of a carrier plasmid, pUC118) in 100 ml of OptiMEM 
were mixed with 1.5 µl of Lipofectamine in 100 µl of OptiMEM.  Lipid amalgams (200 
µl) were incubated at ambient temperature for 30 min to allow complex formation to 
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occur; the mixture was added to cells in a total volume of 0.5 ml of OptiMEM (7.2 ng of 
liposome:2.4 ng of DNA per ml [final concentration]) and incubated for an additional 4.5 
to 5 h at 37°C.  The transfection medium was removed from the wells and replaced with 
complete medium.  Forty-eight hours post-transfection, the cells were washed with 1 ml 
of phosphate-buffered saline and lysed in 0.25 M Tris-Cl (pH 7.6)–0.5% Triton X-100 
(150 µl).  Harvested cellular extracts (100 µl) were centrifuged for 5 min, and the 
supernatant was used for CAT assays and β-galactosidase assays.   
CAT activity was measured according to standard procedures (32).  Cellular 
extracts (40 µl) were mixed with acetyl coenzyme A (0.45 mM [final concentration]; 
Amersham Pharmacia), glycerol (1.8% final), and 14C-labeled chloramphenicol (0.1 mCi; 
50 mCi/mmol; DuPont NEN) in 176 µl of 0.14 M Tris-Cl (pH 7.6).  The reaction mix 
was incubated at 37°C for 1.5 h; control experiments indicated that this was within the 
linear range of the assay.  Chloramphenicol and less polar acetylated products were ethyl 
acetate extracted and separated by thin-layer chromatography in 5% methanol–95% 
chloroform on silica gel IB2 sheets (J. T. Baker Co.).  The labeled chloramphenicol 
products were quantitated with a Phosphorimager (Molecular Dynamics).  The amount of 
CAT activity present in each extract was defined as the percentage of total 
chloramphenicol that had been converted to acetylated products.  CAT activities were 
normalized to the amount of β-galactosidase activity detected in each extract.  
β-galactosidase levels were determined by incubating 15 µl of cell extract with 
0.1 mM MgCl2, 0.35% b-mercaptoethanol (Sigma-Aldrich), and 0.88 mg of o-
nitrophenyl-b-D-galactopyranoside (Sigma-Aldrich) per ml in a final volume of 150 µl of 
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0.1 M NaH2PO4-Na2HPO4. After incubation at 37°C for 45 min, β-galactosidase 
activities were determined with a microtiter plate reader (Cambridge Technology) fitted 
with a 450-nm filter. 
 
Construction of RBE concatemers. 
A modular synthesis scheme was devised for the construction of RBE 
concatemers. Three overlapping pairs of oligonucleotides encoded a 5’ T7 RNA 
polymerase promoter, an RBE-linker monomer, and a 3’ cap, respectively.  The 
sequences for these are as follows: 
 
T7 promoter region 
 
5' AAT TCT AAT ACG ACT CAC TAT AGG GAG ATC GAT 
     A TTA TGC TGA GTG ATA TCC CTC TAG CTA GAG AAG AGA 
 
 
RBE monomer 
5' CTC TTC TCT GGT GGG CGC AGC TTC GGC TGA CGG TAC ACC 
            CCA CCC GCG TCG AAG CCG ACT GCC ATG TGG GAG AAG AGA 
 
3’ cap 
CTC TTC TCT ATC GAT ACC CAA AGT CGT GAC TGG GAA AAC G 
       TAG CTA TGG GTT TCA GCA CTG ACC CTT TTG CCTAG 
 
The paired oligonucleotides corresponding to the RBE-linker monomer contained 
overhangs that facilitated their oligomerization.  These overhangs also facilitated addition 
of a T7 RNA polymerase promoter to the 5’ end of RBE concatemers and a constant 
sequence cap to the 3’ end.  Both constant sequences also contained ClaI restriction sites 
(in italics) to facilitate cloning.  
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All oligonucleotides were phosphorylated by using T4 polynucleotide kinase 
(New England Biolabs) for 30 min at room temperature.  The oligonucleotides encoding 
the RBE linker monomers were denatured for 1 min at 95°C, annealed for 3 min at 45°C, 
and incubated at room temperature for at least 10 min.  The oligonucleotide concatemers 
that were formed were ligated with T4 DNA ligase (New England Biolabs).  The T7 
promoter and 3’ cap were then ligated to the RBE concatemers.  PCR amplification 
yielded a mixture of products which served as templates for Ampliscribe in vitro 
transcription reactions (Epicentre Technologies).  Transcribed RNAs were treated with 
DNase I and gel purified on a 6% polyacrylamide denaturing gel. Individual bands were 
eluted from the gel, ethanol precipitated, and reverse transcribed by using avian 
myeloblastosis virus reverse transcriptase (Seikagaku America) for 1 h at 42°C.  The 
reverse transcription reaction products corresponding to individual concatemers were 
then PCR amplified and cloned into the pCRII vector from the TA cloning kit 
(Invitrogen).  Individual colonies were screened for the presence of RBE-linker inserts.  
Clones containing concatemers corresponding to one to five tandem copies of the RBE 
(T1 to T5) were identified, and the sequences of the concatemers were confirmed by 
standard dideoxy sequencing methods.  The RBE concatemers were PCR amplified from 
the pCRII vector, digested with ClaI, and cloned into ClaIdigested pDM138 to generate 
plasmids pDM138-T1 through pDM138-T5.  The sequences and orientations of the 
concatemers in pDM138 were verified by dideoxy sequencing.  The insert in plasmid 
pDM138-T5 contained point mutations in two of the linker regions (one linker lacked a 
U, while the second had an additional C). 
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Concatemers T1 – T3 were constructed by Dr. Scott Baskerville. 
 
Nuclease mapping.  
A DNA template corresponding to T5 was transcribed in vitro by using an 
Ampliscribe transcription kit according to the manufacturer’s directions.  The transcribed 
RNA was purified on a 6% denaturing polyacrylamide gel, ethanol precipitated, and 
dephosphorylated with alkaline phosphatase (Roche Boehringer Mannheim).  The 
dephosphorylated RNA was phenol-chloroform extracted and treated with T4 
polynucleotide kinase (New England Biolabs) in the presence of 5 fmol of [g-32P]ATP 
(7,000 Ci/mmol; MP Biomedicals).  The radiolabeled RNA was again purified on a 6% 
polyacrylamide gel and precipitated.  
Radiolabeled T5 was digested with various amounts of RNase A (1, 0.1, 0.01, 
0.001, and 0.0001 U) or RNase T1 (10, 5, 2.5, 1.25, 0.63, and 0.31 U) in 6 ml of Hanks 
balanced salt solution (1) at 37°C for 5 min.  The digestion reactions were quenched with 
2 mg of yeast tRNA (Invitrogen) in 4 ml of 0.5 M EDTA, immediately 
phenol:chloroform extracted, and precipitated.  To determine the spacings between 
hydrolysis products, 0.5 mg of radiolabeled T5 RNA was hydrolyzed in the presence of 
25 mM sodium bicarbonate, 1 mM EDTA, and 10 mg of yeast tRNA.   This alkaline 
hydrolysis reaction mixture was heated to 90°C for 10 min, neutralized with 2 ml of 0.5 
M acetic acid, and ethanol precipitated. Hydrolysis products were separated on a 6% 
denaturing polyacrylamide gel, and the digestion patterns were analyzed with a 
PhosphorImager (Molecular Dynamics). 
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CHAPTER 2:   
ANTI-VIRAL APTAMERS FOR INHIBITION OF HIV-1 
 
INTRODUCTION 
Having demonstrated the anti-Rev function of aptamers in vivo and having 
demonstrated the cumulative effect of decoy inhibition, the issue at hand became not 
whether aptamers could be effective in vivo, but how to best deliver them for maximal 
effect.  In most of the animal trials using aptamers, aptamers have simply been injected, 
relying on the specificity of each aptamer to find its target and effect therapy.  This 
generalized systemic approach has worked for aptamers within the extracellular milieu.  
For example, aptamers against VEGF have worked well against macular degeneration 
when injected directly into the eye (2003; Carrasquillo et al., 2003; Drolet et al., 2000).  
However, extracellular aptamer therapy would be impractical for treatment of  
intracellular targets, which would require a more directed approach, such as gene therapy 
using intracellularly expressed therapeutic constructs, or some other means of entry into 
cells.. 
Viral vectors, notably retroviral and adenoviral ones, have been common tools for 
delivering gene therapy expression contructs into cells (reviewed in (Mhashilkar et al., 
2001).  For example, with retroviral vectors, expression constructs are cloned into a 
vector under the control of the strong retroviral LTR, and replication-defective retroviral 
particles are produced in packaging cell lines.  These particles are used to infect target 
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cells isolated from a patient.  The presence of a neomycin or other resistance gene on the 
retrovirus can be used to select for those cells that have stably integrated the retroviral 
sequence. 
Using this strategy, nucleic acid therapies against intracellular and shrouded 
targets such as HIV have already shown great promise.   Bahner et al. transduced human 
CD34+ cells with HIV-1 Rev decoy sequences expressed within a MoMuLV backbone 
and showed 99% inhibition of HIV-1 replication ex vivo in selected primary cells.  These 
cells showed no significant difference in growth and differentiation from control cells 
(Bahner et al., 1996).  Using similar constructs, Bauer et al. (Bauer et al., 1997) showed 
up to 1,000 fold inhibition in CD34+ cells already infected with HIV-1.  In 1999, Kohn 
and coworkers set up a clinical trial in which Rev decoy sequences were introduced into 
four HIV-1 infected patients.  Treatment of the cells showed no adverse effects in any of 
the patients, and transduced vector sequences could be detected up to 330 days after 
infusion (Kohn et al., 1999).  Not only were the constructs capable of integrating into 
target cells and expressed for a long duration, their expression produced no significant 
toxicity.  Bai et al. showed that expression of antiviral constructs in hematopoietic stem 
cells in SCID-hu mice had no effect adverse effects on cell differentiation.  Moreover, the 
expressing cells were significantly more resistant to HIV infection in vitro (Bai et al., 
2002). 
This strategy of attacking HIV from within cells through the continual 
intracellular expression of aptamers has been termed “intramer” therapy or “intracellular 
immunization” (Famulok et al., 2001; Famulok and Mayer, 1999).  In this form of gene 
therapy, aptamer constructs would be introduced into hematopoeitic progenitor cells.  
Differentiation of these cells would eventually yield a population of protected immune 
cells. 
This approach seemed extremely promising for HIV, and we sought to challenge 
HIV in a gene therapy setting with antiviral aptamers.  In addition to our anti-Rev 
aptamers, aptamers have also been selected against several other HIV-1 proteins 
including reverse transcriptase (RT) (Burke et al., 1996; Tuerk et al., 1992), integrase 
(Int) (Allen et al., 1995), the nucleocapsid protein (NC) (Berglund et al., 1997), gp120 
(Sayer et al., 2002) and Tat (Yamamoto et al., 2000).  From this arsenal, we chose to test 
aptamers against RT, Rev (Apt1 and Apt2), the nucleocapsid and integrase (Figure 2.1).  
We reasoned that while an individual aptamer might inhibit HIV to a small degree, 
attacking these multiple targets in parallel should substantially reduce the probability of  
 
Figure 2.1.  Anti-HIV aptamers. 
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viral infection, much as the three-pronged antiretroviral cocktails forestalled AIDS in 
many patients.  Moreover, multiple aptamers against multiple proteins should also 
forestall the development of resistance variants.  To this end, we decided upon a strategy 
by which we would test the multiple aptamers in multiple expression systems and 
multiple infection protocols (Table 2.I).  From these experiments, we would then 
assemble the systems and aptamers that performed best to produce multimeric 
therapeutics. 
TransfectionTransfection (stable)
Co-TransfectionTransfection (transient)
InfectionTransfection (transient)
InfectionElectroporation (stable)
InfectionTransduction (stable)
Viral DeliveryAptamer Delivery
 
Figure 2.1.  Different methods used to test anti-viral aptamers. 
 
 
RESULTS & DISCUSSION: 
 
To best express the aptamers against HIV, we explored the use of several different 
expression constructs consisting of both pol II and pol III promoters (Figure 2.2).  Pol II 
promoters primarily transcribe ribosomal and messenger RNAs and have the advantage 
of expressing high copy numbers of transcripts.  Pol III promoters, on the other hand, are  
associated with transcription of smaller, more stable RNAs such as tRNA and other small  
nuclear RNAs (Paule and White, 2000).   
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 Figure 2.2.  Expression vectors used to test anti-viral aptamers. 
 
 
For the purposes of this chapter, we will only highlight the work done with two of 
the vectors: pDCT2 (Lee et al., 1995) and pcDNA3.1-Rz (Fisher et al., 2002; Joshi and 
Prasad, 2002).  We have previously used pDCT2 to test anti-Rev aptamers in tissue 
culture cells (Symensma et al., 1999).  pDCT2 expresses aptamers fused to tRNA under a 
tRNAimet promoter.  The aptamer is cleaved post-transcriptionally from the tRNA by a 3’ 
tRNA processing signal.  pcDNA3.1-Rz expresses aptamers under a CMV promoter.  
Aptamers expressed from this vector are flanked by cis-acting hammerhead ribozymes, 
such that the aptamers are released from the transcript after transcription. 
Each aptamer was cloned into the different expression systems, delivered into 
cells and then challenged with HIV-1.  The integrase aptamer proved difficult to clone, 
and was, thus, only tested in the pcDNA3.1-Rz vector.  As a first trial, the aptamer-
bearing vectors were transduced into CEM or PM1 lymphocytes and the cells were 
selected with G418 before infection with HIV-1IIIB.  However, the results were sporadic 
and unpredictable. 
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We proceeded to test the constructs by co-transfecting them into HeLa-CD4 cells with a 
proviral HIV-1 strain, NL4-3.  While individual assays were, again, inconclusive and 
sometimes contrary, after several trials, a trend could be discerned showing some degree 
of anti-viral inhibition by the wild type RBE, Apt1, Apt2, and the anti-NC aptamer 
(Figure 2.3).  Nonetheless, the system was plagued with occasional assays where vector-
only controls appeared to cause inhibition.  Other inconsistencies surfaced throughout the 
assays where one aptamer that seemed to produce an effect in one assay failed to do so in 
the next. 
 
Figure 2.3.  Aptamer-HIV challenge assay with the pDCT2 vector.  Aptamers expressed within 
the vector pDCT2 were co-transfected with proviral NL4-3.  The graph represents averages of up 
to 4 trials with each construct, all tested 72 hrs post-transfection.   
 
Given the variability of what we were seeing, we decided to adopt a system from 
Viniyaka Prasad’s lab wherein aptamer-expressing constructs were electroporated into 
Jurkat cells and then stably selected for with G418.  After stabilization, cells were 
challenged with low titers of HIV.  Again, although some individual assays proved 
promising, overall, there was still variability or a general lack of effect (Figure 2.4). 
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Figure 2.4. Examples of variable or negative data. 
 
 In particular, vector-only controls often appeared to inhibit virus.   
One possible reason for the variant data could be excessive variability in the 
infection or assaying process.  To assess experimental variability, vectors-only expressing 
lines were infected 9 times in 9 different assays under constant conditions.  Although 
some variability was seen, the trends seemed acceptable (Figure 2.5). 
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Figure 2.5.  Replicability of infected vector only controls across 9 assays.  Only the 
positive standard deviations are shown. 
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Population variability may also explain for the strange data.  Since these 
experiments were performed on the population that was electroporated with aptamer-
expressing constructs, it was possible that some cells expressed differently than others.  
Additionally, it was possible that aptamer constructs had integrated in cell chromosomes 
or otherwise stabilized into transcriptionally inactive areas and would, therefore, be non-
productive.  In both cases, there remained the possibility that inhibition would not be seen 
within the time frame of our experiments.   
To see what, if any, long term effects there might be with our stabilized cell lines, 
we infected cells with a lower and higher titer of virus (MOI of 0.01 or  0.1, respectively) 
and passaged the virus over 120 days, sampling for infection every few days as well as 
adding the virus to fresh naïve cells (Figure 2.6).  After 72 days, only one of stabilized 
lines, the anti-Rev Apt2 within the pcDNA3.1-Rz vector, PA2, had emerged with virus  
and only in the high titer series.  An AZT control also showed viral load.  By 90 days, the 
AZT control had also emerged in the low titer series, while no aptamer- expressing 
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9 days
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Figure 2.6. Long term infection challenge of aptamer constructs. 
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constructs showed significant viral load.  In the high titer series, the PA2 and AZT 
remained the only infected lines aside from controls.  However, much like the individaul 
assays, we were disheartened to see that one of the vector controls, the pDCT2T control 
Gil4, failed to become infected.  Given this, it is unclear whether any of the other data 
points can be trusted (Figure 2.7).  
In an effort to thwart the variability we were seeing in these assays, we isolated 
clonal lines of each of the aptamer-transfected lines.  The clonal lines were subjected to 
the same assays as the populations had been.  We hoped that by eliminating some of the 
population effects, a more consistent trend could be gathered from multiple assays. 
Eight experiments were undertaken wherein each of clonal lines expressing a 
given aptamer were infected with virus, and viral infection was followed for up to 36 
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Figure 2.7. Long term infection assay of aptamers in cells.  Ja, Jb = infected cells controls; Pra = 
pcDNA3.1-Rz vector; Gil = pDCT2 vector; A = AZT treated cells; and the remainder are anti-Rev aptamer, 
Apt2, expressed in either the pcDNA3.1 (P) or pDCT2 (G) vector. 
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days (summarized in Table 2.II).  A very low number of clones showed significantly 
lowered virus.  Also, similar to what we had seen in the long term assays above, of the 8 
different sets of infection experiments assaying the different aptamer constructs, two sets 
showed significantly lowered viral infection in the vector only samples.  Whether this 
represented an actual vector effect, a variability during the infection process or variations 
on viral health between cultures was unclear.  This did strongly suggest, though, that the 
individual data points were not sufficient for any real conclusion.  With this knowledge in 
mind, the results of the remaining experiments were not fully processed. 
Aside from the frank possibility that these aptamers just didn’t work, there are 
also several other possible explanations why inhibition of the virus was not clear. 
Not completed5570,8-13pcDNA3.1-RzIM8
Not completed77NCpcDNA3.1-RzIM7
Not completed66IntpcDNA3.1-RzIM6
Not completed77NCpDCT2IM5
3661.1pcDNA3.1-RzIM4
05670,8-13pDCT2IM3
257Apt2pDCT2IM2
235Apt2pcDNA3.1-RzIM1
# clones 
inhibitory
# clones 
assayed
# clones 
isolatedAptamerVectorExpt.
 
Table 2.I.  Summary of infection experiments against clonal lines of aptamer-expressing cells. 
 
The very treatment of cells could affect viral infection.  For example, it has been 
suggested that G418 and other aminoglycoside drugs can inhibit viral infection (Zapp et 
al., 1993).  We took care not to include the antibiotic during the course of the assay, a 
decision that could have allowed for non-stabilized or poorly stabilized cells to 
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repopulate.  A significant flaw of these experiments is that expression of the aptamers 
was never confirmed in the cells.  Northern and ribonuclease protection assays along the 
course of these experiments were inconclusive, though it had also been suggested that 
stabilized clonal lines might not produce high levels of inserted RNA, especially if the 
constructs had stabilized poorly.  That is, there is the possibility that aptamer-expressing 
constructs may have stabilized in cells in a manner such that their expression was 
inherently poor or limited, much as a latent virus might exist in a cell.  In this latter case, 
it could be possible that the expression of anti-viral aptamers wouldn’t be seen during our 
assays.  Additionally, others in the literature have reported significant vector only 
inhibition of HIV (Konopka et al., 2000). 
Since learning of our results, our collaborators have gone back and seen similar 
vector and replicability effects and are currently trying to re-establish their system. 
 
 
CONCLUSIONS & FUTURE DIRECTIONS 
 
We aimed to inhibit HIV through a gene therapy approach using anti-viral 
aptamers that had shown great promise in in vitro assays.  After evaluating several 
different approaches with different cells, viruses and expression constructs, we were 
unable to establish an anti-viral intramer therapy system.    Overall, the use of cell culture 
assays to evaluate aptamers and expression constructs should have practical results.  
However, our results remain inconclusive.   
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These experiments do not conclude in any way, though, that the aptamers, in of 
themselves, are ineffective.  In fact, during the progress of this work, several groups 
have, indeed, proofed our approach.  For example, anti-RT aptamers were able to reduce 
HIV infectivity 90 - 99.5% in 293T cells (Joshi and Prasad, 2002).  Anti-Rev aptamers 
were shown to effectively subdue HIV infection in several tissue culture lines (Good et 
al., 1997; Konopka et al., 1998; Konopka et al., 2000). In an experiment that presages 
gene therapy, an anti-Rev aptamer expression construct was transduced into CD34(+) 
cells and the differentiated cells were significantly more resistant to HIV infection than 
control cells (Bai et al., 2002).   
More anti-HIV aptamers have now been selected against HIV targets and most 
have proven effective against HIV infection (reviewed in (Held et al., 2006; Joshi et al., 
2003; Nimjee et al., 2005; Scherer et al., 2007; Zhang et al., 2004)).  The fact that there 
are multiple aptamers against multiple HIV targets may now allow for combinatorial 
aptamer therapies to be developed.  Just as the current HAART treatments achieved 
success by attacking many different sites, multiple aptamers should be even more 
effective.  Moreover, multiple aptamers against multiple proteins should also hinder the 
development of resistance variants, a further boost to the fact that aptamers may already 
be more ‘resistant to resistance’ (see Chapter 1).   
Though not able to prove aptamer therapy against HIV, our work has been 
instructive on the technical feats associated with how to best design expression constructs 
or how to actually deliver these therapies to cells.  As one example, rather than targeting 
each of the viral proteins, it should be possible to target many proteins within one 
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construct.  One way to express multimeric aptamers would be to link each aptamer in 
tandem separated by self-cleaving ribozymes, such as should have been the case with 
pcDNA3.1-Rz constructs we attempted.  This way, each aptamer could post-
transcriptionally diverge to their specific sites of activity.   
The delivery aspect is a little more of a conundrum.  Clearly, our approach 
(electroporation followed by long term antibiotic selection), would be far too 
cumbersome for actual clinical use.  While work continues on moving these intramer 
therapies toward human use, further techniques need to be explored to improve the 
clinical efficacy of this approach.  In particular, delivery methods must be devised that 
will effectively transport these constructs to and into specific cells.   
 
MATERIALS & METHODS 
 
Plasmids and cells 
The plasmid pDCT2 was supplied by Bruce Sullenger.  The plasmid pcDNA3.1-
Rz was supplied by Viniyaka Prasad. 
H9, H9-HIVIIIB, CEM, Jurkat, HeLa-CD4, HeLa-CD4-βgal and 293T cells as well 
as the proviral plasmid, pNL4-3, were obtained from the NIH AIDS Research and 
Reference Reagent Program.  HeLa cells were obtained from ATCC. 
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Cell and virus culture 
The H9, CEM, Jurkat and HeLa-CD4 cell lines were grown in RPMI-1640 
supplemented with 10% FBS.  293T and HeLa-CD4-βgal cells were grown in DMEM 
supplemented with 10% fbs.  All cells were grown at 37°C with 5% CO2 and 95% 
humidity.  All cell centrifuging steps were at 1,500 rpm at 4°C for 5 min.  All cell and 
viral wash steps were done with DPBS without Mg2+ or Ca2+. 
Clonal lines of cells were made by serially diluting cells across multiple 96-well 
plates in selective media.  Plates were scanned under a microscope for wells that only had 
one cell.  These were marked and assessed over multiple days to ensure expansion of 
cells that correlated to clonal expansion. 
 For making viral stocks from the H9-HIVIIIB cells, H9-HIVIIIB cells were grown to 
80% confluency, then cells were pelleted, washed and resuspended in warmed media 
supplemented with 20% fbs.  Culture medium was collected two and four days after the 
wash, filtered through 0.45 µm filters, aliquoted into cryovials and stored in liquid 
nitrogen.   
 For making viral stocks from pNL4-3 provirus, 1 µg proviral plasmid DNA was 
transfected onto 70% confluent 293T cells in a 10 cm2 tissue culture plates using Fugene 
(Roche), with a media change after 4 hr.  Twenty four hrs later, the growth media was 
replaced.  Two and three days later, culture media was harvested and stored as described 
for the HIVIIIB virus. 
 To quantitate the infectivity of the frozen, the titer of virus was determined in one 
of three ways.  In one, a thawed aliquot of virus was serially diluted across two 96-well 
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plates seeded with H9 cells at 1x106 cells/mL, where the same dilution is added to each 
column of 8 wells.  After two weeks, the column in which half the wells show viral 
pathology (i.e., synctial growth, ballooning cytoplasm, cytotoxicity, etc.) represented the 
dilution of virus that equals the TCID50.  
 In a second method, dilutions of virus were used to infect HeLa-CD4-βgal cells.  
These cells express β-galactosidase (β-gal) under the HIV-1 LTR.  When infected, viral 
Tat upregulates transcription of β-gal.  Briefly, cells were seeded in 24-well plates at 
approximately 4x104 cells/well.  The next day, media was removed from the cells, and 
dilutions of virus in 250 µL was added to each well.  The virus was allowed to adsorb for 
two hours, then warmed culture media was added to each well.  Two days later, the cells 
were washed and a fixing solution (1% formaldehyde and 0.2% glutaraldehyde in PBS) 
was added to cells and incubated for exactly 5 min.  The cells were washed twice and a 
staining solution (4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 2 mM 
MgCl2 and 0.04% X-gal in PBS) was added to cells.   The cells were incubated at 37°C 
for exactly 50 min, after which the staining solution was removed and cells were washed 
twice.  The number of infective virions in the stock was calculated by multiplying the 
number of blue cells in a given well by the dilution. 
 A final method to assess the amount of virus was to assay for p24 via ELISA.  
ELISA assays were performed following manufacturer protocols (Zeptometrix).  
Although this method does not actually measure the infectious particles, we and others 
have shown that p24 levels correlate strongly to viral titer in infected cultures. 
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Constructing the expression vectors 
Aptamers synthesized by overlapping PCR from two or more oligonucleotides 
that ranged either end of the aptamer sequence with restriction enzyme cut sites included 
into each end of the PCR product.  The PCR products were cloned into PCR2.1 using the 
TOPO-TA cloning kit (Invitrogen).  Positive transformants were determined both by 
blue-white screening and colony PCR using one aptamer-specific primer and one vector-
specific primer.  The plasmids with inserts were Qiagen-cleaned and sequenced to 
confirm the presence of the aptamer.   
After confirmation, plasmids, as well as the recipient vectors were digested with 
the appropriate restriction sites.  Aptamer digestions were gel-purified on 4% agarose 
gels.  The digested vector was dephosphorylated using calf intestinal phosphatase 
(Roche) and gel purified on 1% agarose gels.  The purified aptamers were ligated into the 
dephosphorylated vectors by mixing 60 fmol aptamer with 20 fmol vector using T4 DNA 
ligase (New England Biolabs) in a 10 µL reaction and incubated at 16°C overnight.  Two 
microliters of the ligation reaction was transformed into TOP10 competent cells.  Positive 
transformants were selected using either kanamycin (for the pcDNA3.1-Rz-based 
constructs) or ampicillin (for the pDCT2-based vectors). 
The ligated plasmid constructs were Qiagen purified and sequenced with plasmid 
specific primers to confirm the identity and location of inserted aptamer sequences. 
Megan Breeden helped construct many of the aptamer-expressing vectors. 
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Aptamer challenge assays by infection with virus 
 For infection challenges, 3x107 Jurkat or CEM cells in 500 µL media without 
antibiotics were electroporated with 30 µg each plasmid in a 0.4 cm cuvette at 0.25RV 
and 960 µF.  Cells were incubated briefly at room temperature for 10 min, then the 
contents of the cuvette was transferred by large-mouth pipet to 15 mL prewarmed media.  
Two days later, 500 µg/mL G418 was added to select for transformants.  
 For viral challenge, a T75 flask of cells was treated with polybrene to a final 
concentration of 2 µg/mL at 37°C for 20 to 30 min.  Cells were pelleted, counted and 
2x106 cells were transferred to a tube and re-pelleted.  The cell pellet was resuspended in 
0.5 mL virus solution containing virus to achieve the desired MOI.  Cells were incubated 
for 1 hr with agitation every 10 min to keep cells in suspension.  After incubation, cells 
were pelleted, washed once and resuspended in 10 mL growth media. 
 Viral infection typically became detectable by p24 assay approximately 9 days 
post-infection.  On Day 9 and every 3 days thereafter, 1 mL culture was removed and 
mixed with lysis buffer from the Zeptometrix p24 kit.  The cultures were replenished 
each time with 1 mL of fresh media.  We have shown that the 1:10 split does not 
significantly alter downstream viral titers or p24 measurements (data not shown).  The 
harvested cultures were assayed for p24 using a commercial ELISA kit (Zeptometrix) 
 
Aptamer challenge assays by co-transfection with provirus 
 For assays involving co-transfection with provirus, 5x104 HeLa-CD4 cells were 
seeded into 24-well plates or 2x104 cells were seeded into 48-well plates and incubated 
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overnight.  For infection/transfection of 24-well plates, 100 ng pNL4-3 plasmid was 
mixed with 1.6 µg test plasmid and 2 µL Fugene in 100 µL OptiMEM.  The mixture was 
incubated at room temperature for 20 to 40 min.  During that incubation, media was 
removed from the wells and replaced with 300 µL OptiMEM.  Cells were returned to the 
incubator until the time of transfection.  After incubation, the Fugene mixtures were 
added dropwise to each well.  The plates were rocked back and forth to evenly distribute 
the mix and plates were returned to the incubator.  Four hours later, an equal volume of 
media supplemented with 20% fbs was added to each well. 
 The following day, all media was removed and replaced with growth media.  
Samples were taken every day thereafter for p24 analysis. 
 
Long-term aptamer:infection challenges 
 To assess long-term effects of aptamers in cells, 2x105 cells were infected with 
either an MOI of 0.1 or 0.01 as described above.  Cultures were incubated for 9 days, at 
which point, 5 mL culture was removed for analysis.  The remaining 5 mL culture was 
pelleted to remove cells and the supernatant was filtered through 0.45 µm filters to 
remove cells and cell debris.  The cell-free virus was added to 5 mL containing 2.5x105 
naïve cells, and the process was repeated every 3 days for up to 120 days. 
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CHAPTER 3:   
INTRODUCING “PORTALS” INTO CELLS FOR APTAMER-MEDIATED 
DELIVERY  
 
INTRODUCTION 
How to specifically deliver aptamers to certain desired sites and not to others is a 
puzzle that is tantamount to the success of aptamer therapeutics.  To deliver specifically 
to cells, some mechanism of distinction between different cell or tissue types, at the 
caliber of the immune system itself, must be implemented.  Some strategies have, in fact, 
made use of immune components.  For example, Song et al. used the Fab fragment of an 
anti-envelope antibody to deliver an antiviral siRNA specifically into cells expressing 
HIV proteins on their surfaces.  The delivered siRNAs were able to inhibit HIV 
replication in T-lymphocytes (Song et al., 2005). 
The ability to discern one cell type from another is a challenge that aptamer 
therapeutics may be uniquely suited for.  As aptamers have previously been shown to 
recognize slight differences between similar targets, slight differences in cell surface 
features should be equally exploitable for an aptamer selection.  One approach to doing 
this is to directly select against a known cell-surface marker that is expressed on distinct 
cells.  Several aptamers have already been generated and used against a number of tumor-
related targets in this way.  For example, Lupold et al., selected aptamers against the 
prostate-specific membrane antigen (PSMA), which is highly expressed in some prostate 
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cancer cells (Lupold et al., 2002).  Two aptamers from the selection, A9 and A10, were 
isolated that bound specifically to PSMA expressing (LnCap) cells, but not to a non-
PSMA expressing (PC3) cell line.  Fortuitously, it was later shown that binding of either 
aptamer to the receptor mediated internalization of the aptamer.  Several groups later 
found that other molecules could be co-delivered to PSMA(+) cells by appending them to 
the aptamers.  These aptamers have since been exploited for labeling of PSMA-
expressing cells and delivery of siRNAs, nanoparticles and toxins specifically into 
PSMA-expressing cells (Chu et al., 2006a; Chu et al., 2006b; Farokhzad et al., 2006; 
Farokhzad et al., 2004; McNamara et al., 2006).   
Aptamer technology also provides a means to generate cell-specific aptamers 
without prior knowledge of a relevant target.   In one strategy, a selection could be 
performed against one cell type using different cell types as negative controls in what has 
been termed a “toggle” selection.  First, the pool would be incubated against the non-
target cells.  All species that did not bind would be harvested and applied to target cells.  
Non-target binding species would be washed away and bound species would be 
recovered and amplified, and the process is repeated.  The selection thus enriches for 
species that recognize the target cells but not the non-target cells.  In this manner, 
aptamers are selected against some aspect of the target cell surface that is not present or is 
altered on the non-target cells, regardless of what that factor is. 
As a nice demonstration of this, the Tan group developed cell-specific aptamers 
against CEM and Ramos leukemia cells without any knowledge of what the aptamers 
actually bound to.  Using an N52 ssDNA pool, the Tan group first incubated the pool on 
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the B-cell line, Ramos, then transferred the non-bound species for incubation on CEM T-
lymphocyte cells.  After 20 rounds of selection, 20 clones were chosen for 
characterization.  Of these, 13 were identified that bound CEM cells, ten of which had 
binding affinities in the nanomolar range.  For the most part, the aptamers were capable 
of binding only to CEM cells; three selected aptamers were able to bind to both Ramos 
and CEM cells.  Several of the aptamers were shown to bind to a number of other T-cell 
lines, but not to other B-cell lines (Shangguan et al., 2006).   
The Tan group went on to characterize what the aptamers bound to on the cell 
surface.  One aptamer, sgc8, bound cell surface protein tyrosine kinase 7 (PTK7).  
Similar to the anti-PSMA aptamers, A9 and A10, it was later discovered that binding of 
the aptamer to this protein mediated internalization of the aptamer.  Colocalization 
studies with transferrin showed that the labeled aptamers likely localized to endosomes 
(Xiao et al., 2008). 
These delivery portals could have far-reaching applications but are limited by the 
fact that delivery can only transgress into cells expressing the selected epitope.  One 
method to circumvent this, as outlined in Chapter 4, is to directly select for aptamers that 
can internalize along with therapeutic cargoes.  However, it should also be possible to 
deliver into any cell type, independent of known cell surface epitopes or selections 
against the cell surface, by expressing the aptamer target on the surface of those cells .   
As a proof of principle, we developed a heterologous PSMA-expressing cell line 
(het.HeLa) that should enable delivery of A9- or A10-linked cargos into the cells.  
Expression of PSMA in these heterologously-expressing HeLas (het.HeLas) was 
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analyzed by FACS and also confirmed by Western blots.  These het.HeLa cells stand as 
an early example of an alternate portal, or “back-door,” into cells for specific delivery of 
any number of cargos and may be used to modulate experimental cell expression, develop 
animal models or track cells in research protocols. 
 
 
RESULTS & DISCUSSION 
 
Heterologously expressing PSMA 
A PSMA expression plasmid was constructed by cloning the cDNA of PSMA 
from LnCap cells into the plasmid pEF6 (Invitrogen).  The plasmid was transfected into 
HeLa cells and PSMA-expressing cells were selected for with G418.  After several 
weeks, two lines of cells were expanded, Red and Orange.  A third line (Yellow) failed to 
stabilize.  Western analysis confirmed that both lines expressed PSMA.  However, the 
PSMA band from the Orange line was significantly fainter and clearly of a smaller size 
(Figure 3.1).  Sequencing results showed that this band appeared to correspond to a 
variant of PSMA, PSMAΔ18, that is missing exon 18 (Williams and Kole, 2006).  This 
deletion maps to a portion of the extracellular domain thought to be important for 
dimerization of the protein on the cell surface (Davis et al., 2005).  Dimerization has been 
shown necessary for the folate hydrolase activity of this protein, and thus this variant is 
likely inactive (Schulke et al., 2003).  The antibody recognition portion remains intact in 
the truncated form; however, it is unknown whether the truncation affects antibody 
 Figure 3.1. Westerns of PSMA-expressing HeLa cells (het.HeLas).  At left, the PSMA- 
expressing HeLa line, Red, is compared to a known PSMA-expressing cell line, LnCap,  
as well as the HeLa parental line and HeLa cells transfected with the vector alone (trfx HeLa).  
At right, PSMA expression for the three expanded lines is shown.  The very faint band  
associated with the Orange line is slightly smaller than that from the Red line. 
 
 
 
Figure 3.2.  FACS analysis of PSMA expression of the het.HeLa Red cell line compared  
to the PSMA(+) cell line, LnCap, the variably PSMA(+) cell line, 22RV1, and the  
PSMA(-) cell line, PC3, using a PE-conjugated anti-PSMA antibody.  
 
recognition, which may correlate to the fainter bands we were seeing in Westerns. 
PSMA expression was also confirmed by FACS analysis with a PE-labeled anti-
PSMA antibody which showed a moderate population shift compared to cells not treated 
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with antibody (data not shown).  The 10% of the population representing highest 
expression levels were sorted for and expanded.  After re-growing, the sorted Red line 
showed a dramatic FACS shift when treated with antibody (Figure 3.2).  Interestingly, 
the Orange line, even after sorting and expansion, did not show any more shift than prior 
to sorting (data not shown).  It is possible that although the actual antibody binding site is 
not directly altered, folding of the protein may be altered so as to impede antibody 
recognition.  
 
Figure 3.3.  A9- and TRITC-labeled SA conjugates are specific for PSMA-expressing cells. 
 
Anti-PSMA aptamers recognize and deliver to het.HeLa cells 
Having shown that PSMA could be expressed in non-indigenous cells, it remained 
to be seen whether PSMA would still function in its new context.  We first sought to 
demonstrate aptamer recognition of the heterologously expressed PSMA.  The anti-
PSMA aptamer, A9, was biotinylated and attached to TRITC-labeled streptavidin (SA).  
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A9/SA complexes were incubated on fixed het.HeLa cells.  The A9-conjugated SA 
localized specifically to PSMA-expressing cells (Figure 3.3).  Moreover, this localization 
was shown to be dependent on co-treatment with A9 (Figure 3.4). 
 
Figure 3.4.  TRITC-labeled SA only localizes to cells when conjugated to A9. 
 
FACS analysis also supported the microscopy data.  Stabilized cells were 
incubated with fluorescein-labeled A9 aptamer and sorted.  The Red het.HeLa cells 
shifted significantly after treatment with the aptamer.  Again, the Orange line 
demonstrated minimal shift (Figure 3.5). 
 
PSMA-specific internalization into het.HeLa cells 
Anti-PSMA aptamers have already been used for delivery of a number of cargoes 
including nanoparticles (Farokhzad et al., 2006; Farokhzad et al., 2004), siRNA (Chu et 
al., 2006b; McNamara et al., 2006) and a toxin  (Chu et al., 2006a).  With PSMA stably 
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 Figure 3.5.  FACS analysis of A9 binding to  het.HeLa Red and Orange cell lines. 
 
expressed on HeLa cells, we proceeded to test whether we could exploit the 
heterologously expressed PSMA for delivery.  Streptavidin-coated 655 nm quantum dots 
(QDs) were complexed to the biotinylated version of the anti-PSMA aptamer, A10.  
LnCap or het.HeLa cells were treated with the complexes for an hour, then fixed, 
 
het.HeLa
+ SA-QD
+ N40 pool
LnCap
+ SA-QD
+ N40 pool
het.HeLa
+ SA-QD
(no RNA)
het.HeLa
+ SA-QD
+ A10
(area 1)
het.HeLa
+ SA-QD
+ A10
(area 2)
LnCap
+ SA-QD
+ A10
 
Figure 3.6.  Aptamer conjugate internalization is dependent on the aptamer.   
SA = streptavidin; QD = 655 nm quantum dot (red).  Nuclei are Hoescht stained (blue). 
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permeabilized and examined by confocal microscopy.  Aptamer:SA conjugates were 
found internalized into PSMA-expressing cells.  An N40 random pool was also examined 
as a control and showed minimal internalization (Figure 3.6).  
We were also curious to see if aptamer conjugates would be co-localized with PSMA 
itself.  Aptamer:SA conjugates were incubated on het.HeLa cells.  Then cells were fixed, 
permeabilized and treated with FITC-labeled antibodies against PSMA.  While 
internalization of A10-conjugates was obvious, co-localization was not evident (Figure 
3.7).  This may be due, in part, to the fact that a soluble form of PSMA also exists in the 
cytoplasm which may also be recognized by the anti-PSMA antibody (Williams and 
Kole, 2006).  PSMA and its cargo may also part ways after internalization; while the 
receptor recycles to the surface, the conjugates may be retained.  However, this would 
A10 mutant A10 no RNA
 
Figure 3.7.  Aptamer conjugates (red) appear to be retained in endosomes.  PSMA has 
been labeled in green and nuclei have been stained with Hoescht (blue). 
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likely be difficult to see given the strong and disperse PSMA signal we saw.  The focused 
localization of the aptamer conjugates suggests they may be, in fact, within an endosome.  
A mutant form of A10 failed to mediate internalization. 
Although we were able to visualize aptamer conjugates in cells, we noted that 
internalization was not seen in the whole population, despite clear expression of PSMA in 
almost all of the cells.  While it is possible that different stages of the cell cycle may 
respond differently to our treatment, we also reasoned that some of the population may 
not express PSMA as well as others.  Fifteen clonal lines of the Red het.HeLa cells were 
made by serial dilution and expansion.  FACS analysis of the clones showed that almost 
all lines expressed PSMA.  However, there were indeed several lines that did not respond 
to anti-PSMA antibodies as well or displayed a heterogeneous pattern (Figure 3.8). 
 
 
Figure 3.8.  FACS of clonal lines of het.HeLa cells with an anti-PSMA antibody. 
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CONCLUSIONS & FUTURE DIRECTIONS 
 
We have established an alternate portal into HeLa cells by the heterologous 
expression of PSMA on these cells.  These het.HeLa cells are capable of recognizing and 
internalizing anti-PSMA aptamers.  Previous work by our group and others have shown 
that this PSMA:aptamer interaction can be exploited for delivery of a number of different 
cargos (Chu et al., 2006a; Chu et al., 2006b; Farokhzad et al., 2006; Farokhzad et al., 
2004; McNamara et al., 2006).  This work essentially establishes the delivery system in a 
previously non-receptive cell and demonstrates that by modifying cells with an 
established receptor:aptamer system, delivery of cargoes can be established for any cell 
type.  Having this ability may be of great practical use in research and gene therapy 
applications. 
 
Modulation, monitoring and tracking of gene therapies 
As the technology for stem cell research and ex vivo transplantations becomes 
more realized, the need to monitor, control and modulate transplanted cells becomes 
more pressing.  Perhaps the most extensive work to address these needs come from 
experimental T-cell therapies.  For example, T-cells have been re-engineered ex vivo to 
recognize different targets (e.g., via modified or chimeric receptors, reviewed in 
(Baxevanis and Papamichail, 2004)) or have been injected with DNA to boost immune 
response to specific antigens (Shedlock and Weiner, 2000).  T-cells have also been 
treated with a number of genes that aid in monitoring transgene expression, purification 
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prior to implantation (Phillips et al., 1996) or to act as safety measures after 
transplantation (e.g., suicide switches, reviewed in (June, 2007)).  One example, the 
herpes simplex virus thymidine kinase (HSV-TK) has been used to eliminate infused T-
cell populations at the earliest indication of graft-versus-host disease (Ciceri et al., 2005). 
However, most of these systems essentially operate on an on/off basis.  For 
example, with the HSV-TK genes, cells either live or die.  By engineering a delivery 
portal into cells and altering the cargos we choose to deliver, we can discreetly re-
program cell expression, deliver therapeutic loads, or track cell growth and expansion of 
transplanted cells.  For example, siRNA against any number of genes can be delivered to 
tweak expression levels.  Because of the very modular nature of this delivery system, 
different cargos to effect different outcomes could be simultaneously delivered. 
Another consideration is that the expression of exogenous, non-human proteins, 
even intracellular proteins, has led to problems of immunogenicity.  A number of studies 
have observed rapid clearance of engineered T cells (Berger et al., 2006; Riddell et al., 
1996; Thomis et al., 2001).  The use of an indigenous human protein should minimize 
immunogenic effects.   
 
Research applications 
 Aside from clinical use, this “back-door” approach can be applied to a number of 
research applications.  All the benefits of such a system for gene therapy can be applied 
for animal use or in tissue culture systems.  In both areas, this method essentially 
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becomes a nontoxic way of delivery any number of cargos directly into cells, a 
transfection method without actual transfection reagents. 
Beyond the PSMA-A10 interaction pair, this back-door delivery principle could 
be applied to a number of other receptor portals.  By performing selections against any 
given receptor or cell surface marker, affinity ligand:receptor pairs can be readily made.  
Such a system may be particularly attractive for tissues that have been difficult to target, 
such as the brain. 
 
MATERIALS & METHODS: 
 
Sequences, templates and primers: 
The PSMA gene was amplified from total LnCap cell RNA by Matt Levy.  The 
templates for the anti-PSMA aptamers, A9 and A10, and their extended forms had the 
following sequences: 
 
A9:5’GGGAGGACGATGCGGACCGAAAAAGACCTGACTTCTATACTAAGTCTACGTTCCCAGA
CGACTCGCCCGA 3’ 
 
(A10):5’GGGAGGACGATGCGGATCAGCCATGTTTACGTCACTCCTTGTCAATCCTCATCGGCA
GACGACTCGCCCGA 3’ 
 
where the underlined sequences represent constant regions used to amplify the actual 
aptamers within.  Amplification primers for A9 and A10 were as follows: 
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psma5: 5’ TTCTAATACGACTCACTATAGGGAGGACGATGCGG 3’ 
psma3:  5’ TCGGGCGAGTCGTCTG 3’ 
 
Extended versions of the aptamers were created by amplifying the aptamer templates 
with the forward primer, psma5, and the augmented reverse primer: 
 
psma.3ext.R:5’CTGGTCATGGCGGGCATTTAATTCTCGGGCGAGTCGTCTG 3’ 
 
which added extra sequence to the aptamer for hybridization to a capture oligo.  To make 
the template for fluoresceinated transcription, templates were amplified with a variant of 
psma5 that added the requisite thymidine residue (in red): 
 
psma5+T: 5’TTCTAATACGACTCACTATTAGGGAGGACGATGCGG 
 
All primers and the A9 template were ordered from IDT (Coralville, IA). 
 
Cell lines and culture: 
All cell lines were grown in media supplemented with 10% FBS at 5% CO2 and 
37°C.  LnCap and 22RV1 cells were grown in RPMI-1640, while HeLa cells and all 
HeLa derivatives were grown in DMEM.  PC3 cells were grown in Ham’s F12K media.  
All media was purchased from ATCC.  For selection of PSMA-expressing cells, HeLa 
derivative lines were grown in 5 µg/mL blasticidin (Invitrogen).  All cell centrifuging 
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steps were at 1,500 rpm at 4°C for 5 min.  DPBS and DPBS with Mg2+ and Ca2+ were 
purchased from Invitrogen. 
 
Making PSMA expression lines: 
The PSMA gene was amplified by Dr. Matthew Levy from total cell RNA 
extracted from LnCap cells.  Total cell RNA was RT-PCR’d using the gene-specific 
primers, and the purified gene product was cloned into the pEF6 plasmid (Invitrogen) 
which expresses constructs under the EF1 promoter and has blasticidin resistance. 
Three plasmids, termed Red, Orange and Yellow, from the cloning process were 
used to transfect cells.  One day prior to transfection, approximately 106 HeLa cells were 
seeded into each well of a 12-well plate.  For each transfection, 300 ng of each Qiagen-
purified plasmid was transfected into each well via Fugene using manufacturer protocols 
(Roche).  After 72 hrs, cells were submitted to selection using 2.5 µg/mL blasticidin.  
After a week, the selection was increased to 5 µg/mL blasticidin.  When non-transfected 
cells were fully eliminated, cells were submitted to FACS and high-expressing lines were 
sorted and re-grown. 
 
Westerns for PSMA expression 
Cells for Western analysis were trypsinized, counted, washed and resuspended in 
the number of microliters of MPER (Thermo Fisher Scientific) equal to 1/1000 the cell 
count.  For example, for 105 cells, the cells were resuspended into 100 µL MPER. 
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Twenty microliters of each lysate was loaded onto a 4-20% gradient gel (Thermo 
Fisher Scientific) in Tris-HEPES buffer (100 mM Tris base,  100 mM HEPES free acid, 
35 mM SDS).  After electrophoresis, the gel was transferred to nitrocellulose in 1X 
blotting buffer (25 mM Tris base, 250 mM glycine, 0.1% SDS and 20% methanol).  The 
transferred nitrocellulose was blocked in 5% milk in PBST (PBS with 0.1% Tween) for 
15 min.  The top half of the gel was incubated in 3 mL 5% milk solution containing 2.5 
µg mouse anti-PSMA antibody (Invitrogen).  The bottom half of the gel was incubated in 
3 mL 5% milk solution with 10 µg mouse anti-β-actin antibody (Sigma-Aldrich).  Both 
halves were incubated overnight at 4°C with rocking.  Following incubation, the 
nitrocellulose halves were each washed 3 times with PBST.  A 1:10,000 dilution of anti-
mouse alkaline phosphatase was added to each half and shaken at room temperature for 
1-2 hrs.  The nitrocellulose halves were again washed 3 times with PBST for 
approximately 5 min each wash.  The halves were rinsed with dH2O and a developing 
reagent was added to each half.  For the bottom half containing β-actin, developing was 
stopped after approximately 1 min.  For the top half containing PSMA, developing went 
for approximately 5 min. 
 
Labeling of aptamers 
To make biotinylated aptamer, aptamer RNA was incubated in 100 mM NaOAc 
(pH = 5.2) and 100 mM NaIO4 for 90 min at room temperature in the dark.  The reaction 
was stopped by adding KCl to a 250 mM final concentration and icing for 15 min.  
Precipitated salts were removed by centrifugation at 13,000 rpm for 1 min followed by 
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transfer through a 0.45 µm Microcon tube.  NaOAc to a final volume of 200 mM and 2.5 
volumes of 100% were added to the tubes for precipitation.  After a 15 min cold exposure 
at -80°C, the tubes were spun at 13,000 rpm at 4° for 45 min.  The ethanol supernatant 
was removed, the pellets were air dried and the pellet was resuspended in 100 mM 
NaOAc and 10 mM biotin hydrazide.  The reaction was incubated overnight at room 
temperature.  NaCl to a final concentration of 0.3 M and 2.5 volumes 100% ethanol was 
added to precipitate the RNAs as before.  The pelleted RNA was gel purified on an 8% 
acrylamide:7 M urea gel.  The RNA from the gels were excised from the gel and eluted at 
37°C overnight in 0.3 M NaCl.  The eluted RNA was precipitated as before using 2.5 
volumes of ethanol and resuspended in dH2O. 
Fluoresceinated aptamers were produced in one of two ways.  In one, the 
templates for the aptamers were re-amplified with alternate primers to add a thymidine 
residue at the 5’ end.  For the ensuing transcription, a 5’ fluoresceinated and modified 
ATP residue (FL-ATP; Adegenix) was directly added to the transcription mix.  
Incorporation of the FL-ATP was shown to be about 50% efficient (data not shown).  The 
transcribed RNA was gel purified on 8% acrylamide:7M urea gels, eluted and then 
precipitated as described above. 
An alternate way to produce fluoresceinated or biotinylated RNA involved 
making an extended version of the aptamer templates.  A fluoresceinated or biotinylated 
RNA tag (capture oligo) was synthesized and hybridized to the aptamer RNA by heating 
both in a binding buffer to 70°C for 3 min and slow cooling to room temperature. 
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FACS analysis: 
For antibody-based FACS, approximately 106 cells were trypsinized, pelleted and 
washed with 5 mL FACS buffer (2% fbs in DPBS).  After the wash, cells were 
resuspended in 10 µL blocking buffer (0.1% BSA in DPBS) and sat for 5 min at room 
temperature.  After incubation, 10 µL PE-conjugated anti-PSMA antibody (MBL 
International) was added to the cells and incubated for 20’ at room temperature.  For 
negative controls, cells were incubated in DPBS.  
After incubation, cells were pelleted, resuspended in the FACS buffer and sorted 
with an FACS-Aria using a 70 µm nozzle.  Cells were collected directly into DMEM 
supplemented with 10% fbs and 5 µg/mL G418.  For assays in which cells were not 
collected afterwards, the FACS and blocking buffers also contained 0.1% NaN3.   
For analysis of fluorescein-labeled aptamer to cells, FACS assays were as 
performed with the antibody assays except that incubation with the aptamers was for 30 
min and each wash buffer also included 0.1% NaN3. 
 
Fluorescence and confocal microscopy: 
For fluorescence microscopy assays involving streptavidin (SA), aptamer:SA 
complexes were made by first denaturing the aptamer in DPBS with Mg2+ and Ca2+ at 
70°C for 3 min, then slow cooling it to room temperature.  The renatured aptamer was 
then mixed with SA at a molar ratio of either 2:1 or 4:1.  Unless otherwise noted, 
complexes were typically used at 50 nM, where the concentration reflects the 
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concentration of the whole complex (i.e., usually the SA concentration).  In the 
fluorescence microscopy data, a FITC-labeled SA was used (Invitrogen). 
One day prior to the assay, het.HeLa cells were plated into 8-chamber slides at a 
density of 4x104 cells/chamber.  The next day, cells were washed three times with DPBS 
and then overlay with aptamer:SA complexes in DPBS + Mg2+, Ca2+.  Cells were 
incubated at room temperature for 30 min, then the chambers were washed 3 times with 
DPBS before microscopy. 
For confocal microscopy,  aptamer:SA complexes were made using either SA-
conjugated 655 nm  or 715 nm quantum dots (Invitrogen) in place of free SA and the 
extended aptamer sequences hybridized to a biotinylated capture sequence.  Complexes 
were assembled using a 4:1 ratio of RNA to SA, assuming approximately 5 SA molecules 
per dot.   The complexes were added to cells at 50 nM and incubated for 1 hr on cells in 
8-chamber slides as above.  After incubation, cells were washed and fixed with 4% 
paraformaldehyde in DPBS at room temperature for 15 min.  For the initial tests, cells 
were just washed after fixation and examined on a Leica AOBS confocal microscope.  
For later tests, cells were then permeabilized with 0.1% Triton-X-100 and 0.2% BSA in 
DPBS room temperature for 10 min.  The cells were blocked with 2% BSA in PBS at 
room temperature for 30 min.  The cells were then treated with 0.4 µg mouse anti-PSMA 
antibody in 0.2% BSA in DPBS at room temperature for 45 min.  Cells were washed and 
0.4 µg of FITC-labeled anti-mouse antibody in 0.2% BSA in DPBS was incubated on 
cells for 15 min along with a 1:10,000 Hoescht solution.  Cells were washed and 
examined by confocal microscopy.  Confocal images were taken by Tim Larson. 
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CHAPTER 4:   
A SELECTION FOR SELF-INTERNALIZING RNA 
 
INTRODUCTION 
Many small molecule and nucleic acid based therapeutics and diagnostic reagents 
are rendered impotent, given the difficulty of delivering these agents into cells and 
targeting them to the appropriate sites of action.  Currently, delivery of agents into cells 
requires coordinate delivery mechanisms that are often toxic, inefficient or highly non-
specific.  There do exist RNA-based cell delivery technologies exist that circumvent this 
problem which rely on aptamers that bind to cell-surface markers and are then 
endocytosed (e.g. the anti-PSMA aptamers, A9 and A10, see (Chu et al., 2006a; Chu et 
al., 2006b; Farokhzad et al., 2006; Lupold et al., 2002; McNamara et al., 2006)).  
However, while delivery via aptamers such as A9 or A10 represents a great step forward 
in cell-specific targeted therapy, the selection that made these possible may not apply to 
other targets.  The selection that generated the anti-PSMA aptamers was originally an in 
vitro selection against a specific target.  That is, the target was chosen and purified 
specifically for the selection.  Having to identify and generate therapies against individual 
and appropriate disease epitopes will prove to be a most tedious task.  There also exists 
the possibility that, unlike the anti-PSMA aptamers, aptamers selected against specific 
epitopes may not necessarily function as potential delivery agents, since cell-surface 
recognition doesn’t necessarily equate to internalization or delivery.   
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Aptamer technology should enable the selection of nucleic acids that can not only 
recognize a cell, but also enter it.  Much like the cell-surface selections described in 
earlier, these types of selections should be possible independent of any knowledge of the 
cell surface architecture.  By establishing conditions during the selection that eliminate 
cell-surface binders as well as non-internalizers, only extremely tightly bound aptamers 
or aptamers that had internalized would be recovered.   
We have developed such a selection scheme for RNA capable of internalizing into 
cells without the aid of conventional transfection or delivery mechanisms (e.g. cationic 
liposomes, electroporation, transfection reagents, etc).  This scheme should be adaptable 
to produce RNAs that internalize into specific cells, different states of cells, or to cells in 
general.   
 
 
RESULTS & DISCUSSION 
 
We have developed a selection scheme to identify nucleic acids from randomized 
sequence pools that can internalize into cells without the aid of delivery agents or 
methods.  Briefly, a nucleic acid pool is added directly to cells and incubated for 
decreasing lengths of time over the course of the selection.  The cells are washed several 
times, and a stringent nucleasing step after the incubation removes molecules that remain 
bound after washing, but have not internalized.  Total cell RNA is extracted, and 
internalized sequences are recovered by RT-PCR and transcription (Figure 4.1).  
 Figure 4.1.  A method to select RNA capable of internalizing into cells. 
 
Proofing the selection method 
For our initial selection, we chose to use a 2’-fluoro-modified RNA pool with a 
30-base random region to select for sequences that would internalize into HeLa-CD4 
cells.  A modified RNA pool was chosen since modified RNAs should remain largely 
nuclease-resistant.  Only pyrimidines were modified, since incorporation of the modified 
nucleotides is inefficient and substituting all the bases would result in low yields.  While 
we opted for a pool that was nuclease-resistant, our selection protocol required a stringent 
nuclease step to remove cell-surface binders.  To determine which nuclease would be 
most apt for our selection, we digested Round 0 pool with various commercial nucleases.  
An example of such digestions is shown in Figure 4.2, where pool RNA was incubated 
with RNAse T1 (which cleaves after G residues) or Riboshredder, a commercial cocktail 
of nucleases.  Surprisingly, RNAse T1 was only capable of cleaving some of the pool.  
Meanwhile, Riboshredder effectively eliminated all full-sized pool RNA.   
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 Figure 4.2.  Digestion of the 2’fluoro-modified pool with varying units of Riboshredder 
(Rb) or nuclease T1 in the presence of cells.  Non-digested RNA in the presence of cell 
lysate is shown at left (lysate).  Two controls not exposed to nuclease is shown at right.   
 
To proof that the procedure would occlude binders and ensure survival of 
internalizers, we tested a known internalizing RNA sequence, the anti-PSMA aptamer, 
A9 (Lupold et al., 2002), with our nucleasing conditions (Figure 4.3).  Approximately 
106 LnCap cells were treated with one of four conditions: anti-PSMA aptamer was added 
directly to media on cells (RNA); cells were first treated for 10 min with 10 mM sodium 
azide (az; an inhibitor of oxidative phosphorylation) and 50 mM 2-deoxyglucose (dG; an 
inhibitor of glycolysis)  to prevent endocytosis, then RNA was added to the media after 
washing (az-dG);  RNA was added to cells, and then cells were nuclease treated with 
Riboshredder (Invitrogen) to digest binders (Rb); or cells were treated with az-dG before 
adding RNA, and cells were nuclease treated after RNA digestion.  To further prevent 
internalization by other mechanisms, samples that were treated with sodium azide and  
deoxyglucose were also incubated on ice-cold blocks after the addition of RNA.  Each 
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Figure 4.3.  Proofing the selection protocol.  The anti-PSMA aptamer was tested for 
internalization as described in the text.  
 
treatment was performed in triplicate.  
Total cell RNA from each of the treatments was reverse-transcribed with aptamer-
specific primers, and real-time PCR cycles were determined relative to non-treated cell 
controls.  Treatment with az-dG reduced the ΔCT signal slightly while treatment with Rb 
reduced the signal drastically, indicating that much of the aptamer remained extracellular, 
but some were being protected.  Treatment with both az-dG and Rb abolished signal 
completely suggesting that the signal from the Rb treatment was due to internalized 
aptamer. 
 
Internalization selection 
The selection was performed as outlined in Figure 4.1.  The nucleasing step was 
not included in the first two rounds.  For rounds 2 - 6, the RNA pool was incubated on 
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cells for 1 day (Table 4.I).  At certain rounds of the selection, pool-treated cells were 
Trizol-extracted and the total RNA was reverse transcribed and amplified in real-time 
PCR reactions to check for the presence of pool RNA in cells. 
Round 1 2 3 4-6 7-9
input RNA 57.5 ug 20 ug 20 ug 10 ug 10 ug
incubation 3 days 1 day 1 day 1 day 1 hour
RNAse No Yes Yes Yes Yes  
Table 4.I.  Conditions for the internalization selection.  After 6 rounds,  
incubation time was reduced to 1 hr. 
 
After Round 6, amplification signal appeared to have peaked (see Figure 4.4).  
Subsequent rounds were only incubated on cells for 1 hour.  Decreasing the length of 
time the pool was exposed to cell surfaces should effectively winnow away species that 
internalize very slowly (and are, therefore, not as useful for downstream applications) or 
that may have internalized by non-specific cell processes over time.  This method of 
reducing incubation times, therefore, selects for RNAs that functionally and quickly enter 
the cell.  
-1
0
1
2
3
4
5
6
7
8
cells Rd.0 Rd.3 Rd.6 Rd.9 psma-A9
(d
)(d
)C
t (
re
la
tiv
e 
to
 G
A
PD
H
)
 
Figure 4.4. Progress of 2’-fluoro-modified internalization selection against HeLa-CD4 cells 
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CONCLUSIONS & FUTURE DIRECTIONS 
 
The necessity for a facile, robust and effective means of delivery drugs into cells 
without triggering negative side-effects led us to design a selection scheme for RNA that 
could internalize into cells independent of transfection reagents or physical manipulation.    
We have selected for RNA that appears to internalize into cells without any means of 
transfection.  Further work will determine if these sequences are capable co-delivering 
various cargoes.  Additionally, it would be interesting to determine if these selected 
sequences are cell-type specific or if they can internalize into any cell type.  Regardless 
of which, it would also be interesting to further develop the method to be finely cell type-
specific, as further described below. 
This procedure thus provides a means for selecting self-delivering RNA species.  
Moreover, we demonstrate how this should be possible without prior knowledge of the 
specific ligands or receptors the aptamer might bind to.  Unlike other delivery methods, 
internalizing RNAs should be non-toxic and could be target cell-specific.  This could be 
of great benefit in in vivo applications and offers several advantages over other delivery 
methods. 
For example, selections using this method would take into account the different 
states of cells.  The anti-PSMA aptamer may internalize into PSMA-expressing cells; 
however, PSMA expression levels vary significantly between cell types and tumor 
progression (Bostwick et al., 1998).  The internalizers of this scheme could be selected 
against specific cell types or disease states and could, therefore, be engineered to 
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internalize according to the specific requirements of delivery, including to multiple cell 
types or disease states if necessary.   
These internalizing RNAs would also have a significant advantage over 
diagnostic and detection applications where cells must be harvested or fixed for 
processing.  The carrier RNAs from these selections could potentially internalize without 
compromising the cell, such that intracellular processes can be detected in real time with 
live cells.   
Most importantly, selected internalizing RNAs may also be capable of co-
internalizing cargo.  One strategy to accomplish this would be to simply append the cargo 
to the selected sequence itself.  Bruce Sullenger’s group has demonstrated the feasibility 
of this technique using the anti-PSMA aptamer, A10 (McNamara et al., 2006).  Two 
different siRNA sequences, against plk1 and Bcl2, were joined to the A10 sequence and 
layered on PSMA(+) (LnCap) and PSMA(-) (PC3) cells.  Significant knockdown was 
seen in the PSMA(+) cells, while knockdown in PSMA(-) cells was negligible.  A mutant 
A10 sequence was also used as a control which did not effect siRNA knockdown.   
A different approach was used by Chu et al.  Instead of a direct conjugation to the 
aptamer itself, Chu et al. biotinylated the anti-PSMA aptamer, A9 and the siRNA and 
attached these to the tetravalent protein streptavidin (SA) to produce aptamer/siRNA/SA 
complexes (Chu et al., 2006c).  Adding these complexes to the LnCap PSMA(+) cells 
showed significant knockdown of Lamin A/C while the PSMA(-) cell line, PC3, showed 
no knockdown.   
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Aside from these post-selection schemes, a modification of our internalization 
selection procedure could be added from the get-go to ensure that nucleic acids not only 
enter the cell, but also carry some type of cargo with it.  To do such, the selection would 
be designed to include the cargo as part of the selection: 
 
i. The cargo could be directly synthesized as part of the pool.  For example, 
a selection for RNAs to deliver an siRNA would use a pool in which the 
siRNA sequence would be added as a constant region near the random 
region. 
 
ii. The pool could be synthesized with a constant sequence or hybridization 
sequence tag that could be used for attachment.  After selection, an 
oligonucleotide complementary to the tag sequence can be used to tether 
the selected sequence to labels or cargo.  For example, if the complement 
primer were biotinylated, it could be used to attach the selected RNAs to 
streptavidin.  Cargo could also be attached to the same streptavidin 
molecule, and the whole complex would be delivered by the selected 
RNA. 
 
iii. Although it could be a little more cumbersome, the pool could be 
synthesized with a number of other modifications that would be carried 
out throughout the entire selection.  For example, the addition of a 
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fluorophore or some other marker would facilitate monitoring of the 
progress of the selection.  Additionally, a marker would allow for easier 
characterization of localization, internalization rates and other aspects of 
the selected aptamers. 
 
Limitations of the selection 
 There may exist several limitations to this selection process.  For example, there 
exists the possibility that sequences in the pool may fold into nuclease-resistant structures 
and therefore, survive the process and be carried through the selection.  Similarly, species 
could be carried through rounds of selection that do not, in fact, internalize but happen to 
bind very tightly to the cell.  These types of sequences should be readily identified during 
functional or characterization assays.  For example, individual sequences could be tagged 
with a marker or some sort of cargo, and cell-surface binders could be separated from 
those capable of internalizing.  Alternately, individual sequences could be tested with a 
battery of different nucleases to ensure that their “protection” during selection is due to 
internalization and not just resistance. 
Another potential limitation of these internalizing RNAs is that a selected RNA 
might no longer function once attached to its cargo.  To address this, a variation of the 
selection scheme could include tags or even the cargo itself as part of the selection to 
ensure internalization in the presence of the cargo.   
A pronounced setback in our selection scheme rests in the fact that the selected 
RNAs were not readily detectable.  That is, the only way to detect them was by 
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destroying the cells and amplifying the internalized pieces or establishing a functional 
assay.  This also made it difficult to characterize the aptamer.  For instance, data could 
not be immediately drawn regarding the amount of aptamer that internalized, where it 
localized and how stable the aptamer is in the cell.  Our lab aims to answer these 
unknowns by labeling clones of our selected sequences with fluorescent tags for FACS 
and confocal microscopy.  Future selections along these lines could include labeled 
RNAs as the selection pool or include constant regions that can be used as affinity tags 
during the selection to monitor progress (see above). 
 Many potentially undesirable results associated with this selection method could 
readily be addressed by adjusting the selection procedure.  In addition to changing the 
selection conditions to address specific problems, variations can be introduced at several 
different points of the protocol for a number of different reasons.  The nucleic acid pool 
could be RNA, ssDNA, or RNA incorporating different types of modifications such as 
2’-fluoro-modified nucleotides, 2’-amino-modified nucleotides, 2’-O-methyl-modified 
RNAs, nucleic acids with peptide backbones, etc or combinations of such.  The type of 
cells, length of incubation, washing solution, number of washes, types of nucleasing, 
number of cycles and methods of nucleic acid extraction could also be varied.  A further 
modification of the selection might be employed wherein functional assays would be part 
of or performed periodically over the course of the selection.  For example, an siRNA-
delivering RNA selection might involve shorter incubation times (if the siRNA could 
have lethal effects) or could include assessing target levels as along the course of the 
selection. 
 145 
 Importantly, this selection method can be also be adjusted to address a number of 
delivery-specific requirements.  To find nucleic acids that would only enter liver cells, 
but not any other type of cell, the selection could incorporate a step involving non-target 
cells to fine-tune specificity.  The pool would first be added to any of a number of other 
cell types.  After incubation, the non-target cells would be washed of any species that 
didn’t bind or enter the non-target cells.  These non-internalizing species would then be 
added to the target liver cells, and the selection would proceed as illustrated to select for 
internalizers.  The selection technique could be adjusted to find internalizers of specific 
cell types, disease types or of any cell in general.  Furthermore, these RNAs can be 
selected to enter cells in serum-containing media or any number of buffers and solutions.  
It is, therefore, readily conceivable that these RNAs would also internalize into tissue 
cells in vivo. 
 
Other internalizing aptamers: 
During the course of this work, in addition to the anti-PSMA aptamers by Lupold 
et al., two other groups have also developed aptamers capable of internalizing.  Wu et al. 
selected against the Burkitt’s lymphoma Ramos cells using a single-stranded DNA pool 
(Wu et al., 2003).  Instead of a nucleasing step to remove cell-surface bound aptamers, 
they incorporated an acidic stripping solution of 0.2 M glycine/HCl.  After 10 rounds of 
selection, they sequenced their aptamers and analyzed them for internalization.  The 
authors came to the conclusion that their aptamers abounded with G-rich 3’ ends which 
they claimed helped to mediate binding to cell surfaces.  Internalization assays showed a 
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marked improvement of at least one of the two aptamers over a control oligonucleotide, 
but the other aptamer they analyzed fared as poorly as a control oligonucleotide that they 
also tested.  While promising, this internalization data and a few other inconsistencies 
need to be addressed. 
Dr. Weihong Tan’s group indirectly developed internalizing aptamers in a 
different manner.  The Tan group performed a selection to find ssDNA that would bind to 
the acute lymphoblastic leukemia cell line, CEM (Shangguan et al., 2006).  They 
successfully reported aptamers that could bind to different states of CEM cells as well as 
distinguish them from closely related cells in a mixed-cell environment.  After analyzing 
their sequences, the Tan group found that one, sgc8, bound the cell surface marker, 
protein tyrosine kinase-7 (PTK7).  Like the anti-PSMA aptamer, this aptamer proved 
capable of being internalized, as demonstrated by confocal microscopy.  The group went 
on to show that internalized sgc8 localized to endosomes (Xiao et al., 2008). 
 
Conclusion: 
Our selection and those by the Carson and Tan groups represent a first step in 
developing specific and non-immunogenic delivery agents for in vivo applications.  In 
summary, this ability to directly enter cells makes these RNAs a unique bio-tool with 
broad-reaching applications.  RNAs selected to enter certain types of cells could be 
attached to a variety of therapeutic molecules.  For example, they could be attached to 
gene modulators such as siRNA or aptamers.  Alternately, they could be attached to other 
small molecule drugs such as toxins.  These internalizing RNAs could also be labeled 
 147 
with fluorescent tags or other probes and used to type, locate or otherwise mark specific 
cells (e.g. cancer cells).  Appended to aptamers or beacons, the internalizing RNAs could 
signal the internal expression profile of cells without compromising cell integrity, as 
current FISH techniques do.  Such labeled agents could be used for diagnostics as well as 
in microscopy, FACS, microarray and a variety of other techniques.   
 
 
MATERIALS & METHODS: 
 
Sequences and primers: 
The N30 pool used for these selections had the following sequence: 
 
5’GGGAATGGATCCACATCTACGAATTCNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNTTCAC
TGCAGACTTGACGAAGCTT 3’ 
 
where N is any of the four bases.  The pool was synthesized and purified as described 
below.  Amplification primers for the N30 pool were as follows: 
 
41.30: 5’GATAATACGACTCACTATAGGGAATGGATCCACATCTACGA 3’ 
24.30: 5’AAGCTTCGTCAAGTCTGCAGTGAA 3’ 
 
The template for the anti-PSMA aptamer, A9, used in these assays had the following 
sequence: 
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5’GGGAGGACGAUGCGGACCGAAAAAGACCUGACUUCUAUACUAAGUCUACGUUCCCAGACGA
CUCGCCCGA 3’ 
 
where the underlined sequences represent constant regions used to amplify the aptamer. 
Amplification primers for A9 were as follows: 
 
psma5:5’TTCTAATACGACTCACTAT AGGGAGGACGATGCGG 3’ 
psma3:5’TCGGGCGAGTCGTCTG 3’ 
 
All primers and the A9 template were ordered from Integrated DNA Technologies (IDT). 
 
Pool synthesis and purification: 
The pool used in this selection consisted of 30 random residues flanked by 
constant regions.  The pool was synthesized on an ABI Expedite 8909 synthesizer.  
Randomized positions were generated by mixing the phosphoramidites for A, C, G and T 
at a molar ratio of 3:3:2:2.4 such that the coupling efficiency of each base is 
approximately equal, and the final composition of a random position has a 25% chance of 
being an A, C, G or T.  
The solid phase resin of the synthesis was suspended in 1 mL of 30% NH4OH 
overnight at 55°C to deprotect the DNA.  The reaction was centrifuged to pellet the resin, 
and the NH4OH layer containing the DNA was precipitated in 10 mL n-butanol at 4° and 
13,000 rpm for 45 min.  The pellet was washed with 70% ethanol and then dried.  Given 
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that aborted synthesis products are often present in long sequences, the DNA was gel-
purified on a 10% acrylamide / 7M urea gel.  The band corresponding to full-length 
product was excised from the gel, chopped into fragments and eluted overnight in dH2O.  
The eluted DNA was precipitated in 100% ethanol with glycogen as a precipitation 
carrier, washed with 70% ethanol and dried. 
Following deprotection and purification, the single stranded DNA pool was 
converted to dsDNA by extension and large scale PCR using the primers 41.30 and 
24.30.  The 41.30 primer also served to add a T7 promoter sequence to the pool for later 
transcription steps.  Approximately 2.8 nmol single stranded pool DNA was mixed with 
115 nmol 24.30 primer and 0.2 mM each nucleotide (dATP, dCTP, dGTP and dTTP, GE 
Healthcare) in a total volume of 43 mL.  The sample was denatured at 65°C for 5 min and 
then chilled to 4°C.  A master mix of 50 mM KCl, 100 mL Tris-Cl (pH = 8.3), 1.5 mM 
MgCl2,  1,440 U Taq polymerase (New England Biolabs) in a total volume of 43.3 mL 
was added to the denatured pool and incubated at 72° for 1 hr.  At the end of the 
extension, 115 nmol 41.30 in a total volume of 28.7 mL was added, and the reaction was 
cycled at 94°C for 30 sec, 50°C for 30 sec and 72° for 1 min for 8 to 9 cycles, followed 
by a 72°C step for 2 min.  PCR products were precipitated in 2.5X volumes 100% 
ethanol at 4° for 45 min followed by a 70% ethanol wash and then dried. 
A large scale transcription was performed to generate the starting Round 0 pool in 
which 75 µg pool PCR was added to a 1.5 mL transcription mix of 40 mM Tris (pH = 
8.0), 26 mM MgCl2, 5 mM DTT, 5 mM ATP, 5 mM GTP, 5 mM 2’-fluoro-CTP, 2’-
fluoro-UTP, 0.01 U pyrophosphatase and 75 U of Y639F T7 polymerase (made in the 
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Ellington lab by Chi Tai (Ted) Chu).  The N30 pool had previously been estimated to 
have a complexity of approximately 1015 sequences.  This input amount would, therefore, 
represent about 1.5 genome’s worth of sequences.  In other words, this scale of 
transcription should adequately account for each possible sequence synthesized and 
therefore, represented maximal diversity. 
The transcription reaction was allowed to run overnight at 37°C.  After 
incubation, 75 U of DNAse I (Epicentre) was added to the reaction, and the reaction was 
further incubated for 30 min.  An equal volume of 2X denaturing dye (7 M urea, 90 mM 
Trizma base, 90 mM boric acid, 0.5 mM EDTA and 0.1% bromophenol blue) was added, 
and the reaction was denatured at 70°C for 3 min before gel purification, as described 
above. 
 
Cell lines and culture: 
HeLa-CD4 cells were obtained from the NIH AIDS Research & Reference 
Reagent Program.  LnCap cells were purchased through ATCC.  Both lines were 
maintained in RPMI-1640 (ATCC) supplemented with 10% fbs (Invitrogen) and grown 
at 37°C and 5% CO2 atmosphere.   For trypsinization, cells were washed once with 1 
culture volume of DPBS, then 1/10 volume of 0.05% trypsin-EDTA (Invitrogen) was 
added to the cells.  Cells were incubated at 37°C for approximately 2 min until cells lifted 
off.  The trypsin was inactivated by adding culture media. 
All cell washing steps used room temperature PBS.  All cell centrifugation steps 
were at 4°C and 1500 rpm for 5 min. 
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Nuclease assays 
To ensure that the modified RNAs and cells could survive the digestion and 
selection protocol, the dsDNA pool was transcribed as described above iin a scaled-down 
reaction.  α-32P-labeled-GTP (Perkin Elmer) was included in the reaction to generate 
body-labeled radioactive transcripts.   
For the assay, approximately 4 x 106 HeLa-CD4 cells were aliquoted into each 
experimental tube, spun down at 1500 rpm at 4°C for 5 min.  After washing once with 
500 µL PBS, each tube of cells was resuspended into 85 µL of RNA and incubated at 
room temperature for 15 min.  Different amounts of Riboshredder or RNAse T1 were 
added and the cells were incubated for another 30 min.  The cells were spun away and the 
recovered RNA was run on an 8% acrylamide gel with 1X TBE and 7 M urea.  The gel 
was dried onto filter paper (Whatman) and exposed overnight on a phosphorimager 
screen for scanning. 
In addition to the survivability of the selected RNAs, it was also important to 
determine that cells were not adversely affected by the washing, incubation or nucleasing 
steps.  For the several repeats of these nuclease digestion assays, cells were counted and 
aliquoted into separate tubes.  At different intervals, cells from each of the tubes were 
mixed and counted again.  No significant cell health issues were observed. 
 
Internalization assay 
To proof that the techniques we proposed would not select for RNAs just bound 
the cell-surface without internalizing, we performed an internalizing assay with a known 
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cell surface aptamer, the anti-PSMA aptamer, A9 (Lupold et al., 2002).  A9 was 
transcribed from an oligo template using a scaled-down version of the pool transcription 
outlined above in “Pool synthesis and purification”.   
 Three days prior to the assay, 1x105 LnCap cells were seeded into a 24-well plate.  
After the cells had settled, cells were washed and fresh media was added.  After 
equilibrating for an hour at 37° and 5% CO2, the cells were treated with one of four 
conditions.  In the “RNA” sample, 50 nM A9 was added directly to media on cells for 45 
min.  In the “az-dG” sample, cells were first treated for 10 min with 10 mM sodium azide 
and 50 mM deoxyglucose to prevent endocytosis, then RNA was added to the media after 
washing with 250 µL DPBS.  In the “Rb” sample, RNA was incubated on cells, and then 
cells were washed with 250 µL DPBS before nuclease treatment with 0.02 U/uL 
Riboshredder (Epicentre, Madison, WI) for 15 min to digest binders.  Finally, in the “az-
dG/Rb” sample, cells were treated with az-dG before adding RNA, and cells were 
nuclease treated after RNA digestion.  Following addition of RNA, those samples treated 
with az-dG were also incubated on ice-cold blocks to arrest other internalization 
mechanisms.  Each treatment was performed in triplicate.   
 After treatment, all samples were washed with 500 µL DPBS, and total cell RNA 
from each sample was extracted with Trizol (Invitrogen) using Phase Lock tubes 
according to manufacturer protocols (Eppendorf).  Quantitation of the RNAs showed 
similar amounts of recovered RNA (data not shown), suggesting that none of the 
treatments significantly varied in content.  The total extracted RNA was reverse-
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transcribed with aptamer-specific primers in scaled-down reactions akin to those 
described in “Pool synthesis and purification” and assayed by real-time PCR. 
 
Real-time PCR 
 For real-time PCR, 600 nM psma5 and psma3 was mixed with 12.5 µL 2X 
SybrMix and 10 µL of a 1:10 dilution of each of the RT reactions.  The samples were 
loaded onto an ABI 7300 real time machine and cycled as follows:  95°C for 10 min, 
followed by 40 cycles of 95° for 30 sec, 50°C for 30 sec and 72°C for 1 min.  Following 
cycling, a dissociation step was included to check the integrity of products as follows:  
95°C for 15 sec, 60°C for 30 sec and 95° for 15 sec.  The ΔCT was determined by 
comparing the CT of each sample to a non-treated cell control.  
 
Internalization selection: 
One day prior to a selection round, 4 x 105 HeLa-CD4 cells were plated onto two 
60 mm tissue culture plates.  One hour prior to each selection round, the culture media 
was replaced with fresh media.  For the first round of selection, 54 µg of modified pool 
RNA (1.2 mM), representing approximately 1 genome’s worth of the pool, was added to 
one of the two plates.  After incubation for 3 days, the cells were trypsinized, washed 
twice with D-PBS (Invitrogen, Carlsbad, CA) and total cell RNA was extracted from 
both plates using 1 mL Trizol and Phase Lock tubes following the manufacturer’s 
instructions.   
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The recovered total cell RNA was reverse transcribed as follows: a reaction 
containing 84 µg total extracted RNA and 10 µM 24.30 reverse primer in 1X RT buffer 
(Invitrogen) was denatured at 70° for 5 min and then slow cooled to room temperature.  
A master mix of 10 mM DTT, 1 mM each dNTP and 28 U Superscript III reverse 
transcriptase (Invitrogen) was added into the mix and incubated at 50°C for 1 hr.  Smaller 
scaled no-RT controls of both pool-exposed and non-exposed cells were also performed 
to confirm that any recovered product was input pool RNA and not cell artifact or 
carryover DNA template. 
One half of the RT reaction was used to seed the large scale PCR for the next 
round.  Each round’s pool was regenerated as per the protocol outlined in “Pool synthesis 
and purification” with modifications to adjust for the lowered scale of nucleic acid each 
round.  In later rounds, it was also discovered that the primer concentrations used in the 
original pool amplification was in gross excess, and the concentrations of PCR primers 
were reduced to 0.4 mM each primer. 
The rounds of the selection were performed with increasingly less input RNA, 
shorter incubation times and more wash steps (see Figure).  The progress of the selection 
was determined by assessing the number of PCR cycles required before an amplification 
product could be seen.  This is often directly correlated to the amount of input material – 
in this case, how much pool RNA was likely recovered during that round of selection.  A 
drastic drop in cycle # was seen after Round 3 (the first round to significantly reduce the 
amount of pool put onto cells) and after Round 5 when a fresh stock of cells was used. 
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After Round 9, the PCRs did not appear to improve in cycle number, and the 
selection was deemed finished. 
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APPENDIX A:   
SCREENING DRUG MOLECULAR INTERACTIONS BASED ON RIBOZYMES 
(with Dr. Michael Famulok) 
 
INTRODUCTION & BACKGROUND 
 Most drugs to date have been small organic compounds, identified through 
tedious screening of small compound libraries.  Advancements in high-throughput 
screening and automated processes have helped in this process.  However, the general 
approach is expensive and still lacks functional assays for many of the targets.  Each 
target must be identified, purified, processed and adapted to the screening process or have 
its own unique assays or readouts. 
 Dr. Michael Famulok and his laboratory devised a method to readily screen for 
anti-HIV drugs which could be reported in real-time (Hartig et al., 2002).  In brief, they 
made use of ribozymes and RNA sequences, which have high affinity for the critical 
HIV-1 protein, Rev.  Two approaches were used.  In the first, the Rev Binding Element 
(RBE), Rev’s native ligand target, was appended to helix II of a hammerhead ribozyme.  
The ribozyme substrate was labeled with a fluorophore and quencher at either end, such 
that cleavage of the substrate correlates to fluorescence.  Rev binding to the RBE would 
misfold the ribozyme and inactivate cleavage, resulting in lowered or no fluorescence.  
Any small molecule that could interact with Rev would prevent the Rev:RBE binding 
interaction and allow for cleavage, resulting in fluorescence (Figure A.1.A). 
 In the second approach, the an anti-Rev, Apt2, was appended directly to the 5’ 
end of the hammerhead to create what is known as an aptazyme, or an aptamer:ribozyme 
chimera (Giver et al., 1993a; Giver et al., 1993b; Tang and Breaker, 1997).  The aptamer 
folds in such a way that the 5’ end of the aptamer loops back on the hammerhead and 
hybridizes to a portion of the substrate recognition arm, preventing substrate binding.  
Upon Rev binding, the aptamer refolds, ceding its hold of the ribozyme arm.  The 
substrate can then bind and be cleaved, resulting in fluorescence.  In the presence of a 
Rev-binding small molecule drug, the aptazyme would remain in its native state, and 
fluorescence is not detected (Figure A.1.B). 
 
 
Figure A.1.  Two ribozyme-based systems to screen for molecular interactions.  (A) Binding of a 
ligand (Rev) to the RBE (orange) disrupts the folding of the ribozyme, and cleavage of a 
fluorescent substrate is impaired.  (B)  The ligand-binding aptamer (orange) occupies one of the 
substrate-binding arms of the ribozymes.  Binding of the ligand retracts the aptamer allowing for 
hybridization of the fluorescent substrate and subsequent cleavage. 
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The Famulok group applied a 96-compound library to their ribozyme constructs.  
Instead of full-length Rev protein, they used a 15 amino acid peptide corresponding to the 
arginine rich motif (ARM) of Rev which has been shown previously to be responsible 
and fully capable of binding the RBE and Apt2 (Tan et al., 1993; Ye et al., 1996).  Three 
compounds were identified from the screen, coumermycin A1, nosiheptide and patulin 
(Figure A.2) that mediated the  
 
Figure A.2.  Compounds isolated from the ribozymes screens. 
 
 
appropriate response in both the RRR and AIR systems.  Ribozyme only controls were 
also performed to ensure that signal was not due to background cleavage of the 
ribozymes.  A representative response is shown in Figure A.3 for coumermycin A1 and 
the control ribozymes.   
Coumermycin A1 and patulin were tested using surface plasmon resonance for 
specificity against a number of other molecules including: RNA, Tat, reverse 
transcriptase (RT), NF-κB p52 and cytohesin-1.  While coumermycin A1 clearly had 
strong specificity for Rev, patulin appeared to bind non-specifically. 
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Having successfully identified a compound from these molecular screens, it 
remained to be seen if the screen  was actually successful in isolating an effective drug.  
To this end, we challenged the isolated compounds with HIV-1 to test for antiviral 
effects. 
 
 
Figure A.3.  Ribozyme (Rz) activation and inactivation by Rev or the Rev peptide (ARM).  (A)  
Inactivation of the RRR system by 1 µM ARM or 5 µM Rev and inactivation of AIR by 250 nM ARM or 1 
µM Rev.  (B)  Reactivation of the RRR and AIR systems with 100 µM coumermycin A1. 
 
 
RESULTS & DISCUSSION 
 
 The isolated compounds, labeled as B and C, were blindly tested for toxicity and 
ability to inhibit HIV-1 replication in tissue culture cells.  Toxic responses were first 
performed to determine the concentration to use in infectivity assays.  Each compound 
was added to tissue culture cells in varying doses. General culture health as well as cell 
counts were assessed at different days for up to two weeks (see, for example, Figure 
A.4).  After broad ranges of toxicity were determined, a more narrow range of druge 
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concentrations were also tested (Figure A.5).  As higher doses of patulin was clearly 
extremely toxic to cells, so lower doses were chosen for the infection assays.  
H9 T-lymphocyte cells were infected with HIVIIIB and cultures were grown in the 
presence of 1 µM, 5 µM or no compound.  A mock-infection set was also established to 
distinguish between effects of the drug on cell health versus effect of the drug on viral 
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Figure A.4.  H9 cell viability in different concentrations of coumermycin A1 over 12 days. 
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Figure A.5.  Short term effects of patulin and coumermycin A1 on H9 cell viability. 
 
replication.  Samples of culture for p24 analysis and cell counting were taken every two 
days for the first 10 days, and every 3 days thereafter. 
 At the 5 µM concentration, it was clear that patulin was too toxic on cells.  The 
equivalent concentrations of coumermycin did not affect culture health significantly 
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(Figure A.6).  A quick assessment of the infection rates determined that the 
concentrations of patulin that would make any effect on viral replication would be too 
detrimental on the viability of the culture (data not shown).  We chose, therefore to focus 
futher studies on coumermycin A1, which only showed toxicity at slightly higher doses.  
At 5 µM, coumermycin A1 was able to reduce viral p24 levels up to 80% 
compared to infected cell controls.  At 7.4 µM, the effect was slightly more pronounced, 
however, low level toxicity could be seen.  At 1 µM, the effect was present, but minimal 
compared to the higher concentrations (Figure A.7).  
 
Figure A.6.  Viability of infected (closed symbols) and non-infected (open symbols) cells over the course 
of an infection assay.  (A)  Cells were grown with 5 µM coumermycin A1 (S and U) or 5 µM patulin () 
relative to cell controls (and ).  (B)  The same experiment was performed with cells grown in 7.5 µM 
coumermycin A1 (z and {). 
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Figure A.7.  Effect of coumermycin A1 on HIVIIIB replication.  Cells were grown in the presence of 1 µM 
(), 5 µM (S), 7.5 µM (z) or no coumermycin A1 (¡).   The p24 values are shown relative to infected 
cells treated with the equivalent amounts of DMSO used in the drug dosage. 
  
Given that these concentrations did not appear too detrimental to cell health, we 
wondered if these compounds could be used in a prophylactic manner.  Cells for the 
infection assays were treated with 7.5 µM coumerymycin A1 for 48 hrs before infection.  
The cultures were maintained in coumermycin A1, and samples were taken and analyzed 
as before.  In general, viral load during the very early phase of infection was not 
significantly altered from infected cells controls.  At later timepoints, the effect of the 
drug was not more improved than what we’d previously seen without pre-treatment of the 
drug (Figure A.8).  A better experiment would run a parallel series without pre-treatment 
alongside the pre-treated one. 
 
Figure A.8.  Pre-treating cells with coumermycin A1 did not appear to further  
harm HIV-1 replication. 
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CONCLUSION & FUTURE DIRECTIONS 
 
 The Famulok Group has developed a system to screen for molecular interactions 
with a real-time fluorescence readout.  We assayed the outcomes of their screen and 
demonstrated that, indeed, their method was able to pull out a drug compound that could 
bind to and inhibit HIV-1 replication in tissue culture cells. 
 While HIV-1, and more specifically, the Rev protein, was initially chosen as the 
proof-of-principle target, one could envision where the system could be readily adapted 
to other targets and other interacting pairs.  Because aptamers are readily selected for and 
can discriminate between very closely related targets, different interacting pairs can be 
readily made by swapping out the Rev-binding motifs with ones that recognize other 
targets.  As nucleic acid synthesis is relatively straightforward and inexpensive, 
turnaround and cost of redesign should be minimal.  Particularly as more and more 
potential drug and cell targets are identified, this would be most useful. 
 Along these lines, the Famulok group went on to demonstrate a different version 
of the system using an anti-α-thrombin aptamer.  In this case, they re-engineered 
hammerhead and hairpin ribozymes to have a sequence that matched parts of the aptamer 
sequence.  In the presence of aptamer, the aptamer bound to the ribozyme in an anti-sense 
manner and inhibit cleavage of the fluorescent substrate.  Other DNA sequences did not 
trigger the same response.  In the presence of excess α-thrombin, the aptamer released the 
ribozymes, preferring to bind to thrombin instead, as was detected by an increase in 
fluorescence.  Interestingly, γ-thrombin, which only differs from α-thrombin in that it 
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lacks aptamer binding site, exosite-1, was not able to reactivate the ribozymes (Hartig et 
al., 2002; Najafi-Shoushtari and Famulok, 2007). 
 Different proteins were assayed for interaction with α-thrombin in the presence of 
the ribozymes constructs.  Only one of the proteins, hirudin, is known to bind α-
thrombin.  In the presence of increasing concentrations of hirudin, both the hammerhead 
and hairpin systems dropped in fluorescence intensity, demonstrating a decoy effect as 
hirudin binds α-thrombin, allowing for the aptamer to bind and inhibit the ribozymes. 
 The Famulok has gone on to demonstrate the technology with an anti-reverse 
transcriptase aptamer which is effected by HIV-1 RT (Hartig and Famulok, 2002).  More 
recently, they adapted their RT system to identify small molecule inhibitors of RT.  The 
two lead molecules were able to inhibit HIV-1 replication in tissue culture cells.  Several 
interesting and significant features were found about the molecules that were isolated.  
The different molecules appeared to bind to different parts of RT.  Moreover, the most 
promising one, SY-3E4, appeared to bind to a site not targeted by other anti-RT drugs.  
Unlike aptamers against RT, SY-3E4 was able to bind to RT from both HIV-1 and HIV-2 
(though there was a preference for HIV-1) as well as drug-resistant variant of HIV-1 
(Yamazaki et al., 2007).  This identified drug could, therefore, have applications against 
many viral variants. 
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MATERIALS: & METHODS 
 
Test compounds 
The test compounds were received from Michael Famulok as dried powder.  Each 
of the compounds, coumermycin A1, patulin and noshipeptide, were stored at a 
concentration of 10mM in DMSO at -20°C.  The volumes of DMSO used in these 
experiments have previously been shown to have no significant toxic effects on these 
cells (data not included).  
 
Cell and virus culture 
 H9 cells and HIV-1IIIb were obtained from the NIH AIDS Research and Reference 
Reagent Program.  Cells were grown at 37°C in a 5% CO2 atmosphere in RPMI-1640 
supplemented with 10% fetal bovine serum, 10 mM HEPES, 1 mM sodium pyruvate, 1.5 
g/mL sodium bicarbonate, 2 mM L-glutamine 2.5 U/mL penicillin and 2.5 μg/mL 
streptomycin (R10; Invitrogen).  Viral stocks at 40ng/mL of p24 were stored in liquid 
nitrogen until the assays. 
 
Infection and viability assays 
 1.2x107 H9 cells were washed in sterile PBS and pelleted by spinning at 1500 rpm 
at 4°C for 5 min.  Half of the cells were resuspended in 3 mL of HIV-1IIIb in R10 with a 
p24 concentration of 4 ng/mL and incubated for 1 hr with agitation every 10 min to 
redisperse cells.  A parallel mock infection was performed in which the other half of the 
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cells were incubated in 3 mL of R10 only.  The cells were washed and pelleted as before 
and resuspended in fresh R10.  Infected cells were divided into three 25cm2 flasks in a 
total volume of 7.5 mL R10 supplemented with 0 μM, 1 μM, or 5 μM each compound.  
Mock-infected cells were likewise divided into three flasks with equivalent 
concentrations of the compound.  
 1.5mL of each cell culture was taken approximately every two days for the first 
10 days and every three days thereafter, counted for cell viability and assayed following 
the protocol for a standard p24 antigen ELISA kit (Zeptometrix).  Briefly, culture 
supernatants were lysed at room temperature for 40 min in Triton-X 100 and 2-
chloroacetamide supplied by the kit.  Supernatants were then transferred to a 96-well tray 
precoated with human monoclonal antibodies to p24 and incubated for 1 hr at 37°C.  The 
culture solution was removed, wells were washed six times with Plate Wash Buffer (PBS, 
Tween 20 and 2-chloroacetamide), and 100 μL of human biotin-labeled antibody to HIV-
1 was added.  The plate was again incubated for 1 hr @ 37°C, and the wash steps 
repeated.  Strepdavidin-conjugation horseradish peroxidase was then added and incubated 
for 30 min @ 37°C, washed away as before, and tetramethylbenzidine (TMB) was added 
to the plate.  After a 30 min incubation at room temperature, 2M sulfuric acid was added 
to stop the reaction, and the resultant color was detected using a BioTek FL600 96 well 
plate reader (BioTek Instruments).  p24 concentrations were calculated from p24 
standards assayed on the same plate.  The total volume of each culture was maintained by 
adding 1.5mL fresh R10 supplemented with the appropriate concentration each 
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compound.  For the prophylactic test, cells were grown in 7.5 µM coumermycin A1 for 
48 hr before the infection assay described above. 
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APPENDIX B: 
EFFICACY OF L-CANAVANINE AS AN ANTI-VIRAL 
 
INTRODUCTION & BACKGROUND 
 As part of the continuing struggle against 
the AIDS epidemic in South Africa, medical and 
non-medical personnel have been dispensing 
plants from the genus Sutherlandia to AIDS 
patients.  Sutherlandia frutescens is a traditional 
herbal remedy throughout Southern Africa used to treat a variety of ailments ranging 
from fevers to cancer and, more recently, HIV infection (Figure B.1).  
Figure B.1.  Sutherlandia frutescens. 
Sutherlandia frutescens contains high concentrations of L-canavanine (L-can) as 
well as pinitol and GABA (Mills et al., 2005).  GABA is a neurotransmitter that has been 
associated with relaxation and a desensitization of 
pain (Jasmin et al., 2004).  GABA has also been 
associate with lean muscle gain.  Pinitol has insulin-
like properties in that it increases glucose uptake 
and glycogen synthesis, and is also associated with 
muscle growth (Kim et al., 2007).  L-can is an 
arginine analog reputed to be the actual source of Figure B.2.  The structures of L-arginine
and its analog, L-canavanine. 
 
 170 
 171 
Sutherlandia’s anti-viral and anti-cancer effects, in that incorporation of the analog would 
disrupt the high rate of replication in both cancer and HIV.  Additionally, the altered pKa 
of L-can (Figure B.2) could affect important interactions when incorporated into 
proteins.  For example, the HIV transport protein, Rev, is heavily dependent on Arg 
residues within its RNA-binding motif as well as the transcription activator, Tat.(Calnan 
et al., 1991a; Calnan et al., 1991b; Ellington et al., 1995; Subramanian et al., 1990; Tan et 
al., 1993)  In addition, the reverse transcriptase contains a number of arginine residues 
that are important for function.(Kim et al., 1999; Mitchell and Cooperman, 1992; 
Sarafianos et al., 1995)  Disruption of such an interaction could have severe effects on 
HIV’s ability to replicate.(Rosenthal and Dahlman, 1991)   
It is speculated that the combination of these three compounds has led to the 
belief that Sutherlandia is effective, especially since patients seem to feel better after 
taking the drug.  Reports attest the successful treatment of AIDS patients at clinics 
throughout Africa.  While these ‘clinical trials’ are anecdotal and uncontrolled, they raise 
two important questions:  first, can research into the putative anti-viral efficacy of L-
canavanine potentially add an important compound to the arsenal of anti-AIDS drugs in 
use in developed countries?  Conversely, can research into the therapeutic index of L-
canavanine potentially provide evidence that will guide or temper the spreading use of a 
possibly harmful medicinal plant?  These questions are more pertinent given its known 
toxicity to cells and its potential to impair lymphocyte interactions and exacerbate or 
even induce autoimmune disorders (Montanaro and Bardana, 1991; Prete, 1986).   
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Despite the fact that L-can, a structural analog of arginine, has long had a 
reputation as an anticancer, antiviral, antibacterial and antifungal agent,(Rosenthal, 1977) 
there is still little research into its anti-HIV potential.  What knowledge there is seem to 
suggest L-can may indeed have antiviral effects.  Melvin Green at UCSD showed some 
evidence that L-can was significantly more toxic to infected lymphocyte cells than non-
infected cells but did not present evidence that the viral replication was directly 
inhibited.(Green, 1988)  Animal studies with L-can have been carried out, and it has been 
proposed as an anti-cancer drug.(Crooks and Rosenthal, 1994; Crooks and Rosenthal, 
1996)  Indeed, canavanine could be administered in single oral doses in rats at the 
astonishing level of 2 g/kg without adverse effect, although multiple subcutaneous 
dosings at a similar level resulted in alopecia (hair loss) and weight loss.(Thomas and 
Rosenthal, 1987a; Thomas and Rosenthal, 1987b)  These side effects quickly disappeared 
once treatment was terminated.  In fact, the immunotoxic effects of L-can on PBMC 
proliferation were reversed in the presence of Arg,(Bence et al., 2002) and doping with 
Arg prevented canavanine death in bacterial cultures.(Volcani and Snell, 1948)  Should 
this effect also apply to humans, side-effects from the course of treatment could 
potentially be eliminated merely by dosing with arginine.  The fact that L-can has an 
exceptional pharmacokinetic profile (bioavailability in rats of 43%; only 1% secretion in 
urine after 24 hours)(Thomas and Rosenthal, 1987a; Thomas and Rosenthal, 1987b) and 
is taken up by cells as a function of normal metabolic replenishment may allow this 
analogue to attack HIV-1 reservoirs that are currently protected from other 
pharmaceuticals.   
To the extent that our experiments demonstrate a path to clinical utility, and to the 
extent that clinical trials in the United States or elsewhere generically validate L-can’s 
potential as a drug, then it is possible that L-can could be immediately used for the 
treatment of AIDS without the years of research that are typically required for 
pharmacological development.   
 
 
RESULTS & DISCUSSION 
 
Toxicity of L-can on cells 
We began by examining the effects of L-can on Jurkat cell viability to determine 
the optimal concentrations to use for infection assays.  In general, we determined that L-
can did indeed have some toxicity on cells.  However, cells did not seem to be severely 
affected until past 500 µM L-can in the media (Figure B.3).  Based on the dosage 
recommended by PhytoNova, a distributor of a Sutherlandia-based pill, Tai et al. had  
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Figure B.3.  Rate of Jurkat cell growth over 6 days in increasing concentrations of L-can. 
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estimated the biological concentration of L-can in plasma would be approximately 2.8 
µM, significantly lower than the toxicity levels we were observing (Tai et al., 2004).  
This was promising if the recommended dosages were indeed effective against the virus.  
 
L-can inhibition of HIV-1 replication 
 We examined the ability of HIV-1IIIB (NIH AIDS Research and Reference 
Reagent Program) to replicate in T-lymphocytes in the presence of increasing 
concentrations of L-can.  Some preliminary data from Melvin Green at UCSD had 
suggested that infected cells were more prone to toxicity effects from L-can than non-
infected cells.  With this fully in mind, we were also keen to monitor cell health as well 
as viral load in the samples tested. 
We found that when L-can was present at 10% of the total arginine content in 
media (110 µM final concentration L-can, a concentration that is in fact, similar to that of 
arginine in human blood, 70-80 µM (Cynober, 2002)) that HIV-1 replication, as 
measured by p24 production, was reduced by 90% at 9 days post-infection.  At these 
levels of L-can there was no significant cellular toxicity (Figure B.4).    
 We repeated these experiments with a greater spread of L-can concentrations to 
more precisely determine IC50 and LD50 values.  Cells were infected with HIVIIIB  and 
grown in Arg-deficient RPMI-1640 media supplemented with varying ratios of L-can to 
Arg such that supplemental L-can plus Arg concentrations totaled 1.1 mM, the 
concentration of Arg found in commercial RPMI-1640 (Invitrogen).  To ensure that any  
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Figure B.4.  Inhibition of viral replication as  function of L-can concentration.   
Cell viability (green) are charted relative to infected cells not treated with the analog. 
 
effects were due to the presence of L-can, and not to Arg depletion, controls cultures 
were also tested in R10 media supplemented only with diminishing concentrations of 
Arg.  The viability of all cultures was determined every three days by cell counts.  
Cultures were split into fresh media every three days to maintain log-phase growth and to 
reset Arg/L-can concentrations.  Viral replication was determined by assaying the media 
samples for p24 concentrations.  
 We determined that while we were beginning to see toxic effects between 100 – 
200 µM L-can, the LD50 of L-can in our cultures was closer to the range of 600 µM.  
Meanwhile, the IC50 was in the 100 µM range.  While it may seem promising that the 
dose needed to render an effect was lower than the dosage that actually harmed the cell, 
the actual difference may not be enough to qualify this as a good drug.   
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The therapeutic index (TI) is ratio of the dosage of drug that can harm a patient 
over the dosage of drug needed to mediate the effect.  The ratio of LD50 over IC50 is 
typically used to estimate approximate TI in cell culture systems.  A low TI means that 
the gap between helpful and hurtful is extremely narrow.  A high TI represents a higher 
safety of the drug.  As an example, the TI of pseudoephedrine is approximately 1400 
(Shi, 2004).  We determined that the TI in our assays ranged around 5 (Figure B.5).   
 
LD50 stdev
d = 12 596.53 132.95
d = 14 647.39 146.21
trial LD50 IC50 TI
d = 12 LC3 617 73.05 8.45
LC4 585 121.91 4.80
d = 14 LC3 685.38 100.48 6.82
LC4 644.69 117.29 5.50
A. B.
 
Figure B.5.  LD50, IC50 and TI analysis of L-can on infected and non-infected cells.  (A)  Two 
independent infection series were examined 12 and 14 days post infection.  (B) Values for two infected and 
two non-infected series were summed together to determine an overall LD50 at 12 and 14 days post-
infection.  
 
This level does not necessarily classify L-can as a narrow TI drug (which the 
FDA defines as a drug with less than 2-fold difference in LD50 versus EC50).  Many 
narrow TI drugs are on the market.  In fact, TI may not always be the best evaluation of a 
drug.  A low TI may result from high toxicity (i.e., low LD50), but it could also result 
from rapid clearance from the blood or other factors may play a role.  For example, 
corticosteroids have been associated with many toxic side-effects and have been found on 
some narrow therapeutic index lists.  However, inhaled corticosteroids, such as that used 
for asthma treatment, reach effective levels very quickly, are absorbed primarily at the 
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site of action (i.e., the lungs) and do not necessarily have systemic effects.  Moreover, it 
has been shown that lung cells of asthmatic patients may absorb the drug differently than 
healthy patients (Israel, 2000).  Thus, delivery, absorption and host factors all contribute 
to the relative efficacy and toxicity levels.  
Contrary to previous data, we have also determined that L-can does not have 
higher toxic effects on infected cells than non-infected cells.  Infected cells, in of 
themselves, seemed to fare slightly worse than their non-infected counterparts, but the 
trends in L-can effects were similar for both.  Additionally, LD50 determinations in both 
infected and uninfected cells showed no significant difference (Figure B.6). 
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Figure B.6.  Health of infected vs. non-infected cells in L-can.  Representative data showing that 
the health of infected cells are not significantly more affected than uninfected cells.  
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CONCLUSIONS 
 
The herb Sutherlandia frutescens has been used in several developing countries 
for its purported effects against HIV-1.  We have examined L-canavanine, the putative 
anti-viral agent in Sutherlandia, for its toxicity to cells and its antiviral efficacy.  We have 
found that L-can, indeed does have marked antiviral effects and at doses about a fifth of 
what would be toxic to cells.  This concentration falls substantially below the plasma 
concentrations that have been estimated in patients based on one of the recommended 
dosages.  However, this is not to say that higher concentrations may not be tolerated in a 
patient, especially when there is a choice between side effects of the herb versus the 
ravages of AIDS.  Moreover, as L-can has been administered within the context of the 
herb, there may be synergistic, as well as possibly deleterious, effects between L-can and 
other components of Sutherlandia, such as pinitol and GABA.  Additionally, the numbers 
we present here are based on those needed to substantially kill the virus.  There may still 
be some benefit in smaller effects that could possibly delay replication.  
We, therefore, conclude that L-can does have anti-viral properties.  However, the 
current dosages may not be fully effective.  However, due to its potentially toxic nature, 
real clinical and animal studies should be undertaken before serious consideration of L-
can as a drug.  Moreover, L-can usage should be carefully monitored if administered 
within the therapeutic amounts we determined to be effective. 
 Aside from clinical studies, this work also raises questions for further 
investigation.  Though L-can may be toxic, perhaps other natural or engineered analogs 
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might also be effective for this purpose.  Also, the incorporation of L-can by HIV may 
prove interesting for the study of any resistance mutants that may arise.  The Ellington 
lab has previously grown E. coli arginine auxtrophs in the presence of high 
concentrations of L-canavanine (95% of total arginine), and have generated proteins that 
largely contain canavanine in place of arginine.  However, growth of these organisms 
were quite compromised.  Given how critical arginine residues are in HIV-1 Rev, Tat and 
other proteins, HIV need to change significantly.    
 
 
MATERIALS & METHODS 
 
Cell and virus culture 
H9 and Jurkat cells as well as the virus HIVIIIB were obtained from the NIH AIDS 
Research and Reference Reagent Program.  The cell lines were grown in RPMI-1640 
supplemented with 10% fbs at 37°C with 5% CO2 and 95% humidity.  For assays 
involving different concentrations of Arg or L-can, three separate RPMI-1640 media 
stocks were made following the recipe published by Invitrogen: one containing 1.1 mM 
Arg, one containing L-can in place of Arg and one depleted of Arg and L-can.  Different 
concentration stocks were made by mixing the appropriate volumes from these stocks. 
All cell centrifuging steps were at 1,500 rpm at 4°C for 5 min.  All cell and viral 
wash steps were done with DPBS without Mg2+ or Ca2+. 
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 For making viral stocks from the H9-HIVIIIB cells, H9-HIVIIIB cells were grown to 
80% confluency, then cells were pelleted, washed and resuspended in warmed media 
supplemented with 20% fbs.  Culture medium was collected two and four days after the 
wash, filtered through 0.45 µm filters, aliquoted into cryovials and stored in liquid 
nitrogen.   
 To quantitate the infectivity of the frozen, viral titers were determined as 
described in Chapter 2. 
 
Infection challenge assays with L-can  
 For viral challenge, a T75 flask of cells was treated with polybrene to a final 
concentration of 2 µg/mL at 37°C for 20 to 30 min.  Cells were pelleted, counted and 
2x106 cells were transferred to a tube and re-pelleted.  The cell pellet was resuspended in 
0.5 mL virus solution containing virus to achieve the desired MOI.  Cells were incubated 
for 1 hr with agitation every 10 min to keep cells in suspension.  After incubation, cells 
were divided, pelleted, washed once, resuspended in 1 mL growth media and added to 
wells of a 24-well plate. 
 The viability of all cultures was determined every three days by cell counts.  
Cultures were split into fresh media every three days to maintain log-phase growth and to 
reset Arg/L-can concentrations.  Viral infection typically became detectable by p24 assay 
approximately 9 days post-infection.  After 1 week post-infection, samples of culture 
were removed and mixed with lysis buffer from the Zeptometrix p24 kit.  The harvested 
cultures were assayed for p24 using a commercial ELISA kit (Zeptometrix) 
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Determining LD50 and IC50 
 LD50’s were determined by fitting viability curves to the equation:  y = 
(y0+ax)/(c+x), where y = intensity of the effect (here, the level of cell death, as measured 
by cell count), y0 = value of the minimal effect (100% survival), x = [L-can], a = 
maximal effect (complete death) and c = the concentration at ½ maximal effect.  IC50s 
were determined by fitting the viral curve to the equation:  y = ae-bx, where y = viral load 
(as measured by p24), x = [L-can] at 50% maximal load, a = maximal viral load, and b is 
a slope factor.  The therapeutic index (TI) for L-can was calculated by LD50 for a given 
treatment by the IC50. 
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